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INTRODUCTION 
 
Helicobacter pylori colonizes the stomach of approximately half the world's population. 
The bacteria are primarily observed on the mucosa of the gastric antrum [19]. Colonization 
with H. pylori itself is not a disease, but H. pylori is an etiologic agent of acute or chronic 
gastritis, and a predisposing condition to peptic ulcer disease, gastric carcinoma, and 
B-cell mucosa associated lymphoid tissue (MALT) lymphoma [7, 23, 24]. The clinical 
outcome of H. pylori infection depends on a variety of factors, which are related to the 
host (e.g. blood group antigens and polymorphisms in interleukin 1 gene cluster), the 
bacterium (e.g. strain-specific genes, differential gene expression, phase variation and 
allelic variation), and the environment (e.g. age and smoking) [14]. 
H. pylori is Gram-negative rod, with a spiral or slightly curved shape (Figure 1). The 
bacterium is relatively small, 2.5 to 3.5 µm in length and 0.5 to 1.0 µm in width, and con- 
tains 4 to 6 unipolar sheathed flagellae [9]. H. pylori may change into a coccoid form, 
especially after antibiotic treatment or prolonged in vitro subculturing [17, 22]. Whether 
the coccoid forms are viable and do have the capacity to return into the spiral shape, is 
still being discussed [17, 26, 32].  
 
Figure 1. Helicobacter pylori. Modified from image L. Marshall, www.hpylori.com.au  
 
Recently, the complete genome sequence of two different H. pylori clinical isolates 
(i.e. 26695 and J99) have been determined and annotated [1, 28]. The genome of these 
strains are circular and relatively small (1.64 to 1.67 Mb) compared to Escherichia coli 
(4.6 Mb), and have a GC content of 39%. For H. pylori strain 26695, 1590 putative open 
reading frames (ORFs) have been identified, whereas the H. pylori genome of strain J99 
enclosed 1496 putative ORFs. For approximately 60% of the ORFs a function could be 
predicted, including several well-known virulence factors such as cagA, vacA and iceA. 
Roughly 6% of the putative ORFs appear to be strain specific [1, 28]. The high genetic 
diversity observed among H. pylori strains might be explained by naturally competence of 
H. pylori for DNA uptake and/or by the ability of H. pylori to rearrange its genome [15, 16]. 
Chapter 1 
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H. pylori infection can be diagnosed by a variety of invasive and non-invasive tests 
(Table 1). Histological examination, bacterial culture and rapid urease testing require an 
gastric biopsy sample [10, 11, 13, 25], whereas serology, polymerase chain reaction (PCR), 
and the stool antigen test can be performed on alternative clinical samples such as whole 
blood, serum, saliva, urine or faeces [2, 8, 12, 18, 30]. The choice for use of a specific test 
depends on several factors including gastric complaints, age, local availability, costs and 
clinical information sought. As none of the tests to diagnose H. pylori infections is 100% 
reliable, a combination of two tests is advisable [29].   
Some clinical conditions warrant endoscopic examination, for instance patients with 
alarm symptoms such as bleeding and weight loss as well as older patients with newly 
developed dyspepsia. Endoscopy is also advised for patients who have failed eradication 
therapy, for culturing and antimicrobial susceptibility testing in order to select an appropriate 
therapy. When alarm symptoms are absent, the non-invasive 'test and treat' strategy has 
shown to be safe and cost effective in diagnosis and treatment of H. pylori in uninvesti-
gated, young (< 50 years), dyspeptic patients [3].  
 
 
Table 1. Tests to diagnose H. pylori infections.  
 
Test methods References 
Invasive test  
Histological examination [11] 
Bacterial culture [13] 
Rapid urease test  [10, 25] 
Polymerase chain reaction (PCR) analysis [4] 
  
Non-invasive test  
Urea Breath Test [5] 
Serology [2, 12] 
Stool antigen test [8, 30] 
PCR analysis [18] 
 
 
H. pylori eradication leads to healing of gastritis and peptic ulcer disease, and probably 
also has a beneficial effect on regression of atrophic gastritis and prevention of distal 
gastric cancer [6, 27]. In vitro, H. pylori is susceptible to the majority of antibiotics, but in 
vivo only a few antibiotics can be used successfully for eradication of H. pylori, i.e. 
amoxicillin, clarithromycin, metronidazole and tetracycline [20]. As none of these drugs is 
effective enough to eradicate H. pylori in monotherapy, successful treatment of H. pylori 
infection requires combination therapy, consisting of one or two antibiotics, an acid inhibitor 
and/or a bismuth component. The extensive use and limited choice of the antibiotics have 
resulted in the development of antibiotic resistance in H. pylori. The increased prevalence 
of antibiotic resistance in H. pylori is problematic since it is one of the most important 
causes of therapy failure.  
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Antibiotic susceptibility in H. pylori is usually assessed by culture-based methods such 
as E-test, agar dilution and disc diffusion. These tests are slow, as results are usually 
obtained only after 6 to 10 days. Furthermore, they fail in approximately 5-10% of the 
cases, and are difficult to compare between different institutes due to lack of standardi-
zation [21, 31]. In this light molecular-based methods can offer an attractive alternative. 
They are independent of cell viability and growth rates of the bacteria, and are easily 
standardized. In order to develop molecular-based methods for the detection of antibiotic 
resistance in H. pylori, knowledge of the molecular mechanisms underlying antibiotic 
resistance is mandatory.     
 
AIMS AND OUTLINE OF THIS THESIS  
 
The aims of this thesis were to gain more insight in the molecular mechanisms underlying 
antibiotic resistance in H. pylori. Chapter 2 described the clinical implications and 
molecular mechanisms of antibiotic resistance in H. pylori, and the molecular detection 
method developed thus far. Chapter 3 describes the isolation and characterization of the 
first Dutch tetracycline-resistant H. pylori clinical isolate. As tetracycline resistance in 
H. pylori seems to be related to the presence of the triple-base-pair substitution AGA926-928TTC 
(underlined letters are used to represent the base pair changes) in both the 16S rRNA 
genes, the preference for this mutation was studied (Chapter 4). Site-directed mutants 
were created in a similar isogenic background, and growth rates, levels of resistance and 
stability of the mutations were tested. The data obtained in these two studies was then 
used for the development and validation of molecular detection methods for tetracycline 
resistance in H. pylori. Chapter 5 describes a PCR-based restriction fragment length 
polymorphism (RFLP), and Chapter 6 describes a real-time PCR assay followed by 
melting curve analysis using LightCycler technology.  
Chapter 7 describes the role of metronidazole reducing enzymes in oxygen-dependent 
metronidazole resistance in H. pylori. Several metronidazole-resistant H. pylori isolates, 
containing null mutation in the rdxA and/or frxA genes, were exposed to short periods of 
anaerobiosis, and the effect on cell viability and level of metronidazole resistance was 
investigated. 
Chapter 8 reports the isolation of the first stable amoxicillin-resistant H. pylori isolate 
worldwide, and Chapter 9 describes the characterization of the molecular mechanism 
underlying amoxicillin resistance in the H. pylori strain isolated in Chapter 8. 
Chapter 10 describes the molecular mechanism of seven additional amoxicillin-resistant 
H. pylori isolates obtained from dyspeptic patients from Brazil and The Netherlands.  
Finally, the research described in this thesis is summarized and discussed in Chapter 11. 
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ABSTRACT 
 
Helicobacter pylori is a Gram-negative rod which colonizes the stomach of approximately 
half the world's population. First identified in 1983 as a pathogen, it has now been 
accepted as the causative agent of several gastric disorders ranging from chronic active 
gastritis and peptic ulcer disease to gastric cancer. The recognition of H. pylori as a 
pathogen has had a significant impact on gastroenterologic practice and has made 
diagnosis and treatment of H. pylori clinically relevant. Although H. pylori is 
susceptible to many antibiotics in vitro, only a few antibiotics can be used in vivo to 
cure infected patients. The frequent indication for eradication therapy, and the limited 
choice of antibiotics have resulted in the development of antibiotic resistance in 
H. pylori, which significantly impairs the treatment of H. pylori-associated disorders. 
The prevalence of antibiotic resistance of H. pylori shows regional variation per 
antibiotic, but can be as high as 95%. In this review the clinical implications, the 
molecular mechanisms, and recently developed molecular detection methods for 
antibiotic resistance in H. pylori are discussed. 
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1. INTRODUCTION 
 
In 1983, Warren and Marshall were the first to report the successful cultivation of the 
human pathogen Helicobacter pylori from gastric biopsy samples [159]. They went on to 
fulfill Koch’s postulates in a self-infection experiment, in which they demonstrated that 
H. pylori colonization results in active gastritis, which could be cured by treatment with 
antibiotics [91]. This important discovery has significantly changed the management of  
gastroduodenal diseases and has in particular changed peptic ulcer disease from a chronic, 
relapsing disease of uncertain cause to a curable infectious condition.   
Infection with H. pylori occurs worldwide. In industrialized countries 20% to 50% of 
the middle-aged adults is infected with H. pylori, compared to 80% or more in many 
developing countries [36, 120, 125]. In the latter, most people become colonized with 
H. pylori before the age of ten, whereas in industrialized countries only a few children are 
infected at this age [125, 138]. In industrialized countries, the incidence of H. pylori 
infections has decreased substantially over the recent decades, probably due to improved 
socio-economic status, sanitation and/or living conditions. Therefore, the increase in 
prevalence of H. pylori with age seen in the industrialized countries is generally explained 
by a cohort effect [74]. 
Infection with H. pylori is associated with an acute pangastritis. This acute gastritis 
may be symptomatic with nausea, vomiting and abdominal pain. Although the infection is 
cleared in some patients, it progresses to chronic active gastritis in most subjects [74]. In a 
proportion of them, this eventually gives rise to peptic ulcer disease, and atrophic gastritis, 
and gastric adenocarcinoma [75]. Furthermore, H. pylori infections have been associated 
with gastric B-cell mucosa associated lymphoid tissue (MALT) lymphoma, hypertrophic 
gastropathy, and hypochlorhydria [55, 115, 131].  
 
 
2. TREATMENT OF H. PYLORI INFECTIONS 
 
Peptic ulcer disease and other H. pylori-associated disorders usually regress or heal 
completely after eradication of H. pylori with antibiotics [5, 133]. In vitro, H. pylori is 
susceptible to the majority of antibiotics [94], but in vivo most antibiotics are unable to 
cure infected patients [49]. This is thought to be due to a combination of factors, including 
(i) the inability of drugs to achieve appropriate levels in the gastric mucus layer [95, 152], 
(ii) inactivation of drugs at low pH [22, 51], and (iii) the slow growth rate of H. pylori. 
Metronidazole, clarithromycin, amoxicillin and tetracycline are the most widely used 
antimicrobial drugs for treatment of H. pylori [99] (Table 1). Fluoroquinolones, 
nitrofurans, and rifamycins are occasionally used as alternatives [40, 45, 52, 143, 164]. 
None of the above-mentioned antibiotics is effective enough to be used as monotherapy. 
Successful eradication of H. pylori therefore requires combination therapy, consisting of 
one or more antibiotics in combination with an acid-suppressive drug and/or a bismuth 
component. 
Inclusion of an acid-suppressive drug was shown to increase the efficacy of the 
combination therapy [146]. There is a preference for the use of proton pump inhibitors 
(PPI), such as omeprazole and lansoprazole rather than H2-receptor antagonists, even 
though H2-receptor antagonists-based regimens, in particular those with ranitidine, were 
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shown to be equally effective as PPI-based ones [50]. Acid-suppressive drugs primarily 
increase the intragastric pH, and enhance the activity of the antibiotics. An additional 
beneficial effect of acid-suppressive drugs is that they decrease the severity of side effects 
of a given regimen [9], resulting in an increased compliance and chance for successful 
treatment. 
Bismuth salts have already been used in medicine since the 19th century, particularly in 
the treatment of peptic diseases. Colloidal bismuth subcitrate, bismuth subsalicylate and 
the newer ranitidine bismuth citrate (acid inhibitor combined with a bismuth compound) 
are commonly used agents in anti-H. pylori therapy [15]. The mode of action of bismuth 
salt on H. pylori is complex and includes inhibition of protein, ATP, and cell wall 
synthesis [85]. Although bismuth monotherapy effectively suppresses growth of H. pylori, 
the eradication rates with this therapy are low [48]. However, when used in combination 
with one or two antibiotics, these compounds have synergistic activity. While bismuth-
based triple and quadruple therapies seem to be even more effective against H. pylori 
infection than PPI-based therapies, they are usually not given as first-line treatment, 
because of their more complex dosing schedule and/or frequent side effects [39]. 
Triple therapies consisting of two of the previous mentioned antibiotics, and a PPI or 
ranitidine bismuth citrate for 7-10 days are now mostly recommended [19, 43, 90]. There 
seems to be preference for combination therapy that includes amoxicillin and clarithro-
mycin [90]. Despite good results in many clinical trails, these therapies are not always as 
successful in daily clinical practice. Failure of first-line therapy is usually related to 
insufficient patient compliance and/or development of antibiotic resistance. For retreat-
ment, 10 to 14 day treatment courses with higher doses of the antibiotics and/or bismuth 
component is often advised, usually with inclusion of previously unused antibiotics [40]. 
Standard third-line ‘rescue’ therapies are lacking due to a limited choice of antibiotics 
and the need to individualized treatment depending on which therapies previously failed. 
Most patients who remain H. pylori-positive after two consecutive courses of eradication 
treatment have been infected with an H. pylori strain that is resistant to one or more of the 
previously used antibiotics [96, 148]. To select an appropriate third-line treatment, 
endoscopy followed by bacterial culture and antibiotic susceptibility testing is advisable. 
An overview of the commonly used dual-, triple- and quadruple therapies is given in 
Table 2. 
 
 
3. PREVALENCE OF ANTIMICROBIAL RESISTANCE 
 
As antibiotic resistance in H. pylori seems to be the main reason of therapy failure, 
detection of antibiotic resistance is of importance. Antibiotic susceptibility of H. pylori is 
usually assessed by culture-based methods such as E-test, agar dilution and disc diffusion. 
These methods offer the opportunity to determine the minimal inhibitory concentration 
(MIC) of antibiotics, but on the other hand they are time-consuming and results are not 
always consistent [100, 147]. Factors such as cell viability, inoculation size, incubation 
conditions, and growth media may affect their outcome [57]. Molecular-based methods 
are independent of these factors, and thus they offer an attractive alternative. These tests 
give reproducible results and are easily standardized. Moreover, they are faster than the 
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conventional culture-based assays, and when applied directly on gastric biopsy samples, 
data can be obtained at the day of endoscopy. Currently available molecular detection 
methods are summarized in Table 4 and will be discussed in paragraph 6.  
The prevalence of antibiotic resistance in H. pylori has been assessed worldwide. 
However, most studies originated from single centers, included only a small number of 
strains, were often restricted to selected patients, and used different techniques to assess 
antibiotic susceptibility. Antibiotic resistance rates should preferentially be obtained from 
large-scale multicenter surveillance programs using standardized detection methods in 
order to reduce the probability of under- or overestimation of the prevalence of antibiotic 
resistance in H. pylori. However, these surveillance programs are expensive; and only 
performed in few countries [12, 42, 60, 71, 72, 100, 105, 160], more often investigator 
driven rather than government induced.  
Antibiotic resistance in H. pylori is already widespread and increasing. Metronidazole 
resistance (MIC > 8 mg/L) is the most common antimicrobial resistance in H. pylori. In 
industrialized countries approximately 35% of the H. pylori strains are metronidazole-
resistant [42, 105], whereas in developing countries, the H. pylori resistance rates for 
metronidazole are very high, and in some areas virtually all H. pylori strains are metro-
nidazole-resistant [36]. This correlates with the frequent use of metronidazole and related 
nitroimidazoles for gynaecological-, dental-, and parasitic-related diseases [97].   
In comparison with metronidazole resistance, the prevalence of clarithromycin 
resistance (MIC ≥ 2 mg/L) in H. pylori is much lower. In industrialized countries, 
approximately 10% of the H. pylori strains is clarithromycin-resistant [33, 42, 105]. In 
developing countries, resistance rates to clarithromycin are higher and vary between 25 to 
50% [102, 141, 153]. 
Until the end of the 20th century, it was thought that amoxicillin resistance 
(MIC ≥ 0.5 mg/L) and tetracycline resistance (MIC ≥ 4 mg/L) were very rare or absent in 
H. pylori. This is in contrast with various other bacteria, where resistance to these 
antibiotics is widespread. However, the incidence of amoxicillin and tetracycline 
resistance in H. pylori seems to increase [18, 28, 30, 102], especially in certain geographic 
regions (e.g. Italy, Brazil, Salvador, India, and Lithuania), where these antibiotics can be 
obtained without prescription. H. pylori resistance rates of 72% and 59% for amoxicillin 
and tetracycline, respectively, have recently been reported in Shanghai, China [161]. 
 
 
4. CLINICAL IMPACT OF ANTIBIOTIC RESISTANCE 
 
Numerous studies have shown that antimicrobial resistance significantly impairs the 
efficacy of anti-H. pylori therapy [63, 84, 149], nevertheless, the clinical relevance of 
antibiotic resistance in H. pylori-associated diseases is still challenged. The extent to 
which antibiotic resistance reduces H. pylori eradication rates depends on a variety of 
factors, such as the components used in therapy, the dose of the antimicrobial drugs, the 
duration of therapy, and the level of resistance present in the H. pylori strain [148, 162].  
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Several studies have shown that when a patient is colonized with a metronidazole-
resistant H. pylori strain, the eradication rates of metronidazole-containing PPI-based 
triple therapies drops about 20%, from 93% (86-100%) for metronidazole-susceptible 
strains to 71% (45-94%) for resistant strains [63, 98, 149]. Metronidazole resistance may 
even have a larger impact on eradication rates obtained with metronidazole-containing 
PPI-based triple therapies. With these therapies, eradication rates was 91% (56-97%) for 
susceptible strains versus 63% (17-96%) for resistant strains [63, 98, 149]. Addition of a 
bismuth component to a PPI-based therapy (quadruple therapy) increased the efficacy of 
the therapy, from 91% (80-100%) for metronidazole-susceptible strains versus 77% (53-
100%) for resistant strains [149]. Although studies on ranitidine bismuth citrate-based 
triple therapies versus metronidazole resistance are limited, it seems that the eradication 
rates were almost similar to that of the quadruple therapy, 99% (97-100%) for 
metronidazole-susceptible strains to 76% (57-95%) for resistant strains [19, 63]. 
As the prevalence of clarithromycin resistance in H. pylori is low, most studies that 
assessed the effect of clarithromycin resistance on therapy efficacy only included a small 
number of patients. Despite this limitation, it seems that clarithromycin resistance reduces 
the efficacy of all clarithromycin-containing regimens dramatically [98]. The eradication 
rates of clarithromycin-containing dual therapies (PPI or bismuth compounds) decreased 
approximately with 40%, from 67% (62-74%) for clarithromycin-susceptible strains to 
28% (20-40%) for clarithromycin-resistant strains [98]. Although the eradication rates for 
clarithromycin-containing triple therapies (PPI and amoxicillin or metronidazole) increa-
sed (90%) for clarithromycin-susceptible strains, the rates remained low (36%) for 
clarithromycin-resistant strains [63, 98].  
Therapy failure due to the presence of amoxicillin- and tetracycline-resistant H. pylori 
strains has been reported [27, 29, 30, 106, 122], however there is not enough data 
available yet to measure the impact of these resistances on treatment success.  
 
 
5. MOLECULAR MECHANISMS OF ANTIBIOTIC RESISTANCE  
 
Antibiotic resistance in H. pylori has been described for all of the above-mentioned 
antibiotics. The molecular mechanisms of antibiotic resistance characterized thus far are 
all based on point mutations located on chromosome (Table 1). This is in contrast with 
antibiotic resistance mechanisms observed in other bacteria, where they are frequently 
located on plasmids, transposons or integrons [44]. In H. pylori the majority of antibiotic 
resistances probably arise de novo, although in vivo horizontal gene transfer among 
susceptible and resistant strains has been described [127].  
    
5.1 Metronidazole activity and mechanism of resistance  
 
Metronidazole was initially promoted for the treatment of gynaecological infections 
caused by Trichomonas vaginalis, but soon it became apparent that the drug was also 
active against anaerobic and some microaerophilic bacteria [35, 103]. As metronidazole is 
actively released into the gastric juice [152] and its antimicrobial activity is only margi-
nally affected by low pH [22], this drug is highly effective against H. pylori.  
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Metronidazole is administered as a prodrug that needs to be activated within the target 
cell by one or two electron reduction processes (Figure 1A). This reduction leads to the 
formation of nitro-anion radicals and metronidazole intermediates that cause lethal 
damage to subcellular structures and DNA [126]. Theoretically, any protein that possesses 
a low redox potential can accept electrons from metronidazole, and thus activate the drug. 
In H. pylori several putative electron acceptors have been identified, including ferredoxin 
(fdxA), ferredoxin-like protein (fdxB), flavodoxin (fldA), NAD(P)H flavin nitroreductase 
(frxA), 2-oxoglutarate oxidoreductase (oorD), pyruvate:ferredoxin oxidoreductase (porD), 
and oxygen-insensitive NAD(P)H nitroreductase (rdxA) [3, 139].  
In H. pylori, levels of metronidazole resistance are very diverse, with MICs ranging 
from 8 to ≥ 256 mg/L [21, 78]. This spread in MIC values suggests that high-level metro-
nidazole resistance can result from mutational changes in one locus, but it is more likely 
that several pathways are involved. Potential mechanisms of metronidazole resistance 
studied in H. pylori include (i) deficient drug uptake and/or increased drug efflux [83, 
108]; (ii) enhanced activity of DNA repair enzymes [14, 137]; (iii) increased oxygen-
scavenging capabilities [104, 129]; and (iv) decreased drug activation arising from 
changes in metronidazole-reducing enzymes [46, 78, 80].  
Metronidazole is a typical substrate of resistance-nodulation-division (RDN) multiple-
drug efflux mechanism that plays a role in the antibiotic resistance of several bacteria. In 
the H. pylori genome three putative RDN efflux systems have been identified [8]. When 
these three RDN operons were mutated, it did not affect the in vitro susceptibility of 
H. pylori to nineteen antibiotics. Although metronidazole was not included in this study, it 
was suggested that the expression levels of these proteins were too low to influence 
antibiotic susceptibility in general [8]. 
The recA gene encodes a protein that plays an essential role in DNA recombination 
and DNA repair. In H. pylori, a recA homologue has been identified and functionally 
characterized. H. pylori mutants with an inactivated recA gene are severely impaired in 
their ability to survive UV light treatment and exhibit enhanced susceptibility to metroni-
dazole [14, 137]. Although transfer of the recA gene of several metronidazole-resistant 
H. pylori strains to metronidazole-susceptible H. pylori strains resulted in an increased 
MIC of metronidazole, sequence analysis did not established that observed resistance was 
caused by mutational changes in the recA gene [14]. 
Classic NAD(P)H oxidase activities have been found in several organisms, including 
H. pylori [129]. The exact role of this type of enzymes in metronidazole resistance is 
unknown, but it has been postulated that they are involved in scavenging of oxygen. 
NADPH oxidase activity was almost identical for metronidazole-susceptible and metro-
nidazole-resistant H. pylori isolates, whereas NADH oxidase activity was three times 
higher in metronidazole-susceptible H. pylori isolates than in metronidazole-resistant 
H. pylori isolates [67, 129]. Low levels of NADH oxidase may compromise intracellular 
oxygen tension, allowing the redox potential to rise sufficiently to prevent the activation 
of metronidazole, leading to metronidazole resistance. In H. pylori, no genes homologous 
to NADH oxidase have been found; however, the NADH oxidase activity seems to be 
associated with the proteins pyruvate oxidoreductase, alkyl hydroperoxide reductase, and 
glutathione reductase [104, 129, 144]. 
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Figure 1. Mode of action of metronidazole and the proposed mechanisms of metronidazole resistance in 
H. pylori. (A) Metronidazole is a prodrug that needs to be activated within the target cell by one (oxygen-
sensitive) or two (oxygen-insensitive) electron reduction processes. Reduction of metronidazole leads to the 
formation of nitro-anion radicals and metronidazole intermediates (NO2- and NO22-) that cause lethal damage to 
subcellular structures and DNA. (B) Proposed mechanism of metronidazole resistance in H. pylori. 
Metronidazole resistance in H. pylori is mediated by  1  mutations in the rdxA gene;  2  mutations in the frxA and 
fdxB genes; and/or  3  decreased levels of NADH oxidase that compromise intracellular oxygen tension. 
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An important step in the elucidation of the molecular mechanism of metronidazole 
resistance in H. pylori came with the discovery that null mutations in the rdxA gene 
induced metronidazole resistance in a formerly metronidazole-susceptible strain [50]. 
Many studies have subsequently shown that the majority of metronidazole-resistant 
H. pylori strains contain various mutations within the rdxA gene, including frameshifts, 
premature stop codons, insertion of transposable elements, codon changes resulting in 
amino acid substitution, and promoter alterations [6, 23, 68, 69, 82, 135]. However, it 
soon became apparent that the mechanism of metronidazole resistance in H. pylori was 
even more complex, as indications for the involvement of other reducing factors became 
available [69, 78-80]. Mutational changes of the frxA and fdxB genes may contribute to 
metronidazole resistance [69, 78-80].  
As metronidazole-resistant H. pylori isolates in vitro become metronidazole-
susceptible after exposure to short periods of anaerobiosis [13, 128], it was suggested that 
metronidazole susceptibility may be restored at low oxygen conditions through the 
activation of potential anaerobic reduction pathways that function less, or not all, under 
microaerophilic conditions. [67, 129]. Using the protein synthesis inhibitor chloramphenicol, 
the loss of metronidazole resistance under anaerobic conditions still occurred. This 
suggests that metronidazole is reduced by processes that work under anaerobic conditions 
and does not require de novo protein synthesis (Chapter 7). 
A schematic overview of the molecular mechanisms underlying metronidazole resistance 
in H. pylori is given in Figure 1B. 
 
5.2 Clarithromycin activity and mechanism of resistance  
 
Clarithromycin is a bacteriostatic antibiotic that belongs to a group of macrolides that bind 
to peptidyl transferase loop of domain V the 23S rRNA molecule. This binding interferes 
with protein elongation, and thus effectively blocks bacterial protein synthesis. The 
antibacterial activity of clarithromycin is similar to that of other macrolides, but clarithro-
mycin is better absorbed in the gastric mucus layer, more acid-stable, and therefore more 
effective against H. pylori [117].  
Resistance to clarithromycin in H. pylori is caused by point mutations in two adjacent 
23S rRNA nucleotides, namely 2142 and 2143. It can be induced by an adenine (A) to 
guanine (G) substitution at one of these positions [155] or an adenine (A) to cytosine (C) 
substitution solely at position 2142 (Figure 2) [132]. In H. pylori these substitutions cause 
decreased affinity of the ribosomes for several macrolides, resulting in increased 
resistance [111]. The A2142G and A2142C (underlined letters are used to represent the base 
pair changes) were significantly more present in isolates with a higher MIC of 
clarithromycin (> 64 mg/L), whereas the A2143G substitution was often found in isolates 
with a lower MIC (< 64 mg/L) [111, 150, 154, 155]. Occasionally, other 23S rRNA 
mutations have also been reported for H. pylori; some of them are associated with high-
level resistance, while others are associated with low-level resistance [34, 54, 64, 65, 70, 
124, 140, 157]. To define the apparently high prevalence of the A to G at position 2142 
and 2143 (Table 3) among clarithromycin-resistant H. pylori clinical isolates, site-directed 
mutants were created containing either a G, C, or T (thymine) substitution at position 
2142 or 2143. In a similar isogenic background it was seen that the preference for A to G 
substitutions results from higher growth rates, higher MICs and more stable resistance 
[20, 158].  
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Figure 2. Proposed mechanism of clarithromycine resistance in H. pylori. Schematic representation of domain V 
of the H. pylori 23S rRNA, modified from 23S rRNA structure of Escherichia coli proposed by Vester et al. 
[156]. The nucleotide changes, i.e. A2142G/C and A2143G (numbering according to the 23S rrlA gene of H. pylori 
strain 26695) are associated with clarithromycin resistance in H. pylori. 
  
 
Table 3. Prevalence of 23S rRNA gene mutations conferring clarithromycin resistance in 
H. pylori.  
 
Prevalence 23S rRNA mutation Geographic region 
A2142G A2142C A2143G 
Europe [1, 151] 23-33% 2-10% 44-67% 
North America [132, 154] 48-53% 0-7% 39-45% 
South America [121, 124] 6-19% 0% 74%-83% 
Middle-East [107] 5% 15% 75% 
Far-East [32, 88, 92, 163] 0-8% 0% 66-100% 
  
 
H. pylori contains two 23S rRNA genes and mutations are generally found in both 
copies, however, heterogeneity has been described [65, 132, 155]. Heterogeneity still 
results in clarithromycin resistance, but it generally appears to be associated with lower 
resistance levels than present in homogenic isolates [65, 132]. The higher prevalence of 
homogeneity over heterogeneity in H. pylori may reflect a high efficiency of DNA 
recombination in this organism. The mutation in one copy of the 23S rRNA may be easily 
transferred to the other 23S rRNA gene by efficient homologous DNA recombination 
under selective pressure, conferring higher levels of clarithromycin resistance.  
V
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G
2150
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As expected, clarithromycin resistance coincides with resistance to other macrolides 
[158]. The A2142G and A2142C mutations are linked to high-level cross-resistance to all 
macrolides, whereas the A2143G mutation give rise to high-level resistance to erythro-
mycin and intermediate-level resistance to clindamycin and streptogramin [37, 158].  
 
5.3 Amoxicillin activity and mechanism of resistance   
 
Amoxicillin is a bactericidal antibiotic that belongs to group of penicillins. It binds to 
penicillin-binding proteins (PBPs), and thus interferes with bacterial cell wall synthesis, 
resulting in the lyses of replicating bacteria. The antibacterial affect of amoxicillin is 
similar to that of other β-lactam antibiotics, but amoxicillin is released in the gastric juice 
[110], and thus frequently used in anti-H. pylori therapy. Until recently, it was thought 
that amoxicillin resistance in H. pylori did not exist, although resistance to this 
antimicrobial drug could be induced by continuous exposure of H. pylori to amoxicillin in 
vitro [24, 116].  
In Gram-negative bacteria, resistance to β-lactam antibiotics is mostly due to the 
production of β-lactamase, either chromosomally, or plasmid encoded [11]. In H. pylori, 
however, there are no indications that amoxicillin resistance is due to the acquisition or 
expression of β-lactamase, since no β-lactamase activity has been detected by nitrocephin 
or cephalosporinase assays (Chapters 8-10, and [26-28, 77, 113]). Other potential 
mechanisms in H. pylori that have been studied in relation to amoxicillin resistance are 
(i) structural alterations in penicillin-binding proteins (PBPs); (ii) decreased membrane 
permeability; and (iii) active efflux (Chapter 9, and [8, 24, 77]).  
PBPs are enzymes that are involved in the synthesis and maintenance of the 
peptidoglycan layer of the bacterial cell wall [53]. In H. pylori nine putative PBPs have 
been identified; three high-molecular-weight PBPs and six low-molecular-weight PBPs 
[26, 56, 66, 73]. Two of these proteins have been associated with amoxicillin resistance in 
H. pylori. At first, the molecular mechanism was described for amoxicillin-resistant 
H. pylori isolates (MIC > 256 mg/L) obtained from dyspeptic patients from Italy and the 
United States. As these isolates lost their resistance phenotype upon freezing at -80°C 
[28], they are often referred to amoxicillin-tolerant. PBP binding studies using 3H-benzyl-
penicillin have shown that amoxicillin resistance in these amoxicillin-tolerant H. pylori 
isolates is mediated by a lack of PBP-D (also called PBP4) [26]. Whether the decreased 
labeling was caused by reduced expression of the pbpD gene or decreased affinity of PBP-D 
to amoxicillin was not further discussed.  
Later, stable amoxicillin-resistant H. pylori isolates were obtained with MICs ranging 
from 8 to 64 mg/L (Chapters 8 and 10, and [27, 77, 113]). Amoxicillin resistance in these 
isolates was caused by various point mutations in the pbp1A gene (Chapter 9-10, and [27, 
77, 113]). Additional proof for the role of PBP1A in H. pylori amoxicillin resistance was 
provided by PBP binding studies using biotinylated amoxicillin. Labeling of PBP1A was 
significantly decreased in amoxicillin-resistant H. pylori isolates compared to amoxicillin-
susceptible H. pylori isolates [24, 113]. This decrease in labeling was caused by reduced 
affinity of PBP1A for amoxicillin, instead of diminished production of PBP1A molecules 
[24, 113].  
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In addition to changes in the pbp1A gene, it was postulated that reduced membrane 
permeability and/or active efflux of amoxicillin in H. pylori might also contribute to 
higher levels of amoxicillin resistance. Both aspects have been tested in a quantitative 
uptake experiment using the proton translocator CCCP. In this experiment it was seen that 
amoxicillin-resistant H. pylori strains accumulated <60% [14C]-penicillin G compared to 
amoxicillin-susceptible H. pylori strains, both in the presence and absence of CCCP; 
excluding the role of an active efflux mechanism. This suggests that amoxicillin resistance 
in H. pylori in part is due to an increased diffusional barrier [24, 77], an effect that may be 
explained by alterations in outer membrane proteins [77].  
The molecular mechanisms underlying amoxicillin resistance in H. pylori are summarized 
in Figure 3. 
 
 
 
Figure 3. Schematic overview of proposed mechanisms of amoxicillin resistance in H. pylori. Amoxicillin 
resistance in H. pylori is mediated by  1  decreased membrane permeability; and/or  2  reduced affinity of PBP 
molecules, PBP1A and PBP-D, for amoxicillin.  
 
 
5.4 Tetracycline activity and mechanism of resistance  
 
Tetracycline is a bacteriostatic antibiotic that is active against several Gram-positive and 
Gram-negative bacteria, including H. pylori. It accumulates in the cytoplasm, where it 
binds to the 30S ribosomal subunit. Here it interferes with the attachment of aminoacyl-
tRNA to the ribosome, and inhibits protein synthesis and bacterial growth [10, 119].  
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Tetracycline is an antibiotic that is extensively used in many industrialized countries, 
and as a consequence resistance to this drug has become an emerging problem. In general, 
four tetracycline resistance mechanisms have been identified: (i) deficient drug uptake 
and/or increased drug efflux; decreased antibiotic binding by (ii) changes in ribosomal 
protection proteins, or (iii) mutations 16S rRNA tetracycline binding site; and (iv) 
enzymatic inactivation of tetracycline [17]. In H. pylori only the first three mechanisms 
have been studied (Chapter 3, and [8, 18, 145]), since orthologs of tetracycline-degrading 
enzymes are absent in the H. pylori genome sequence [139].  
In many bacteria, resistance to tetracycline is due to an energy-dependent efflux of 
tetracycline-cation complexes across the cell membrane by membrane-associated proteins. 
The exchange of tetracycline-cations by protons reduces the intracellular drug concen-
tration and protects ribosomes against tetracycline. Overexpression of the efflux proteins 
often confers multidrug resistance, while deletions in these operons increases tetracycline 
susceptibility [17]. In H. pylori the role of several putative efflux proteins in tetracycline 
resistance has been assessed by mutagenesis [8] and natural transformation (Chapter 3). 
However, none of the tested efflux systems seems to play a role in tetracycline resistance 
of H. pylori (Chapter 3, and [8]).  
The second common mechanism that mediates tetracycline resistance acts by 
ribosomal protection proteins. These cytoplasmic proteins confer tetracycline resistance 
either by reduced affinity of ribosomes for tetracycline, or by released binding of the drug 
to the ribosomes [17]. Although the H. pylori genome encodes for several proteins that 
have homology with the known ribosomal protection proteins, such as elongation factors 
EF-G, EF-Tu, and initiation factor IF-2, transformation experiments have shown that they 
probably are not involved in tetracycline resistance of H. pylori (Chapter 3).  
The most likely mechanism for tetracycline resistance in H. pylori is based upon a 
triple-base-pair substitution in three adjacent 16S rRNA residues, namely AGA926-928TTC 
(Figure 4) (Chapters 3-5, and [18, 145]). This mutation is located in the primary binding 
site of tetracycline, and may affect the affinity of the drug-ribosome interaction and thus 
reduce the efficiency of tetracycline as translational inhibitor. Besides this triple-base-pair 
substitution, AGA926-928TTC (Chapters 3 and 5, and [145]), several single- and double-
base-pair substitutions, i.e. A926G, A926T, A928C, AG926-927GT and A926G/A928C have been 
reported to be involved in tetracycline resistance in H. pylori [18]. High-level tetracycline 
seems to be related to the triple-base-pair substitution only (Chapters 3-5, and [145]), 
whereas low-level tetracycline resistance (MICs below susceptibility breakpoint of 4 mg/L) 
is associated the single- and double-base-pair substitutions (Chapters 4 and 6, and [18]). 
Using site-directed mutagenesis, it was demonstrated that the preference for the 
AGA926-928TTC mutation in high-level tetracycline resistance apparently results from 
higher growth rates in the presence of tetracycline, higher MICs and more stable 
resistance (Chapter 4).   
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Figure 4. Proposed mechanism of tetracycline resistance in H. pylori. Schematic representation of the primary 
binding site of tetracycline in H. pylori, modified from the 16S rRNA structure of H. pylori proposed by Trieber 
et al. [145]. In H. pylori the primary binding site for tetracycline is formed by the residues by the 16S rRNA 
residues 1020-1023 (Box A), 1162-1166 (Box B), and 925-928 (Box C) The nucleotide changes AGA926-928TTC 
(numbering according to the 16S rrnA gene of H. pylori strain 26695) located in box C is associated with clinical 
relevant levels of tetracycline resistance in H. pylori.  
 
 
5.5 Activity of to less commonly used antibiotics and their mechanism of resistance 
 
As resistance against the four commonly used antibiotics of the anti-H. pylori therapy is 
increasing, fluoroquinolones, nitrofurans and rifamycins are occasionally being introduced 
in second- and third-line therapies [40, 45, 143, 164]. Initial results obtained with these 
antibiotics were promising, but soon the eradication rates dropped as resistance against 
these drugs developed [21, 62, 81, 102, 109, 136]. The underlying resistance mechanisms 
have been characterized and will be discussed in the next paragraphs.   
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5.5.1 Fluoroquinolones 
Fluoroquinolones (i.e. ciprofloxacin, moxifloxacin, trovafloxacin and levofloxacin) are 
bactericidal antibiotics that exert their antimicrobial activity by inhibiting the enzyme 
DNA gyrase. This enzyme is a tetramer consisting of two A subunits and two B subunits, 
encoded by the gyrA and gyrB genes, respectively [109]. The main function of this 
enzyme is to catalyze the negative supercoiling of DNA [123]. Most H. pylori isolates are 
susceptible to fluoroquilones, but the incidence of fluoroquinolone resistance seems to 
increase [71]. In H. pylori, the resistance is caused by point mutations in the so-called 
quinolone resistance-determining region (QRDR, located between amino acid position 67 
and 106) of the gyrA gene at amino acids position 87, 88, 91 and 97 [109, 136].  
 
5.5.2 Nitrofurans 
Furazolidone and nitrofurantoin are nitroheterocyclic and nitroaromatic compounds that 
share similarities with metronidazole both in their structures and modes of action. 
H. pylori is usually susceptible to furazolidone and nitrofurantoin, but occasionally strains 
with an increased MIC have been reported [81, 102]. The resistance mechanism of 
furazolidone and nitrofurantoin is currently unknown, but it is clear that it differs from 
that of metronidazole, since inactivation of the rdxA, frxA and fdxB genes, did not result in 
furazolidone or nitrofurantoin resistance [81].   
 
5.5.3 Rifamycins 
Rifabutin and several other derivates of rifampin are bactericidal antibiotics that bind to 
the β-subunit of DNA-dependent RNA polymerase, resulting in inhibition of transcription 
[76]. The β-subunit of this complex is encoded by the rpoB gene [76]. Until a few years 
back resistance against rifamycins and rifabutin in vivo was very rare, however, the 
incidence of rifamycin and rifabutin resistance is increasing [71]. In H. pylori resistance to 
these antibiotics is linked to various point mutations in the rpoB gene (corresponding to 
amino acid codon 149, 524-545 and 586) [59, 61, 62].  
 
 
6. MOLECULAR DETECTION OF ANTIBIOTIC RESISTANCE 
 
Since in H. pylori most resistances is due to specific mutations, molecular-based methods 
offer an attractive alternative to the conventional culture-based methods. Molecular-based 
methods are independent of cell viability or growth rate of the bacteria, and thus more 
consistent and reproducible than the culture-based ones. Moreover, molecular-based 
methods are much faster, and if directly applied to gastric biopsy specimens, results can 
be obtained at the day of endoscopy. Although DNA sequencing is the gold standard for 
the detection of mutational changes, this method is not cost effective in a routine setting. 
Numerous molecular-based methods are now available to assess clarithromycin, tetracycline, 
and ciprofloxacin resistance in H. pylori (Table 4), but lack for the assessment of  
metronidazole and amoxicillin resistance.  
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6.1 Molecular detection of metronidazole resistance in H. pylori 
 
The development of rapid, genotype-based tests for metronidazole resistance in H. pylori 
is not easy, because the resistance is associated with various unrelated mutations within 
the rdxA gene and other reductase-encoding genes. Despite these barriers, there is new 
evidence that indicates that a system could be developed based on detection of the RdxA 
protein. Using immunoblot with specific anti-RdxA antibody [87], a 24 kDa immuno-
reactive band was observed in all metronidazole-susceptible isolates but was absent in 
most (90%) metronidazole-resistant isolates [86].  
 
6.2 Molecular detection of clarithromycin resistance in H. pylori 
 
Numerous techniques have been developed for the detection of clarithromycin resistance 
in H. pylori. Most assays are polymerase chain reaction (PCR)-based using different 
methods to study the amplicons. Restriction fragment length polymorphism (RFLP) is an 
simple method that is based on the occurrence of restriction site within the amplicon. This 
assay allows for the detection of the previously mentioned 23S rRNA mutations using the 
restriction endonucleases, MboII (A2142G), BbsI (A2142G), BsaI (A2143G) and BceAI 
(A2142C) [101, 111, 134, 154]. As the PCR-RFLP was initially not able to detect the 
A2142C mutation, a 3'-mismatch reverse primer PCR method (3M-PCR) was developed [2].  
Other methods, such as PCR-DNA enzyme immunoassay (DEIA), PCR oligonucleotide 
ligation assay (OLA), preferential homoduplex formation (PHFA) and PCR-line probe 
assay (LipA), include an additional hybridization step after the PCR. The PCR products 
were hybridized with labeled oligonucleotide probes under highly stringent conditions and 
hybrids were subsequently detected with specific antibodies or streptavidin-alkaline 
phosphatase [89, 118, 132, 150].  
Recently, several real-time PCR hybridization assays have been developed. In these 
assays a 23S rDNA fragment is amplified in the presence of a fluorescent-labeled 
mutation and anchor probe. When these probes hybridize with the PCR product, a 
fluorescence signal is emitted. After completion of the PCR, the temperature is increased 
to determine the melting point of the mutation probe. The temperature at which the 
fluorescent signal drops indicates the point at which the mutation probe dissociates 
(melting point). When there are mismatches present in the target sequence, lower melting 
temperatures are obtained compared to the matched hybrid. This technique is simple and 
quick, and if applied directly on gastric tissue, results can be obtained within 3 hours [16, 
38, 93, 114]. 
There is also a possibility to detect clarithromycin resistance without performing PCR, 
by using fluorescence in situ hybridization (FISH). In this assay intact H. pylori are 
hybridized with fluorescent-labeled H. pylori-specific 16S and 23S rRNA probes. The 
labeled bacteria were subsequently visualized by fluorescence microscopy. This assay 
allows detection of H. pylori and clarithromycin resistance simultaneously. Moreover, this 
assay does not require DNA preparation and can directly be applied to gastric biopsy 
samples [142].  
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6.3 Molecular detection of other antibiotics resistances in H. pylori  
  
As the molecular mechanism underlying tetracycline resistance in H. pylori has only 
recently been identified, data on molecular detection techniques are still limited. Thus far, 
two PCR-based methods have been developed; (i) a PCR-RFLP (Chapter 5), and (ii) a 
real-time PCR assay (Chapter 6). In addition to the molecular detection methods for 
clarithromycin and tetracycline a real-time PCR assay has been develop for ciprofloxacin 
resistance based on the same principle [41]. 
 
 
Table 4. Molecular methods for detection of clarithromycin, metronidazole and 
tetracycline resistance in H. pylori. 
 
Antibiotic Molecular method References 
Metronidazole Immunoblotting with specific antibodies [86, 87] 
   
Clarithromycin PCR-restriction fragment length polymorphism (RFLP) [101, 111, 134, 154] 
 PCR-oligonucleotide ligation assay (OLA) [132] 
 PCR-DNA enzyme immunoassay (DEIA)  [118] 
 PCR-line probe assay (LipA) [150] 
 PCR-preferential homoduplex formation assay (PHFA)  [89] 
 3'-mismatched reverse primer PCR (3M-PCR)  [2, 31] 
 Real time PCR hybridization assay  [16, 38, 93, 114] 
 Fluorescent in situ hybridization (FISH) [142] 
   
Tetracycline PCR-restriction fragment length polymorphism (RFLP) Chapter 5 
 Real time PCR hybridization assay  Chapter 6 
   
Ciprofloxacin Real time PCR hybridization assay  [41] 
 
 
7. CONCLUSIONS  
 
Antibiotic resistance in H. pylori is widespread and further increasing. This constitutes a 
considerable clinical problem, as antibiotic resistance negatively affects the efficacy of 
anti-H. pylori therapy. For this reason antibiotic resistance in H. pylori should be 
monitored. Data obtained in such a surveillance program are of great value to guide anti-
H. pylori therapy and help to gain a better understanding of the effect of resistance on 
therapy outcome. However, in most countries, including The Netherlands, these surveillance 
programs are lacking, and therapy recommendations may be based on insufficient data.  
Conventional culture-based susceptibility testing of H. pylori is relatively slow and 
cumbersome. Thus molecular-based methods offer an attractive alternative. Using the 
knowledge on molecular mechanisms underlying antibiotic resistance in H. pylori, as 
described in this review, several molecular-based method have been developed (Table 4). 
It is likely that real-time PCR will have an expanding role in the rapid detection of 
antibiotic resistance in H. pylori, particularly if results are obtained directly from gastric  
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biopsy samples without the need for cultivation. Since for amoxicillin and metronidazole 
resistance in H. pylori no appropriate tests are available yet, research on the elucidation of 
molecular mechanisms and development of molecular detection methods should be 
continued.   
As novel antibiotics are not rapidly forthcoming the search for new antimicrobial 
agents and co-therapies should be intensified. Antimicrobial peptides [4, 25, 58], porphy-
rines [130], essential oils [7, 112], but also probiotics [47] may prove to be helpful. 
Although initial studies using these components are promising, there is still a long way to 
go before they can and will be used in clinical practice. 
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ABSTRACT 
 
Most Helicobacter pylori strains are susceptible to tetracycline, an antibiotic commonly 
used for the eradication of H. pylori. However, an increase in incidence of tetracycline 
resistance in H. pylori has recently been reported. Here the mechanism of tetracycline 
resistance of the first Dutch tetracycline-resistant (TetR) H. pylori isolate (strain 181) is 
investigated. Twelve genes were selected from the genome sequences of H. pylori 
strains 26695 and J99 as potential candidate genes, based on their homology with 
tetracycline resistance genes in other bacteria. With the exception of the two 16S rRNA 
genes, none of the other putative tetracycline resistance genes was able to transfer 
tetracycline resistance. Genetic transformation of the tetracycline-susceptible (TetS) 
strain 26695 with smaller overlapping PCR fragments of the 16S rRNA genes of 
strain 181, revealed that a 361-bp fragment that spanned nucleotides 711 to 1071 was 
sufficient to transfer resistance. Sequence analysis of the 16S rRNA genes of the TetR 
strain 181, the TetS strain 26695, and four TetR 26695 transformants showed that a 
single triple-base-pair substitution, AGA926-928TTC (underlined letters are used to 
represent the base pair changes), was present within this 361-bp fragment. This triple-
base-pair substitution, present in both copies of the 16S rRNA gene of all our TetR 
H. pylori transformants, resulted in an increased minimal inhibitory concentration for 
tetracycline that was identical to that for the TetR strain 181. 
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INTRODUCTION 
 
Helicobacter pylori is a spiral-shaped, Gram-negative bacterium that causes chronic 
infections in the gastric musoca [6]. This infection will persist for life, unless treated with 
antibiotics. Cure of H. pylori infection results in ulcer healing and may reduce the risk of 
gastric cancer and gastric lymphoma [23, 29]. The highest cure rates have been obtained 
with antimicrobial treatments that include two or more antimicrobial drugs, a bismuth 
component and/or a proton pump inhibitor [14, 26]. For the treatment of H. pylori 
infections, tetracycline-based triple or quadruple therapies are often used as a second-line 
treatment [7, 9, 18]. Until the end of the last century only a few reports were published on 
spontaneous tetracycline resistance [16, 19], and it was generally accepted that tetra-
cycline resistance (MIC ≥ 4 µg/ml) in H. pylori is very rare [5, 12]. However, in the last 
2 years an increase in the incidence of tetracycline resistance in H. pylori has been 
reported [2, 11, 13, 21, 31].  
Tetracycline inhibits the protein synthesis by binding to the 30S ribosomal subunit [3, 
20]. In most bacteria resistance to tetracycline is due to an energy-dependent efflux of 
tetracycline-cation complexes across the cell membrane by membrane-associated efflux 
proteins. Export of tetracycline-complexes out of the cell reduces the intracellular drug 
concentration and protects the ribosomes from tetracycline [4]. Overexpression of the 
efflux genes confers tetracycline resistance, while the sensitivity to tetracycline increases 
by deletions in these genes. The second common mechanism of resistance is mediated 
through ribosomal protection proteins. These cytoplasmic proteins confer tetracycline 
resistance either by a reduction of the affinity of ribosomes for tetracycline or by releasing 
the bound antibiotic from the ribosome. The ribosomal protection proteins, such as TetM, 
TetO and TetS show homology with the elongation factors, EF-G and EF-TU (Table 1) 
[4]. Beside these two most common tetracycline resistance mechanisms two other 
mechanisms have been described. One is based on enzymatic inactivation of tetracycline 
by the product of TetX in the presence of oxygen and NADPH, and the other originates 
from mutations in the 16S rRNA genes that affect the binding site of tetracycline [4, 22, 25]. 
We recently isolated a tetracycline-resistant (TetR) H. pylori isolate (strain 181), from 
a 72-year-old male dyspeptic patient. Here we describe the molecular mechanism of 
tetracycline-resistance in this strain. To achieve this, twelve genes were selected from the 
published H. pylori genomes [1, 24] as potential candidates, based on their homology with 
tetracycline resistance genes in other bacteria (Table 1). These putative tetracycline 
resistance genes were amplified from the genome of the TetR strain 181 and used for 
genetic transformation of the tetracycline-susceptible (TetS) strain 26695 in order to 
identify the changes responsible for tetracycline resistance. 
 
 
MATERIALS AND METHODS 
 
Bacterial strains and growth conditions  
H. pylori strains used in this study were the TetR  strain 181, and the TetS H. pylori strains 
26695 [24], J99 [1], SS1 [15], and ATCC 43504 (American Type Culture Collection). 
Bacteria were routinely grown on Columbia agar plates (Becton Dickonson, Cockeysville, 
MD, USA) supplemented with 7% lysed horse blood (BioTrading, Mijdrecht, the 
Netherlands) and H. pylori Dent selective supplement (Oxoid, Basingstoke, UK), referred
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to as Dent plates. Bacteria were inoculated on these plates and incubated for 48 to 72 hours 
at 37ºC in a microaerophilic atmosphere of 5% O2, 10% CO2, 85% N2. Bacterial stocks 
were prepared by suspending bacteria, harvested from culture plates with a sterile cotton 
swab in Brain Heart Infusion (BHI) with 20% glycerol and stored at -80ºC.  
 
Determination of minimal inhibitory concentration  
The minimal inhibitory concentration (MIC) was routinely determined with the E-test 
(AB Biodisk, Solna, Sweden) [8]. Inocula were prepared from a fresh H. pylori culture 
grown routinely for 2 days on Dent plates. Columbia agar plates containing 7% lysed 
horse blood but no Dent supplement were inoculated with approximately 2×108 CFU 
(colony forming units) in 20 µL of 0.9% NaCl, the plates were dried for 3 to 4 minutes, 
and then the E-test strips were applied to the agar surface. The plates were incubated at 
37ºC under microaerophilic conditions, and three days later the MIC was determined by 
the intercept of the zone of inhibition with the graded E-test strip. By this method the 
susceptibility was determined for tetracycline, doxycycline, minocycline, amoxicillin, 
clarithromycin and metronidazole (AB Biodisk). The isolates were considered resistant 
when the MICs of tetracycline, doxycycline, and minocycline were ≥ 4 mg/L, and of 
amoxicillin, clarithromycin and metronidazole were ≥ 8 mg/L, ≥ 2 mg/L and ≥ 8 mg/L, 
respectively [5, 13]. 
 
Natural transformation of H. pylori.  
Bacteria were transformed with ~1 µg genomic DNA, or ~250 ng PCR amplified gene 
products from strain 181, as described previously [28]. TetR transformants were selected 
on Dent plates containing 2 mg/L tetracycline (Sigma Aldrich Chemie, Zwijndrecht, The 
Netherlands). As controls, bacteria were transformed with either genomic DNA of the 
TetR strain, TE (1 mM Tris-HCl, 0.1 mM EDTA, pH 8.0), or DNA from the TetS strains 
26695, J99, SS1, and ATCC43504. Individual bacterial colonies present on tetracycline 
containing plates (2 mg/L) were selected and their MIC of tetracycline was determined. 
 
PCR 
Oligonucleotide primers (Isogen, Maarsen, The Netherlands) used for PCR amplification 
were based on the genome sequences of H. pylori strains 26695 and J99 (Table 1, Figure 1 
and Figure 2) [1, 24]. PCR was performed in an automated thermal cycler (I-Cycler, 
Biorad), in a final volume of 50 µL using the PCR-core system I (Promega, Madison, WI, 
USA), with approximately 25 pg of template genomic DNA and 25 pmol of each primer. 
 
Sequence analysis  
Direct sequencing of the obtained PCR products was performed by Baseclear Inc. 
(Leiden, The Netherlands). Sequence data were analyzed with help of Lasergene 
(DNAstar, Madison, WI, USA), and Sci Ed Central (Scientific & Educational Software, 
Durham, USA) software.  
 
Nucleotide sequence accession number.  
The 16S rRNA gene sequence of the TetR H. pylori strain 181 has been deposited into to 
the Genbank sequence database, under accession no. AF512997. 
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RESULTS 
 
Determination of the MIC against various antibiotics 
MICs of the four commonly used antibiotics in the anti-H. pylori therapy, as well as two 
antibiotics that belong to the tetracycline family, were determined by E-test for the TetR 
H. pylori strain 181 and the H. pylori reference strain 26695 (Table 2). The MIC of 
tetracycline for strain 181 was 8 mg/L (susceptibility breakpoint ≥ 4 mg/L), while the 
MIC for strain 26695 was 0.19 mg/L. The MIC values of the two other tetracyclines, 
doxycycline and minocycline, were also significantly higher for strain 181 than for strain 
26695. For the three other routinely used antibiotics; amoxicillin, clarithromycin, and 
metronidazole the MICs varied between < 0.016 mg/L and 0.064 mg/L and did not differ 
significantly between strains 181 and 26695.  
 
 
Table 2. MIC values of TetR H. pylori strain 181, TetS reference strain 26695, and TetR 
26695 transformants as determined by E-test. 
 
MIC (mg/L)a  Antibiotic 
TetR strain 181 Reference strain 26695 Tet
R 26695 
transformant 
Tetracycline 8 0.19 8 
Doxycycline 12 0.19 12 
Minocycline 8 0.125 6 
Amoxicillin < 0.016 < 0.016 < 0.016 
Clarithromycin < 0.016 < 0.016 < 0.016 
Metronidazole 0.19 0.016 0.064 
a Data shown are the averages of three independent experiments. The isolates were considered resistant when the 
MICs of the tetracyclines (tetracycline, doxycycline, and minocycline), amoxicillin, clarithromycin and metroni-
dazole were ≥ 4 mg/L, ≥ 8 mg/L, ≥ 2 mg/L and ≥ 8 mg/L, respectively [5, 13]. 
 
 
Transfer of tetracycline resistance by natural transformation 
Transformation of H. pylori strain 26695 (MIC, 0.19 mg/L) with genomic DNA of strain 
181 (MIC, 8 mg/L) resulted in TetR colonies with a transformation frequency of 6×10-5 
CFU/µg DNA. The MIC of tetracycline of the ten randomly selected TetR transformants 
(obtained from three independent transformation experiments), determined by E-test was 
8 mg/L (Table 2), which is identical to that of the TetR H. pylori strain 181. The TetR 
transformants also displayed an increase of MIC of the tetracycline derivatives, 
doxycycline and minocycline (Table 2).   
 
Transformation with PCR products of putative tetracycline resistance genes 
Based on their homology with tetracycline resistance genes in other bacteria, twelve genes 
were selected from the published genome sequences of H. pylori strains 26695 [24] and 
J99 [1] (Table 1). The TetS H. pylori strain 26695 was transformed with the PCR products 
of the selected tetracycline resistance genes, which were amplified from genomic DNA of 
the TetR strain 181. Only transformation with the PCR product of the 16S rRNA genes 
resulted in TetR transformants with a transformation frequency of 4×10-5 CFU/µg DNA. 
No TetR transformants were found after transformation with one of the other selected 
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genes, TE or DNA from the TetS strain 26695. Similar results were found for the TetS 
strains J99 (MIC 0.5 mg/L), SS1 (MIC 0.19 mg/L), and ATCC43504 (MIC 0.125 mg/L). 
For all strains the MIC of tetracycline of ten randomly selected TetR transformants 
(obtained from three independent transformation experiments) determined by E-test was 
8 mg/L, which is identical to that of the TetR donor strain 181.  
Comparison of the 16S rRNA gene sequences of the TetR strain 181, the TetS strain 
26695 and four randomly TetR 26695 transformants (obtained after transformation with 
genomic DNA of strain 181) revealed several base pair differences in the TetR strain 181 
as well as in the TetR transformants that did not occur in the TetS strain 26695 (Figure 1). 
Three TetR 26695 transformants had incorporated the complete 16S rRNA gene of strain 
181, while the fourth transformant contained the first part of the 16S rRNA gene of strain 
26695 and the second part of strain 181. The DNA crossover in this transformant occurred 
between nucleotide 93 and 128 (numbering according to 16S rrnA of H. pylori strain 
26695). For each strain or transformant, only one sequence was obtained for the 16S rRNA 
genes, indicating that these 16S rRNA genes were identical in these strains. 
 
 
Figure 1. Schematic representation of the 16S rRNA genes of H. pylori. Alignment of the 16S rRNA genes 
(rrnA and rrnB) from the TetR strain 181, the TetS strain 26695 and four TetR 26695 transformants. Sequence 
analysis of the 16S rRNA genes revealed only a few base pair substitutions (numbering according to 16S rrnA of 
H. pylori strain 26695) in the TetR strain 181 that did not occur in the TetS strain 26695. For the identification of 
the 16S rRNA region required for tetracycline resistance, the TetS strain 26695 was transformed with smaller 
overlapping PCR fragments of the 16S rRNA gene of the TetR strain 181. The transformants were selected on 
tetracycline (2 mg/L) containing Dent plates. Primers used for the amplification of the smaller overlapping PCR 
fragments started at the outside of the fragment and each had a length of 20 bp. 
 
TetR strain 181
TetS strain 26695
TetR transformants
Transfer of resistance
No
Yes
No
91AG92 C128 926TTC928 C1082 T1161
91GT92 T128 926AGA928 T1082 C1161
91AG/GT92 C128 926TTC928 C1082 T1161
1 AG C 360
711 TTC 1071
939 C T 1240
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Identification of 16S rRNA mutations involved in tetracycline resistance 
To determine which residues of the 16S rRNA genes were responsible for tetracycline 
resistance in strain 181, the TetS strain 26695 was genetically transformed with smaller 
overlapping PCR products of the 16S rRNA gene fragments, amplified from genomic 
DNA of the TetR strain 181. TetR 26695 transformants were only observed after 
transformation with a 361-bp DNA fragment that spanned nucleotides 711 to 1071 
(numbering according to 16S rrnA of H. pylori strain 26695), with a transformation 
frequency of 5×10-6 CFU/µg DNA. Transformation with the other DNA fragments did not 
result in transfer of tetracycline resistance. The MIC of tetracycline of ten randomly 
selected TetR transformants determined by E-test was 8 mg/L, which was identical to that 
of the TetR donor strain 181. The only difference found between these TetR 26695 
transformants and TetS strain was the triple-base-pair substitution AGA926-928 TTC (Figure 1).  
 
Both copies of 16S rRNA genes are involved in tetracycline resistance 
The primers that were originally used for amplification of the 16S rRNA genes did not 
distinguish between the two copies present on the H. pylori chromosome [1, 24]. To 
assess the involvement of each copy of the 16S rRNA genes in tetracycline resistance, 
specific oligonucleotide primers were developed (Figure 2). These specific primers are 
based on sequences which are located approximately 350 to 600 base pairs outside the 
both 16S rRNA genes, rrnA and rrnB. This allowed amplification of rrnA and rrnB 
specific sequences. rrnA and rrnB containing PCR-fragments were obtained both for the 
TetR strain 181, the eight 26695 transformants, and TetS strain 26695, and their DNA 
sequences were determined. As expected, the rrnA and rrnB sequences were identical, 
whereas the sequences outside the 16S rRNA genes were different. While the TetS strain-
derived fragments contained the AGA sequence in both genes, both for strain 181 and the 
eight 26695 transformants, the triple-base-pair substitution AGA926-928TTC was found in 
both copies of the 16S rRNA genes.  
 
 
 
Figure 2. Both 16S rRNA genes are mutated in H. pylori tetracycline resistance. rrnA and rrnB specific sequen-
ces were amplified using specific primers based on sequences which are found outside the two 16S rRNA genes. 
The rrnA-specific primers, F1 and F2, are located at position 1207020 and 1207242 (numbers corresponding to 
the H. pylori 26695 sequence [24]), respectively, and the rrnB-specific primers, F3 and F4, are located at 
position 1510569 and 1510809, respectively. For amplification, primer R1 (located at position 1208293 and 
1511828) was used in combination with one of the other primers. All primers had a length of 20 bp. 
 
rrnBHP1439HP1144 rrnA
R1F1 F2 R1F3 F4
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DISCUSSION 
 
Until recently tetracycline resistance in H. pylori was rare [5, 12], but in the last two years 
several TetR H. pylori strains have been isolated [2, 13, 16, 31]. These TetR clinical 
isolates showed, besides tetracycline resistance, cross-resistance to metronidazole [2, 13, 
16, 31] . The tetracycline resistance present in these strains was always transferred 
together with metronidazole resistance to a TetS strain [13]. In these TetR strains it is not 
clear whether the tetracycline resistance is caused by a known metronidazole resistance 
mechanism, a multidrug resistance mechanism, or an unknown tetracycline resistance 
mechanism [13]. In our TetR H. pylori strain 181, no cross-resistance was found against 
metronidazole, which indicated that the molecular mechanism of tetracycline resistance in 
strain 181 could be different from that of these earlier-described TetR H. pylori strains.  
 
 
 
Figure 3. Schematic representation of the primary binding site of tetracycline, based on the 16S rRNA sequence 
of Thermus thermophilus proposed by Wimberly et al. [30]. The primary binding pocket for tetracycline is 
formed by the 16S rRNA residues 1054-1056 (box A) and 1196-1200 (box B) of helix 34, and 964-967 of 
helix 31 (box C). The interaction between tetracycline and this pocket are formed by hydrophobic interactions, 
hydrogen bonds, and salt bridges (3). The triple-base-pair substitution AGA926-928TTC (corresponding to base 
pair 965-967 of E. coli 16S rRNA) is located in box C, and is indicated by asterisks. 
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In H. pylori strain 181 resistance to tetracycline is mediated by a single triple-base-pair 
substitution, AGA926-928TTC (corresponding to basepair 965-967 of Escherichia coli 
16S rRNA) present in both copies of the 16S rRNA gene. Tetracycline has one primary 
and multiple secondary binding sites within the 30S ribosomal subunit (3, 20). In the 
primary binding site, tetracycline binds exclusively to the 3'-major domain of the 
16S rRNA. The primary binding pocket for tetracycline is formed by the 16S rRNA 
residues 1054-1056 and 1196-1200 of helix 34, and 964-967 of helix 31 (numbers 
corresponding to E. coli 16S rRNA) [3]. The residues 1054 and 1196 interact primarily 
with tetracycline through hydrophobic interactions, but the majority of the interaction with 
the drug is made through hydrogen bonds and salt bridges between tetracycline and the 
16S rRNA residues (Figure 3, [3]). In the TetR H. pylori strain 181, the triple-base-pair 
substitution AGA926-928TTC is located right in the primary binding site of tetracycline. 
Mutations in this primary binding site are likely to affect the affinity of the drug-ribosome 
interaction and thus the efficacy of tetracycline as translational inhibitor. 
In E. coli, the nucleotides G966 and C967 are not only located in the primary binding site 
of tetracycline but also in a functional region of the ribosome, the P-site [17, 27]. 
Mutations in this region may affect protein synthesis [10], either by a change in binding of 
tRNA to the P-site itself or by blocking the conformational change needed for the tRNA 
binding to the A-site. In H. pylori strain 181 and the TetR transformants of strain 26695, 
the triple-base-pair substitution AGA926-928TTC had no effect on the growth rate of the 
bacterium in the presence or absence of tetracycline (data not shown). Similar 
observations were found in E. coli after the substitution of the nucleotides G966 and C967 
[10]. This suggests that the triple-base-pair substitution AGA926-928TTC present in H. pylori 
strain 181 does not seem to affect protein synthesis of H. pylori.  
During revision of this work, Trieber and Taylor [25] reported that the identical 
AGA926-928TTC substitution mediates tetracycline resistance in an unrelated H. pylori 
strain [16]. None of the other mutations found in their isolates (G332A, and the deletions 
G733 and G903, numbering according to 16S rrnA of H. pylori strain 26695) play a role in 
tetracycline resistance of the TetR strain 181, since these mutations were not present in our 
TetR isolate. The differences found in MIC of tetracycline for the triple-base-pair 
substitution between the study of Trieber and ours are only due to the methods used for 
the determination of the MIC (data not shown). The finding that in two unrelated H. pylori 
strains the exact same mutation is responsible for tetracycline resistance opens 
possibilities for the development of molecular screening tests for tetracycline resistance in 
H. pylori. 
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ABSTRACT 
 
The triple-base-pair 16S rDNA mutation AGA926-928TTC mediates high-level tetracycline 
resistance in Helicobacter pylori. In contrast, single- and double-base-pair mutations 
only mediated low-level tetracycline resistance and decreased growth rates in the 
presence of tetracycline, explaining the preference for the TTC mutation in tetracycline-
resistant H. pylori isolates.  
 
 16S rRNA gene mutations confer tetracycline resistance     
 61
Tetracycline is a cheap and effective antibiotic for the treatment on Helicobacter pylori 
infections [7, 8], but in the past few years the incidence of tetracycline resistance has 
significantly increased [1, 5, 6, 9, 13]. The only known mechanism mediating tetracycline 
resistance in H. pylori involves mutations at positions 926 to 928 in both the 16S rRNA 
genes [2, 4, 12]. H. pylori isolates with high-level tetracycline resistance carried the triple-
base-pair mutation AGA926-928TTC in both copies of the 16S rRNA genes [4, 12], whereas 
low-level tetracycline-resistant (TetR) strains only contained single- and double-base-pair 
mutations in the exact same region [2]. As the different mutations were present in 
unrelated strains, it is still unclear whether high-level tetracycline resistance requires the 
AGA926-928TTC mutation or whether single- or double-base-pair mutations at these 
positions may suffice for high-level tetracycline resistance. Therefore, we have created all 
possible combinations of single-, double- and triple-base-pair mutations of the AGA926-
928TTC mutation in tetracycline-susceptible (TetS) H. pylori strain 26695, and have 
determined the effect of the mutations on levels of tetracycline resistance, stability and 
growth rate. 
Site-directed mutants at position 926 to 928 was carried out by using a three-step PCR 
approach [3, 10] with primers listed in Table 1, followed by natural transformation to TetS 
H. pylori reference strain 26695 [4]. TetR H. pylori colonies were selected on plates 
containing tetracycline (1 mg/L). For each possible base pair mutation or combination 
thereof, eight TetR transformants from at least two independent transformation experi-
ments were selected. Both alleles of the 16S rRNA genes were amplified by PCR [4] to 
confirm the presence of the desired base pair mutations. With the exception of the AGC 
mutants, all mutants contained the desired mutations in both alleles of the 16S rRNA 
genes. All AGC mutants were heterozygous; and contained the AGC mutation in the rrnA 
gene and a TTC mutation in the rrnB gene.  
The effects of the 16S rRNA mutations on both the stability and the level of 
tetracycline resistance were determined by subculturing two mutants of each type for 
twenty passages on Columbia agar plates supplemented with 7% lysed horse blood 
(BioTrading, Mijdrecht, The Netherlands) in either the presence or absence of tetracycline 
(1 mg/L). After each five rounds of subculturing the minimal inhibitory concentration 
(MIC) of tetracycline was determined by E-test (AB Biodisk, Solna, Sweden) [4]. In 
addition, for all mutants at time point zero (t0) and after passages 20 (t20) the 16S rRNA 
genes were sequenced. The stability of the various types of mutations and their effects on 
the levels of resistance are summarized in Table 2.  
At t0, the single- and double-base-pair mutations did not result in tetracycline resis-
tance with levels of clinical relevance, as the MIC of tetracycline was below 4 mg/L. With 
the exception of the AGC mutants, the MIC of tetracycline was similar at t20 when 
compared to t0 (Table 2). The MIC of tetracycline of the AGC mutants increased from 1.5 
to 6.0 mg/L. Subsequent analysis of the 16S rRNA gene sequences of all mutants at t0 and 
t20 revealed that the TGA and AGC mutations were unstable. Already during the two 
subculturing steps needed for propagation of the colonies to obtain sufficient material for 
storage at -80ºC, the sequence of both 16S rRNA genes of the TGA mutants had changed 
to TGC, and while stable during the initial propagation steps, after 20 rounds of 
subculturing both AGC mutants contained a TTC sequence at position 926 to 928 within 
both 16S rRNA genes instead of only in the rrnB gene. Apart from these TGC and AGC 
mutations, all other mutations were stable as the complete 16S rRNA genes sequences did 
not reveal any other sequence changes except for the desired mutations. 
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Table 1. Primers used in this study. 
 
Primer name Primer sequence (5'-3')a Position 16S rRNA 
geneb 
16S rRNA 
mutationc 
Sequencing, cloning and PCR   
   Hp16S-F1 CTGACGCTGATTGCGCGAAA 711 to 730, forward N.A. 
   Hp16S-F2 CCTGCTGGAACATTACTGAC 696 to 715, forward N.A. 
   Hp16S-F3 TTTATGGAGAGTTTGATCCT 1 to 20, forward N.A. 
   Hp16S-R1 TCGTTGCGGGACTTAACCCA 1071 to 1052, reverse N.A. 
   Hp16S-R2 TGGCTCCACTTCGCAGTATT 1245 to 1226, reverse N.A. 
   Hp16S-R3 AGGAGGTGATCCAACCGCA 1499 to 1480, reverse N.A. 
   Hp16S-rrnA CCCAAATCCTTGAGCGTTTA 1840 to 1821, reversed N.A. 
   Hp16S-rrnB CGCATTCATAATCAGCTCAG 1826 to 1807, reversee N.A. 
    
Mutagenesis    
   Hp16S-mutF1 TAATTCGATGATACACGAAG 918 to 937, forward TGA 
   Hp16S-mutF2 TAATTCGAATATACACGAAG 918 to 937, forward  ATA 
   Hp16S-mutF3 TAATTCGAAGCTACACGAAG 918 to 937, forward  AGC 
   Hp16S-mutF4 TAATTCGATTATACACGAAG 918 to 937, forward  TTA 
   Hp16S-mutF5 TAATTCGATGCTACACGAAG 918 to 937, forward  TGC 
   Hp16S-mutF6 TAATTCGAATCTACACGAAG 918 to 937, forward  ATC 
   Hp16S-mutF7 TAATTCGATTCTACACGAAG 918 to 937, forward  TTC 
   Hp16S-mutR1 CTTCGTGTATCATCGAATTA 937 to 918, reverse TGA 
   Hp16S-mutR2 CTTCGTGTATATTCGAATTA 937 to 918, reverse  ATA 
   Hp16S-mutR3 CTTCGTGTAGCTTCGAATTA 937 to 918, reverse  AGC 
   Hp16S-mutR4 CTTCGTGTATAATCGAATTA 937 to 918, reverse  TTA 
   Hp16S-mutR5 CTTCGTGTAGCATCGAATTA 937 to 918, reverse  TGC 
   Hp16S-mutR6 CTTCGTGTAGATTCGAATTA 937 to 918, reverse  ATC 
   Hp16S-mutR7 CTTCGTGTAGAATCGAATTA 937 to 918, reverse  TTC 
a Primers used for amplification were based on the published genome sequence of H. pylori strain 26695 [11]. 
The substituted residues are underlined.  
b Position of oligonucleotides correspond to relative start point of the 16S rrnA residues of H. pylori strain 26695 [11]. 
c 16S rRNA mutations at position 926 to 928 (numbering according to 16S rrnA of H. pylori strain 26695 [11]. 
The substituted residues are underlined. N.A., not applicable. 
d The rrnA-specific oligonucleotide is located outside 16S rRNA gene at position 1207242 to 1207261 of the 
H. pylori 26695 genome sequence [4, 11]. 
e The rrnB-specific oligonucleotide is located outside 16S rRNA gene at position 1510809 to 1510828 of the 
H. pylori 26695 genome sequence [4, 11]. 
 
 
To determine whether the 16S rRNA mutations affected the growth rates of the 
mutants in the presence or absence of tetracycline, all mutants from t0 were cultured in 
duplicate in Brucella broth supplemented with 3% newborn calf serum (Life Technologies 
Ltd., Auckland, New Zealand). One culture of each mutant was supplemented with 
tetracycline (1 mg/L), whereas the other culture was kept unsupplemented. Growth was 
monitored by measuring the optical density at 600 nm each 24 hours for a period of 
72 hours. In the absence of tetracycline, the growth of the mutants did not differ from that  
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of the H. pylori wild-type strain 26695 (Table 2). However, in the presence of tetracycline 
the growth of the wild-type strain and the single- and double-base-pair mutants was 
clearly reduced compared to that of the TTC mutant. The reduction was most pronounced 
in the wild-type strain and the AGC, ATA and TGC mutants (Table 2).  
 
 
Table 2. Characterization of site-directed mutants. 
 
MIC of tetracycline (mg/L)b 
t20 
Growth rate Strain or mutantsa  t0c 
On Tet-free 
medium 
On Tet 
(1 mg/L) 
 
On Tet-free 
mediumd 
On Tet 
(1 mg/L)e 
26695 0.19 0.19 0.19  +++ No growth 
TGAf ND ND ND  ND ND 
ATA 1.5 1.5  2.0  +++ + 
AGCg 1.5 6.0  6.0   +++ + 
TTA 1.5  2.0  2.0   +++ ++ 
TGC 1.0  1.5  2.0  +++ + 
ATC 2.0  2.0  3.0  +++ ++ 
TTC 6.0  6.0  8.0  +++ +++ 
a The substituted residues are underlined. 
b MIC were determined by E-test for two independent mutants. MIC shown are means of results from four to six 
independent experiments. Tet, tetracycline, ND not determined. 
c At t0 all mutants were already subcultured twice in order to obtain sufficient bacteria required for storage at -80ºC. 
d Growth rates of the isogenic mutants relative to the growth rate of the WT 26695 (100%), +++, 95 to 100%; 
++, 70 to 95%; +, 50 to 70%. 
e Growth rates of the isogenic mutants containing single- and double-base-pair mutations relative to the growth 
rate of the isogenic mutants containing the triple-base-pair mutation TTC (100%), +++, 95 to 100%; ++, 70 to 
95%; +, 50 to 70%.  
f The TGA sequence had already changed into the TGC sequence during subculturing before storage. 
g Each of the tested mutants contained an AGC mutation in the rrnA gene and a TTC mutation in the rrnB gene. 
 
 
From this study it is apparent that for high-level tetracycline resistance, H. pylori 
requires the triple-base-pair mutation AGA926-928TTC in both copies of the 16S rRNA 
genes. Such high-level tetracycline resistance is most likely generated by a stepwise 
process that is driven by a selection that depends on both the duration and the dose of 
exposure to tetracycline. For this reason, it was not surprising that the previously 
described low-level TetR H. pylori strains contained only single- or double-base-pair 
mutations in the exact same region as the TTC mutation [2]. In this report [2] it was also 
suggested that mutant H. pylori strains with even a small increase in tetracycline 
resistance have an advantage whenever inhibitory concentrations of tetracycline are 
encountered. However, it could not be excluded that the observed differences were due to 
strain differences or secondary mutations. The data presented here have been obtained 
from mutants with an identical genetic background, thus excluding the effect of strain 
differences. Taken together, the preference in H. pylori for particular 16S rRNA gene 
mutations mediating tetracycline resistance not only results from the differences in MICs 
but also from the differences in growth rates in the presence of tetracycline and from the 
stability of the mutations. 
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ABSTRACT 
 
Tetracycline is one of four antibiotics commonly used for the treatment of Helicobacter 
pylori infection, but its effectiveness is decreasing as the incidence of tetracycline 
resistance is increasing. In five Brazilian tetracycline-resistant (TetR) H. pylori isolates, 
high-level tetracycline resistance is mediated by the triple-base-pair substitution 
AGA926-928TTC in both 16S rRNA genes, as was previously observed in two indepen-
dent high-level TetR H. pylori strains. A polymerase chain reaction-based restriction 
fragment length polymorphism (PCR-RFLP) assay was developed for the detection of 
the AGA926-928TTC substitution, and confirmed the presence of the aforementioned 
triple-base-pair substitution in all five Brazilian TetR H. pylori isolates. This PCR-
RFLP based approach distinguishes the high-level TetR H. pylori isolates from the 
low-level TetR and tetracycline-susceptible H. pylori strains and thus allows the direct 
detection of TetR H. pylori isolates. 
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INTRODUCTION 
 
Helicobacter pylori is a spiral-shaped, Gram-negative bacterium that persistently colonizes 
the human stomach. It is the main causative agent of chronic superficial gastritis and 
peptic ulcer disease, and infection with H. pylori is strongly associated with the develop-
ment of gastric cancer and gastric lymphomas [6]. Successful treatment of H. pylori infec-
tion not only results in the eradication of the pathogen, but often also cures and prevents 
the development of the associated diseases [13]. Although most anti-H. pylori regimens 
are still highly effective, the eradication rates of these therapies are negatively affected by 
the increasing incidence of antibiotic resistance [10]. In vitro, H. pylori is susceptible to a 
wide range of antibiotics, but for effective treatment a combination of drugs is required 
[5]. Tetracycline-based combination regimens are often used after first-line treatment with 
amoxicillin, clarithromycin and/or metronidazole fails [9, 16], or when reduction of 
treatment costs are important [12].  
Tetracycline is an antibiotic that binds to the 30S ribosomal subunit, and thus blocks 
protein synthesis, inhibiting the growth of the bacteria [2, 3]. Most H. pylori isolates are 
still susceptible to tetracycline (MIC < 4 mg/L), but in the past few years the incidence of 
tetracycline resistance has increased, in particular in certain geographical regions [17, 18, 
22]. In H. pylori the molecular mechanism underlying this resistance is attributed to 
mutations in the primary binding site of tetracycline [4, 7, 21]. In the two TetR H. pylori 
isolates previously described, high-level tetracycline resistance is mediated by the triple-
base-pair substitution AGA926-928TTC, within both copies of the 16S rRNA genes [7, 21]. 
In this study, we show that this identical triple-base-pair substitution also mediates high-
level tetracycline resistance in five Brazilian H. pylori isolates. We have subsequently 
developed a polymerase chain reaction-based restriction fragment length polymorphism 
(PCR-RFLP) assay allowing rapid and reproducible identification of the mutations media-
ting high-level tetracycline resistance in H. pylori. 
 
 
MATERIALS AND METHODS 
 
Bacterial isolates, growth conditions and resistance testing 
H. pylori isolates used in this study and their origins are listed in Table 1. Five unrelated 
Brazilian TetR isolates (BZ series) were obtained as previously described [11]. All bac-
teria were routinely grown on Brain Heart Infusion (BHI) agar plates (Difco, Detriot, MI, 
USA) supplemented with 2.5 g/L yeast extract (Difco), 10% lysed sheep blood (BBV, 
Campinas, Brazil), and H. pylori selective supplements for 48 to 72 hours at 37ºC in an 
atmosphere of 5% O2, 10% CO2, and 85% N2 [17]. The minimal inhibitory concentration 
(MIC) of tetracycline was routinely determined by E-test (AB Biodisk, Solna, Sweden) 
[7]. The isolates were considered to be resistant when the MIC of tetracycline was 
≥ 4 mg/L [5, 7]. For each experiment, MIC determinations of the tetracycline-susceptible 
(TetS) H. pylori strain 26695 and TetR H. pylori strain 181 were included as controls [7].  
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Table 1. H. pylori isolates used in this study and their MICs of tetracycline determined by 
E-test. 
 
Isolates/reference strainsa Origin/Reference Disease MIC (mg/L) 
Clinical isolates    
   BZ002 [11] Gastric ulcer 6 
   BZ197 [11] Gastritis 6 
   BZ261 [11] Gastric ulcer 6 
   BZ288 [11] Gastric ulcer 4 
   BZ291 [11] Gastric ulcer/ Duodenal ulcer 4 
   181 [7] Gastritis 8 
    
Reference strains    
   26695 [20]  0.19 
   J99 [1]  0.5 
   ATCC 43504 ATCC  0.125 
   NCTC 11638  NCTC  0.38 
   SS1  [14]  0.19 
a TetR isolates were obtained from individual dyspeptic patients [11]. ATCC, American Type Culture Collection; 
NCTC, National Collection of Type Cultures.  
b MIC shown are means of results from three independent experiments. The isolates were considered to be resis-
tant when the MIC of tetracycline was ≥ 4 mg/L [5, 7]. 
 
 
Natural transformation of H. pylori 
The TetS H. pylori reference strain 26695 was transformed [7] with ~1 µg of genomic 
DNA from a TetR strain (Table 1), or ~250 ng of 16S rRNA gene products amplified from 
this genomic DNA. TetR transformants were selected on selective H. pylori media supple-
mented with 2 mg/L tetracycline (Sigma Aldrich Corp.), and their MICs of tetracycline 
were determined. As controls, bacteria were transformed with either DNA from strain 181 
(TetR), DNA from strain 26695 (TetS), or TE (1 mM Tris-HCl (pH 8.0), 0.1 mM EDTA). 
 
General DNA techniques 
Oligonucleotide primers (Isogen, Maarsen, The Netherlands) used in this study are listed 
in Table 2. PCR was performed in an automated thermal cycler (I-cycler, Biorad 
Laboratories BV, Veenendaal, The Netherlands) using the PCR-core system I (Promega, 
Madison, WI, USA). Direct sequencing of the obtained PCR products was performed by 
Baseclear Inc. (Leiden, The Netherlands) and the Hemocentro/UNICAMP genome center 
(Campinas, Brazil).  
 
RFLP analysis  
Genomic DNA of the TetR isolates was amplified with the primers Hp16S-F3 and Hp16S-R2, 
and digested with the restriction enzyme HinfI (Promega). The restriction products were 
analyzed by electrophoresis on a 2% agarose gel, and visualized using ethidium-bromide. 
As controls, 16S rDNA fragments of the TetR H. pylori strain 181 and TetS H. pylori 
reference strains 26695, J99, ATCC 43504, NCTC 11638 and SS1 were included (Table 1). 
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Nucleotide sequence accession numbers 
The nucleotide sequences of the primary binding site of the five Brazilian TetR H. pylori 
isolates (BZ002, BZ197, BZ261, BZ288 and BZ291) analyzed in this study have been 
deposited in GenBank under accession numbers AY278526 to AY278530, respectively.  
 
 
Table 2. Oligonucleotides used in this study. 
 
Primer name Primer sequence (5'-3')a Position 16S rRNA geneb 
Hp16S-F1 TTTATGGAGAGTTTGATCCT 1 to 20, forward  
Hp16S-F2 CCTGCTGGAACATTACTGAC 696 to 715, forward 
Hp16S-F3 CTGACGCTGATTGCGCGAAA 711 to 730, forward 
Hp16S-F4 TAGTTGTTGGAGGGCTTAGT 789 to 808, forward 
Hp16S-R1 TCGTTGCGGGACTTAACCCA 1071 to 1052, reverse 
Hp16S-R2 TGGCTCCACTTCGCAGTATT 1245 to 1226, reverse 
Hp16S-R3 AGGAGGTGATCCAACCGCA 1499 to 1480, reverse 
Hp16S-rrnA CCCAAATCCTTGAGCGTTTA 1840 to 1821, reverse 
Hp16S-rrnB CGCATTCATAATCAGCTCAG 1826 to 1807, reverse 
a Oligonucleotides used for amplification were based on the published genome sequence of H. pylori strain 
26695 [20].  
b Position of oligonucleotides are given to the relative start point of  rrnA gene of H. pylori strain 26695 [20]. 
 
 
RESULTS 
 
MICs of tetracycline for TetR H. pylori isolates 
The MICs of tetracycline were determined by E-test for the five Brazilian TetR H. pylori 
isolates (BZ series), the Dutch TetR H. pylori strain 181, and the TetS reference strains 
26695, J99, ATCC 43504, NCTC 11638 and SS1 (Table 1). For the five Brazilian TetR 
H. pylori isolates the MICs of tetracycline ranged between 4 and 6 mg/L (susceptibility 
breakpoint ≥ 4 mg/L), while the MIC of the TetS strains ranged between 0.125 and 0.5 mg/L. 
The MICs of tetracycline for the control strains TetR strain 181 and TetS reference strain 
26695, were 8 mg/L and 0.19 mg/L, respectively. 
 
Identification of 16S rDNA sequence changes in the primary binding site of tetracycline 
The 16S rDNA fragments containing the primary tetracycline binding sites of the five 
Brazilian TetR H. pylori isolates were amplified and sequenced. Comparison of the 
sequences of the PCR products that spanned nucleotides 696 to 1245 (numbering accor-
ding to the rrnA gene of H. pylori strain 26695) from the five TetR isolates, and TetS 
H. pylori strain 26695 revealed several base pair differences in the five Brazilian TetR 
isolates that did not occur in the TetS strain 26695 (data not shown). However, all the 
sequence changes found in this part of the 16S rDNA fragment were identical to those of 
the previously reported high-level TetR H. pylori strain 181, including the AGA926-928TTC 
mutation that mediates tetracycline resistance in H. pylori strain 181 [7].  
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Transfer of the AGA926-928TTC substitution mediates tetracycline resistance 
To confirm that only the AGA926-928TTC triple-base-pair substitution was responsible for 
the observed high-level tetracycline resistance, the TetS H. pylori strain 26695 was trans-
formed with either genomic DNA of the five TetR Brazilian isolates, or with specific PCR 
products amplified from these isolates. For the latter, the whole 16S rRNA gene was 
amplified using the oligonucleotides Hp16S-1F and Hp16S-3R, while the oligonucleotides 
Hp16S-3F and Hp16S-1R (Table 2) were used to create and sequence a 361-bp fragment 
that only contained the triple-base-pair substitution AGA926-928TTC. For all Brazilian TetR 
isolates, TetR transformants were readily obtained after transformation with either geno-
mic DNA, the 1499-bp DNA fragment (spanning the complete 16S rRNA gene), or the 
smaller 361-bp PCR product. No TetR transformants were found after transformation with 
DNA from the TetS strain 26695 or with TE. The MICs of tetracycline of the TetR trans-
formants were identical to those of the corresponding TetR donor strains. Sequence analysis 
of the 16S rDNA fragment encompassing nucleotides 696 to 1245 of all independent TetR 
transformants confirmed that the transformants had incorporated the triple-base-pair 
substitutions AGA926-928TTC within both copies of the 16S rRNA genes. Apart from this 
triple-base-pair substitution, no other sequence changes were present in this fragment. 
 
Detection of H. pylori 16S rDNA allele-specific mutations  
To analyze whether one or both 16S rRNA genes of these H. pylori strains carried the 
substitution, the two 16S rRNA gene copies were amplified separately [7] and digested 
with the restriction enzyme HinfI (5'-G↓ANTC-3'). This enzyme digests the AGA926-928TTC 
substitution mediating high-level tetracycline resistance (G↓ATTC, from position 924 to 
928 within both copies of the 16S rRNA genes rrnA and rrnB), but not that of the low-
level TetR (AGA926-928GGA, AGC, GTA or GGC) or TetS (AGA926-928) isolates. For both 
16S rDNA allele-specific PCR fragments, the other conserved HinfI sites (i.e. not affected 
by the TetR inducing AGA926-928TTC substitution) were used as internal digestion controls. 
All 16S rDNA allele-specific fragments derived from the five Brazilian high-level TetR 
isolates were completely digested with HinfI at position 926 to 928, while this did not 
occur for the TetS H. pylori reference strain 26695 (data not shown). Thus all five 
Brazilian TetR isolates contain the triple-base-pair substitution AGA926-928TTC within both 
copies of the 16S rRNA genes. 
 
Detection of high-level tetracycline resistance in H. pylori by PCR-RFLP 
In order to set up a molecular screening approach for clinical purposes, the allele-specific 
PCR-RFLP was simplified. Both 16S rRNA genes were amplified within a single PCR 
reaction with the primers Hp16S-F3 and Hp16S-R2, and digested with HinfI. For the five 
TetS H. pylori reference strains one cleavage site was present within the 16S rDNA 
fragment, resulting in a 281- and 254-bp digestion product. This site served as control for 
the correct digestion of the fragments. For the five Brazilian TetR isolates and strain 181, 
the AGA926-928TTC mutation that mediates high-level tetracycline resistance generates an 
additional HinfI cleavage site, resulting in digestion of the 254-bp fragment into a of 214-
and 40-bp fragment (Figure 1). 
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Figure 1. Detection of the 16S rDNA AGA926-928TTC substitution by HinfI mediated PCR-RFLP. The presence 
of the AGA926-928TTC substitution creates an additional HinfI restriction site (wildtype GAAGA, mutant 
G↓ATTC). The 16S rDNA fragments derived from the TetS reference strains 26695, J99, ATCC 43504, NCTC 
11638 and SS1 (lane 1-5, respectively) were cleaved into two fragments, 281-bp and 254-bp, while the digestion 
of the PCR fragments of the five high-level Brazilian TetR isolates BZ002, BZ197, BZ261, BZ228 and BZ291 
(lane 6-10, respectively), and strain 181 (lane 11) results in three fragments, 281-bp, 214-bp, and 40-bp. The 
281-bp, 254-bp and 214-bp fragments are marked by arrows. Due to its small size the 40-bp fragment is not 
visible on this reproduction. R, tetracycline-resistant; S, tetracycline-susceptible; M, marker, 50-bp DNA step 
ladder (Promega). 
 
 
DISCUSSION 
 
Tetracycline is an antibiotic which is frequently used in first- and second-line regimens 
for the treatment of H. pylori [9, 12, 16]. This antimicrobial drug is not only widely 
available and cheap, but until recently had the additional advantage that resistance against 
it was rare in H. pylori. Unfortunately, the incidence of tetracycline resistance appears to 
be increasing, especially in countries where tetracycline can be obtained without prescrip-
tion [17, 18, 22]. This increased incidence of high-level tetracycline resistance in H. pylori 
is a serious concern as it negatively affects the efficacy of tetracycline-containing regi-
mens [9, 19]. 
It was previously demonstrated that in two unrelated high-level TetR H. pylori strains, te-
tracycline resistance is conferred by an identical triple-base-pair substitution (AGA926-928TTC) 
within both copies of the 16S rRNA genes [7, 21]. Subsequently, several low-level TetR 
H. pylori isolates were described, and in all these strains the resistance was based on 
single- and double-base-pair mutations in the exact same region [4]. However, the MIC 
values of tetracycline for these low-level TetR isolates were below the susceptibility 
M 1 2 3 4 5 6 7 8 9 10 11
214 bp
254 bp
S R
281 bp
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breakpoint of 4 mg/L and thus commonly considered as tetracycline-susceptible. Our 
current findings in the five Brazilian high-level TetR clinical isolates confirm and extend 
the conclusions of previous studies in the sense that high-level tetracycline resistance in 
H. pylori is conferred by the same triple-base-pair substitution AGA926-928TTC as 
observed in the two other high-level TetR H. pylori isolates [7]. It is striking that all 
characterized TetR H pylori isolates contain mutations in the exact same 16S rRNA 
region, especially because these isolates were obtained from dyspeptic patients living in 
different geographic regions (Asia, Australia, Eastern- and Western Europe, and Central- 
and South-America) [4, 7, and this study]. This observation suggests that H. pylori 
requires mutations within the 16S rRNA primary binding site for tetracycline resistance. 
Probably this resistance arises by de novo mutations, although the acquisition of mutant 
16S rRNA alleles through horizontal gene transfer cannot be excluded.  
Conventional methods to assess levels of tetracycline resistance of H. pylori are based 
on culture in combination with agar dilution or E-test [15]. Both methods are not only 
time-consuming, but also difficult to standardize. Since tetracycline resistance seems to be 
restricted to the occurrence of specific mutations in a small region of the 16S rRNA mole-
cule [4, 7, 21], molecular methods offer an attractive alternative. In the present study a 
PCR-based RFLP was used to detect the presence of the triple-base-pair substitution 
AGA926-928TTC in the 16S rRNA genes. This PCR-RFLP assay distinguishes the high-
level TetR isolates from the low-level TetR and TetS H. pylori strains. Since all high-level 
TetR H. pylori (MIC ≥ 4 mg/L) isolates characterized thus far contain the AGA926-928TTC 
substitution [4, 7, 8, 21], and to our knowledge low-level tetracycline resistance is not 
linked to therapy failure, this PCR-RFLP approach is useful for the detection of clinically 
relevant levels tetracycline resistance in H. pylori. In conclusion, our PCR-RFLP assay 
allows rapid detection of high-level tetracycline resistance in H. pylori. 
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ABSTRACT 
 
Recommended first-line therapy of Helicobacter pylori usually consists of a proton 
pump inhibitor, combined with two antimicrobials. However, the effectiveness of this 
triple therapy is decreasing due to resistances against metronidazole and clarithromycin. 
Quadruple therapies usually contain tetracycline and/or a bismuth component, and are 
often used as second-line treatment. Nevertheless, resistances against tetracycline, caused 
by mutations in the 16S rRNA genes (rrnA and rrnB), are emerging and can result in 
an unsuccessful eradication treatment of H. pylori. In order to recognize possible 
resistances against tetracycline, we developed a real-time PCR-based on the 
fluorescence resonance energy transfer (FRET)-method. The assay was validated using 
seven tetracycline-resistant (TetR) H. pylori isolates exhibiting the AGA926-928TTC 
triple-base-pair mutation, eight different artificially created mutants showing various 
combinations of mutations affecting the positions 926 to 928 in the 16S rRNA genes 
and 150 H. pylori clinical isolates. Our real-time PCR recognized all TetR isolates and 
artificially created mutants, and distinguished them from the tetracycline-susceptible 
(TetS) isolates. Moreover, this method was applicable to DNA extracted from cultured 
bacteria and gastric biopsy samples. Thus, our real-time PCR is an excellent tool to 
detect tetracycline resistance in H. pylori, particularly in cases when conventional 
susceptibility testing fails.  
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INTRODUCTION 
 
Helicobacter pylori infection is chronic in nature and has been shown to cause gastritis, 
and increases the risk of peptic ulcer disease, MALT-lymphoma and gastric cancer 
development [16, 21, 23]. Increasing resistances against first-line antibiotics like clarithro-
mycin are compromising the eradication of H. pylori resulting in therapy failures [8]. 
Thus, alternative treatment trials including tetracyclines are recommended [1, 17].   
Tetracylines are bacteriostatic drugs with a broad spectrum activity. They exert their 
antimicrobial effects by affecting the 30S ribosomal subunit and blocks the binding of 
aminoacyl-tRNA resulting in an impaired protein biosynthesis [3, 25]. Resistance of 
H. pylori against tetracyclines was reported to be caused by mutations in the 16S rRNA. 
H. pylori isolates showing AGA926-928TTC triple-base-pair substitutions [4, 5, 25] are clas-
sified as high-level tetracycline-resistant, whereas single- or double-base-pair mutations in 
the exact same region were rather associated with low-level tetracycline resistance [3, 4].  
In routine practice, susceptibility of H. pylori against both tetracycline and other 
antibiotics is examined by culturing H. pylori and subsequent agar diffusion (E-test) or 
agar dilution tests, which are accepted to be the reference methods [11]. These methods 
are not only time-consuming but also vulnerable to contaminations. In addition, H. pylori- 
positive patients are often on long term anti-acids and as a consequence gastric biopsy 
samples contain many bacterial species, making it difficult - if possible at all - to obtain a 
pure culture of the fastidious H. pylori. Finally, inappropriate transport conditions, for 
example unsuitable transport media or extended transport times are common. In such 
cases, culture followed by antimicrobial sensitivity testing might be impossible. In the 
case of failure, molecular-based methods seem to be a promising way to solve those 
problems in routine laboratories. Well established methods like PCR and sequencing are 
more robust, but they are often complex, time-consuming, and thus expensive. Fluores-
cence resonance energy transfer (FRET)-based real-time PCR methods, using fluorescent 
labeled hybridization probes, allows a rapid mutation screening of a PCR product by 
melting curve analysis. In H. pylori, it is shown, that FRET-based real-time PCR assays 
are an accurate method for the detection of clarithromycin [18, 19] and ciprofloxacin 
resistance [7].  
In the present study, we developed a rapid and reliable real-time-PCR for the detection 
of 16S rRNA mutations associated with tetracycline resistance in H. pylori using a Light-
Cycler®. To validate the assay seven high-level tetracycline-resistant (TetR) H. pylori 
isolates from The Netherlands, South-America and Canada, and eight artificially created 
TetR H. pylori 16S rRNA mutants and 150 H. pylori clinical isolates and their according 
gastric biopsy samples were tested.  
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MATERIAL AND METHODS 
 
Bacterial strains and culture conditions 
H. pylori strains used in this study were the TetR strain 181 from the Netherlands, one TetR 
Canadian isolate (KC617), the tetracycline-susceptible (TetS) reference strain 26695 [24], 
150 H. pylori clinical isolates from our routine laboratory as well as eight artificially 
16S rRNA mutants created in the H. pylori reference strain 26695 as previously described 
[4]. All bacteria were cultured under microaerophilic conditions (5% O2, 10% CO2, 85% 
N2) at 37°C for 48 hours and identified as H. pylori by standard criteria [13, 22].  
The Canadian isolate KC 617 was kindly provided by Dr. G. Cooper-Lesins from 
Halifax, Canada. 
 
Determination of the minimal inhibitory concentration of tetracycline by E-test 
For all H. pylori isolates, the E-test-method (AB Biodisk, Sweden) was used to determine 
the minimal inhibitory concentration (MIC) of tetracycline. The method was performed 
according to a protocol previously described [11]. Strains showing MICs ≥ 4 mg/L were 
classified as high-level tetracycline-resistant, whereas strains with MICs between > 0.5 mg/L 
and < 4 mg/L, and MICs ≤ 0.5 mg/L were considered low-level resistant and susceptible, 
respectively. 
 
DNA extraction and 16S rRNA gene amplification 
DNA of H. pylori isolates and DNA of the corresponding gastric biopsy samples were 
extracted using the QIAmp DNA mini kit (Qiagen, Hilden, Germany). DNA extracts from 
gastric samples were checked for the presence of H. pylori by amplifying the vacA signal 
sequence as described earlier [22]. Amplification of a 361-bp fragment of the 16S rRNA 
genes was performed using the primers Hp16S-F1 (5'-CTGACGCTGATTGCGCGAAA-3') 
and Hp16S-R1 (5'-TCGTTGCGGGACTTAACCCA-3') as described before [4]. Amplicons 
were examined by applying 7 µL on a 1.2% agarose gel (Peqlab, Erlangen, Germany) and 
then purified using the QIAquick PCR puri-fication kit (Qiagen).  
DNA-extracts of five Brazilian TetR strains (BZ002, BZ197, BZ261, BZ288 and 
BZ291) exhibiting the TTC triple-base-pair mutation were kindly provided by Dr. M.L. 
Ribeiro and Prof.dr. J. Pedrazzoli Jr. from São Francisco University Medical School, 
Brazil. 
 
DNA Sequencing 
Purified PCR products were sequenced with the ABI PRISM BigDye Terminator cycle 
sequencing ready reaction kit (Applied Biosystems, Warrington, U.K.) using the PCR-
primers as sequencing primers. Sequencing was accomplished with an ABI 310 DNA-
Sequencer (Applied Biosystems). 
 
Detection of 16S rRNA gene mutations of H. pylori by a FRET-based real-time-PCR 
FRET-based real-time PCR was performed on bacterial DNA extracted from isolates and 
DNA extracted from gastric biopsy samples. The method included the amplification of the 
16S rDNA gene fragment of H. pylori using the primers mentioned above and the simul-
taneous detection of the PCR-product by hybridization probes.  
For the detection of the 16S rDNA gene mutations, two hybridization probes, an 
anchor-probe Tet-A (5'-TCTAGCGGATTCTCTCAATGTCAAGCCTAG-3'; 3'-labeled 
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with fluorescein) and a mutation-probe Tet-M (5'-AAGGTTCTTCGTGTATCTTCG- 3'; 
5'-labeled with LC-Red®640 and 3'-phosphorylated) were used. Probes were delivered by 
TIB Molbiol (Berlin, Germany), primers by Hermann GmbH (Freiburg, Germany). 
Real-time PCRs were performed in 20 µL-volumes in glass capillaries (Roche 
Diagnostics, Mannheim, Germany) using a LightCycler® (Roche Diagnostics). Twenty 
microliters of PCR mixture contained 10 µL of SYBR-Green Master Mix (Qiagen), 
0.4 µL of each of the primers Hp16S-F1 and Hp16S-R1 (25 µM each), 2 µL of the anchor-
probe and 2 µL of the mutation-probe (2 µM each), 3.2 µL of H2O and 2 µL of template 
DNA. 
Cycling conditions consisted of an initial denaturation step of 95°C for 15 min, 
followed by 15 cycles with denaturation at 95°C for 20 sec, annealing at 65°C for 20 sec 
and an elongation step at 72°C for 30 sec. Then, the annealing temperature was stepwise 
decreased for 1°C per cycle to a final annealing temperature of 57°C, and the PCR was 
continued for 27 cycles at 57°C (50 cycles in total). After amplification, samples were 
denatured at 95°C for 0 sec and cooled down to 30°C, where the temperature was hold for 
30 sec. Then, samples were slowly heated to 85°C at a ramp rate of 0.1°C/sec with 
continuous acquisition of fluorescence decline. Melting curves were plotted automatically 
and analyzed with the LightCycler®-software. 
 
 
RESULTS 
 
Design of hybridization probes 
For the detection of the 16S rRNA mutations, we designed a pair of hybridization probes, 
consisting of an anchor- and a mutation-probe. The anchor-probe is covering the nucleo-
tides 975-946, the mutation-probe the nucleotides 943-923 (Figure 1).  
  
 
Figure 1. Locations and sequences of the hybridization probes used. The mutation-probes is 3'-phosphorylated 
and 5'-labeled with LC-Red640, the anchor probes are each 3'-labeled with fluorescein. The nucleotides are 
numbered according to the GenBank accession no. AF512997 (rrnA). 
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In order to prove the specificity of the hybridization probes, various bacterial species 
were tested, i.e. H. pylori reference strains 26695 [24], Escherichia coli (clinical isolate), 
Campylobacter fetus (clinical isolate), Campylobacter coli (clinical isolate), Campylo-
bacter jejuni (clinical isolate) and Lactobacillus species (clinical isolates). For all bacteria, 
the convential PCR using the Hp16S-F1 and Hp16S-R1 primers rendered a PCR product 
of similar size, but the hybridization probes Tet-A and Tet-M were only H. pylori-specific. 
No melting curve was constructed when applying DNA of other bacteria.  
 
MICs of tetracycline 
The MICs of tetracycline were determined by E-test for the Dutch TetR isolate 181, the 
five Brazilian TetR isolates, the Canadian TetR isolate KC617, eight artificially created TetR 
H. pylori mutants of strain 26695, TetS H. pylori strain 26695 and 150 H. pylori clinical 
isolates. The Dutch, Brazilian and Canadian isolates as well as the artificially generated 
TTC mutant showed MICs between 6 mg/L and 16 mg/L and were classified high-level 
tetracycline-resistant (Table 1). For the five mutants containing double-base-pair mutations 
(i.e. TGC, ATC, GGC, TTA, and GTA), the MICs of tetracycline ranged between 1 and 
2 mg/L (Table 1), while the MICs for the single-base-pair mutants ATA and GGA were 
1.5 mg/L and 0.75 mg/L, respectively (Table 1). All artificial mutants were classified as 
low-level resistant. For the 150 H. pylori clinical isolates, 142 isolates had MICs < 0.5 mg/L 
and were classified as susceptible, whereas eight clinical isolates had a MIC of 0.75 mg/L 
and were classified as low-level resistant. 
 
 
Table 1. MICs of tetracycline, phenotype of the 16S rRNA mutants and melting 
temperatures (Tm) in the real-time PCR assay. 
 
Strain or mutanta MIC of tetracycline 
 (mg/L)b              
Phenotype Tm (°C) 
26695 (AGA) 0.19 susceptible 57.4 
GGA mutant 0.75 low-level resistant 53.8 
ATA mutant 1.5 low-level resistant 49.6 
TGC mutant 1.0 low-level resistant 46.9 
ATC mutant 2.0 low-level resistant  46.3 
TTA mutant 1.5 low-level resistant  47.9 
GTA mutant 1.5 low-level resistant  49.1 
GGC mutant 1.0 low-level resistant  47.4 
TTC mutant 6.0 high-level resistant 46.0 
Strain 181 (TTC) 8.0 high-level resistant  46.0 
BZ002 (TTC) 6.0c high-level resistant  46.0 
BZ197 (TTC) 6.0c high-level resistant  46.0 
BZ261 (TTC) 6.0c high-level resistant  46.0 
BZ288 (TTC) 4.0c high-level resistant  46.0 
BZ291 (TTC) 4.0c high-level resistant  46.0 
KC617 (TTC) 16.0 high-level resistant  46.0 
a Genotype at positions 926-928. The substituted residues are underlined. 
b MICs of tetracycline were determined by E-test. The isolates were considered high-level resistant when the MIC of 
tetracycline was ≥ 4 mg/L [5]; low-level resistant when the MIC > 0.5 mg/L and < 4 mg/L; and susceptible when 
the MIC ≤ 0.5 mg/L. 
c The MICs of tetracycline were determined as described previously [20]. 
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Detection of 16S rDNA mutations by real-time PCR  
The TetS H. pylori reference strain 26695 and the 142 TetS H. pylori isolates had melting 
temperatures of 57.4°C (Figure 2, Table 1), while the eight low-level TetR H. pylori 
clinical isolates had melting temperatures of 53.8°C. Sequence analysis revealed that the 
first 142 isolates contained an AGA wild-type sequence, while for the latter eight isolates 
a GGA sequence was found. The Dutch, Brazilian and Canadian high-level TetR isolate 
(containing the TTC triple-base-pair mutation), as well as the DNA extract of the gastric 
biopsy sample of strain 181, showed in comparison with the TetS H. pylori wild-type 
strain a clearly decreased melting temperature of 46.0°C (Table 1). As expected, the 
artificially generated high-level resistant TTC-mutant of strain 26695 had the same 
melting temperature as the naturally occurring TetR clinical isolates (Table 1).  
 
 
  
Figure 2. Melting curve analysis and detection of the AGA-wild-type, the high-resistant TTC-mutant and the 
low-level resistant GGA-mutant (single mutation) and TTA-mutant (double mutation). Compared to the AGA-
wild-type (57.4°C), the TTC-mutant had the lowest melting temperature (46.0°C). Melting points of the GGA- 
(53.8°C) and the TTA-mutant (47.9°C) are ranging between the AGA wild-type and TTC-mutant. 
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All mutants harboring double-base-pair mutations were also mismatched to the mutation-
probe reflected by a decrease of the melting temperature when compared to the TetS wild-
type 26695. The GTA mutant had a melting temperature of 49.1°C followed by the TTA 
mutant with 47.9°C, the GGC mutant with 47.4°C, the TGC mutant with 46.9°C and the 
ATC mutant with 46.3°C (Figure 2, Table 1). The artificial single-base-pair mutants ATA 
and GGA had melting temperatures of 49.6°C and 53.8°C, respectively (Figure 2, Table 1).  
All isolates tested, including the artificial mutants, showed a homozygous genotype 
(same mutation in the rrnA and rrnB gene), as only one peak was visible in the melting-
curve analysis. 
 
 
DISCUSSION 
 
Conventional H. pylori eradication regimens are normally based on a combination of 
proton pump inhibitors, amoxicillin and clarithromycin [17]. Increasing resistances 
against these antibiotics, mainly clarithromycin [8], jeopardize the successful treatment of 
H. pylori infections, so other strategies are suggested like second-line therapies including 
tetracyclines, fluoroquinolones or RNA-polymerase inhibitors [10, 17, 27]. Recent 
publications provide data about successful treatment trials using proton pump inhibitors, 
metronidazole, a bismuth salt and tetracycline [1, 2, 6, 17]. Before using antibiotics in 
anti-H. pylori therapy, testing their susceptibility is desirable, particularly in patients that 
have already been treated unsuccessfully. Antimicrobial susceptibility testing is routinely 
performed by E-test after successful culture of the bacterium, but sometimes these 
conventional methods are unsuccessful because of heavily contaminated biopsy samples 
or growth failure e.g. due to retarded transport times. In these cases, molecular-based 
methods like real-time PCR can be applied as a diagnostic rescue technique for detection 
of antibiotic resistance in H. pylori. Such real-time PCR assays have recently been 
published for the detection of clarithromycin and ciprofloxacin resistance in H. pylori [7, 
18, 19], and in the present study a real-time PCR method was developed and validated for 
the detection of tetracycline resistance in H. pylori.   
Tetracycline resistance of H. pylori is reported to be mediated by mutations in the 
16S rRNA [3-5, 25], for example an AGA926-928TTC triple-base-pair mutation or an 
AGA926-928GTA double-base-pair mutation [3]. Those mutations lead to alterations of the 
16S rRNA primary binding site of tetracycline resulting in increased MICs of tetracycline 
[3, 25]. The AGA926-928TTC mutation was reported to be associated with clinically relevant 
high-level tetracycline resistance (MICs ≥ 4 mg/L [4, 5]). To our knowledge, strain 181 is 
the only high-level TetR H. pylori isolate reported in Northern Europe [5]. In contrast to 
Northern Europe, about 5% of H. pylori isolates in Japan and Korea [12, 15], 10% in 
Brazil [9], and about 60% of isolates from Shanghai, China [26], were reported to be 
resistant against tetracyclines. Due to the increased double resistances of H. pylori against 
clarithromycin and metronidazole in Germany [14], second-line strategies based on 
tetracycline are more often used, and probably this will lead to an increased incidence of 
TetR H.  pylori isolates. In anticipation of this, we decided to establish a FRET-based real-
time PCR for a rapid screening in order to detect tetracycline resistance in H. pylori. Due 
to the lack of TetR H. pylori isolates in Northern Europe, our method was validated using 
the high-level TetR H. pylori clinical isolate 181 [5], one high-level TetR H. pylori isolate 
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from Canada and five high-level TetR H. pylori isolates from Brazil [20]. Those strains all 
exhibit the AGA926-928TTC triple-base-pair mutation. Additionally, we applied eight 
artificially created 16S rRNA gene mutants of strain 26695 harboring different mutations 
in the 926 to 928 triplet and 150 H. pylori clinical isolates to verify our method  
The majority (142 isolates) of the H. pylori clinical isolates were tetracycline 
susceptible and harbored the AGA926-928 triplet resulting in the highest melting temperature 
57.4°C. Eight H. pylori clinical isolates contained a GGA triplet resulting in a decreased 
melting temperature of 53.8°C. Due to the triple-base-pair exchange, the melting 
temperatures of the naturally occurring high-level TetR H. pylori isolates and the high-
level TetR TTC mutant were clearly decreased (46.0°C). The other mutants showed mel-
ting temperatures between 49.6°C and 46.3°C and were discriminable among each other.  
In conclusion, we have shown that our assay is able to detect 16S rRNA mutations 
which are associated with a clinically relevant high-level tetracycline resistance in H. pylori 
[3-5, 25]. The method was developed and validated on 150 H. pylori clinical isolates from 
our routine laboratory, seven high TetR clinical isolates and eight artificial TetR mutants 
exhibiting alterations in the AGA926-928 triplet of the 16S rRNA. In contrast to the PCR-
RFLP [20], our real-time PCR is not only able to differentiate between wild-type strains 
and high-level resistant strains harboring the AGA926-928TTC triple-base-pair substitution, 
but also between mutants exhibiting single- or double-base-pair substitutions, allowing a 
more accurate classification to TetS or TetR strains. Since our assay is also applicable on 
DNA extracted from gastric biopsy samples and cultured H. pylori isolates, it is an 
excellent tool to detect tetracycline resistance in H. pylori.  
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ABSTRACT 
 
Almost 50% of all Helicobacter pylori isolates are resistant to metronidazole, which 
reduces the efficacy of metronidazole-containing regimens, but it does not make them 
completely ineffective. This discrepancy between in vitro metronidazole resistance 
and treatment outcome may partially be explained by changes in oxygen pressure in 
the gastric environment, as metronidazole-resistant (MtzR) H. pylori isolates become 
metronidazole-susceptible (MtzS) under low oxygen conditions in vitro. In H. pylori 
the rdxA and frxA genes encode reductases are required for the activation of metro-
nidazole, and inactivation of these genes results in metronidazole resistance. Here the 
role of inactivating mutations in these genes on the reversibility of metronidazole 
resistance under low oxygen conditions is established. Clinical H. pylori isolates 
containing mutations resulting in a truncated RdxA and/or FrxA protein were selected 
and incubated under anaerobic conditions, and the effect of these conditions on minimal 
inhibitory concentrations  of metronidazole, amoxicillin, clarithromycin, and tetracycline, 
and cell viability were determined. While anaerobiosis had no effect on amoxicillin, 
clarithromycin and tetracycline resistance, all isolates lost their metronidazole 
resistance when cultured under anaerobic conditions. This loss of metronidazole 
resistance also occurred in the presence of the protein synthesis inhibitor 
chloramphenicol. Thus, factor(s) that activate metronidazole under low oxygen tension 
are not specifically induced by low oxygen conditions, but are already present under 
microaerophilic conditions. As there were no significant differences in cell viability 
between the clinical isolates, it is unlikely that the rdxA and the frxA gene participate in 
the reversibility of metronidazole resistance.  
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INTRODUCTION 
 
Helicobacter pylori is a spiral-shaped, Gram-negative bacterium that colonizes the stomach 
of approximately half the world's population [3]. Colonization with H. pylori is the most 
common cause of chronic active gastritis and peptic ulcer disease, and is strongly asso-
ciated with the development of gastric cancer and gastric lymphoma. Unless treated with 
antibiotics, H. pylori colonization tends to persist for life. Cure of H. pylori infection 
results in ulcer healing and may reduce the risk of gastric cancer and gastric lymphoma 
development [33, 38]. In vitro, H. pylori is susceptible to the majority of antibiotics, but 
for effective treatment a combination of drugs is required [7]. Currently used anti-H. pylori 
therapies often consist of two antibiotics with a proton pump inhibitor and/or a bismuth 
component [27]. Metronidazole (1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole) is a key 
component of such combination therapies [27, 36]. 
In Western Europe it has been estimated that 20 to 45% of the H. pylori isolates are 
metronidazole-resistant (MtzR) [13, 26]. This percentage is even higher in developing 
countries and immigrant populations [10, 25]. Although there are conflicting reports 
concerning the clinical relevance of metronidazole resistance in H. pylori, metronidazole 
resistance reduces the efficacy of metronidazole-containing regimens significantly [17, 37], 
but surprisingly does not render them inactive. 
Metronidazole is a prodrug that needs to be activated by a reduction of the nitro group 
that is attached to the imidazole ring. This reduction step leads to the production of DNA-
damaging nitroso- and hydroxylamine-compounds. Exposure to these toxic compounds 
causes DNA damage, and subsequently results in the death of the bacterium. In H. pylori, 
it is believed that reduction of metronidazole is mainly mediated by an oxygen-insensitive 
NADPH nitroreductase (RdxA) [14, 29], but recently it has been shown that the NADPH-
flavin-oxidoreductase (FrxA) also participates in the reduction of metronidazole [18]. 
In H. pylori, metronidazole resistance is primarily associated with mutational 
inactivation of rdxA gene [8, 14, 16]. However, recently it has been demonstrated that 
inactivation of the frxA gene also confers metronidazole resistance, either alone or in 
association with the rdxA gene [18, 21-23]. Whether mutational inactivation of these two 
enzymes accounts for metronidazole resistance in all clinical isolates is still being debated 
[2, 5, 21], but they most likely reflect the two major contributing factors.  
The discrepancy between the in vitro resistance to metronidazole and treatment 
outcome may be explained by the antimicrobial activity of other components in the regi-
mens and/or duration and doses of the therapy [37]. Apart from these factors, it is likely 
that low oxygen tension in the gastric environment may also be involved [31], since low 
oxygen conditions affect the activity of metronidazole reducing enzymes [15]. As in vitro 
MtzR H. pylori isolates become susceptible to metronidazole after a short period of 
anaerobic incubation [4, 31], it has been suggested that the FrxA protein and/or other 
ferredoxin and flavin reductases may contribute to the activation of metronidazole under 
these conditions [14, 19].  
In this study the role of null mutations in the rdxA and frxA genes on the reversibility 
of metronidazole resistance under low oxygen conditions was determined.  
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METHODS 
 
Strains and growth conditions  
H. pylori isolates used in this study and their respective rdxA and frxA gene status inferred 
from DNA sequences are listed in Table 1. The H. pylori isolates were routinely grown on 
Dent plates as described previously [11]. Broth cultures were grown in Brucella broth 
supplemented with 3% newborn calf serum (BBN). All cultures were incubated either 
under microaerophilic (5% O2, 10% CO2 and 85% N2) or anaerobic conditions (10% H2, 
5% CO2 and 85% N2) at 37°C. The anaerobic culture condition was created using the 
Anoxomat (Mart, Lichtenvoorde, The Netherlands) in combination with a catalyst. 
Escherichia coli strain DH5α MCR (Life Technologies BV) was grown on Luria-Bertani 
agar plates [28] for 24 hours at 37ºC in an aerobic environment. Selection of E. coli trans-
formed with pGEM-T Easy clones was performed on LB-agar plates containing ampicillin 
to a final concentration 100 mg/L (Sigma Aldrich Chemie, Zwijndrecht, The Netherlands). 
 
 
Table 1. MtzR H. pylori strains and their rdxA and frxA gene status 
 
Accession numberb H. pylori isolate MIC 
(mg/L)a 
 
rdxA (HP0954) frxA (HP0642) 
Truncated rdxA gene     
   BH9711-176 24  AY568322 AY568330 
   DM9735-58 > 256  AY568328 AY568336 
     
Truncated frxA gene     
   BH9713-141 > 256  AY568323 AY568331 
   DM9642-108 > 256  AY568325 AY568333 
   DM9716-140 32  AY568326 AY568334 
     
Truncated rdxA and frxA genes     
   BH9714-19 128  AY568324 AY568332 
   DM9727-179 192  AY568327 AY568335 
   ATCC 43504c > 256  [8] [23] 
a MICs shown are means of results from three independent experiments. The isolates were considered to be 
resistant when the MIC of metronidazole was ≥ 8 mg/L [11]. 
b rdxA and frxA gene sequences have been deposited into the Genbank database. 
c ATCC, American Type Culture Collection. 
 
 
DNA manipulation 
DNA manipulations were performed according to standard protocols [28]. Oligonucleo-
tides (Table 2, Isogen, Maarsen, The Netherlands), PCR-core system I (Promega, Madison, 
WI, USA) and pGEM-T Easy vector (Promega) were used according to the manufacturer's 
recommendations. Plasmid DNA was isolated with Wizard Plus SV Minipreps DNA 
Purification System (Promega) according to the manufacturer's instructions. Sequencing 
of the obtained plasmid and PCR products was performed by Baseclear (Leiden, The 
Netherlands). 
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Random amplified polymorpic DNA (RAPD) fingerprinting 
RAPD analysis of chromosomal DNA was performed with three independent primers, 
1254, D11344 and D9355 as described before [1]. RAPD products were separated in 2% 
agarose gels containing 0.5 mg/L ethidium-bromide (Promega).  
 
 
Table 2. Oligonucleotides used in this study  
 
Gene/Primer name Nucleotide sequence (5'→3')a 
rdxA (HP0954)   
   RdxA-F1  GCTGATTGTGGTTTATGGTTTGG 
   RdxA-F2  TTGGATCAAGAAAAAAGAAGACAATTATTAA 
   RdxA-F3  GCTGATTGTGGTTTATGGTTTGG 
   RdxA-F4  GAGAGCCGGACAGCCAAATG 
   RdxA-R1  CACCCCTAAAAGAGCGATTAAAACC 
   RdxA-R2  GCAAGAATGGCGCTCGTT 
   RdxA-R3  CCCACAGCGATATAGCATTG 
   
frxA (HP0642)   
   FrxA-F1  GGATATGGCAGCCGTTTATCATT  
   FrxA-R1  GAATAGGCATCATTTAAGAGATTA 
   FrxA-R2  TGGTTCAAGCCCGATTGAAG 
a Oligonucleotides used for amplification were based on the published genome sequence of H. pylori strain 26695 [34]. 
 
The influence of the length of anaerobic incubation on antibiotic resistance 
Minimal inhibitory concentrations (MICs) were routinely determined by E-test (AB 
Biodisk, Solna, Sweden) [11] or agar dilution [35]. The plates were incubated under 
anaerobic conditions for 0, 0.25, 0.5, 1, 2, 4, and 8 hours, and subsequently incubated for 
3 days at 37 °C under microaerophilic conditions. The isolates were considered resistant 
when the MICs of amoxicillin ≥ 8 mg/L, clarithromycin ≥ 2 mg/L, metronidazole ≥ 8 mg/L 
and tetracycline ≥ 4 mg/L [11]. As controls, resistant strains were included for each tested 
antibiotic [6, 11, 12]. All MIC determinations were performed in triplicate. 
 
The influence of chloramphenicol on metronidazole resistance during anaerobiosis  
Bacteria freshly grown on Dent plates were harvested and inoculated in BBN to a cell 
density of ~1×107 colony forming units per mL (CFU/mL), and incubated overnight with 
gentle agitation under microaerophilic conditions. Fumaric acid (Sigma Aldrich Chemie, 
final concentration 0.1%) was then added to the overnight culture to facilitate the 
generation of anaerobic conditions [16]. The culture was split then into 10 mL portions 
and when indicated either supplemented with metronidazole (Sigma Aldrich Chemie, final 
concentration 16 mg/L) and/or chloramphenicol (Sigma Aldrich Chemie, final concen-
tration 10 mg/L). Subsequently the cultures were incubated under microaerophilic or 
anaerobic conditions for 0, 2, 4, 6 and 8 hours. At each time point 1 mL of the broth was 
taken and washed twice with phosphate buffered saline to remove the antibiotics. In order 
to determine the number of viable bacteria, 50 µL of undiluted suspension and 10-1, 10-2, 
10-3, and 10-4 dilutions were plated on Columbia agar plates containing 7% lysed horse 
blood, and incubated under microaerophilic conditions. Present colonies were counted and 
data was expressed as CFU/mL.  
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Nucleotide sequence accession numbers 
The rdxA and frxA gene sequences of the seven MtzR H. pylori isolates have been 
deposited into the GenBank database (Table 1) 
 
 
RESULTS AND DISCUSSION 
 
Effect of anaerobic incubation on minimal inhibitory concentration  
To evaluate the effect of anaerobic incubation on the MIC of metronidazole, seven MtzR 
H. pylori clinical isolates and the MtzR H. pylori reference strain ATCC 43504 were 
selected for this study. To ensure that these strains represented different isolates, RAPD 
fingerprinting was performed with primers D11344 (Figure 1), 1254 and D9355 (data not 
shown). All strains gave different profiles with each of the three primers, indicating they 
represent unrelated isolates.  
 
 
 
Figure 1. The H. pylori isolates used in this study represent unrelated isolates, as shown by RAPD-PCR. DNA 
isolated from the MtzR isolates were amplified with primer D11344 according to standard procedures [1). The 
RAPD-PCR products were separated on a 2.0% agarose gel and stained with ethidium-bromide. Lane 1, 
represents H. pylori reference strain ATCC 43504, Lane 2 to 8, represent BH9711-176, BH9713-141, BH9714-19, 
DM9735-58, DM9727-179, DM9642-108, and DM9716-140, respectively. M, 1 kb marker (Promega). 
 
 
The seven MtzR isolates and reference strain ATCC 43504 were incubated in 
microaerophilic and anaerobic conditions, and the MIC of metronidazole was determined 
by the E-test and agar dilution. Under standard microaerophilic culture conditions, the 
MIC of metronidazole for the eight isolates, as determined by E-test, ranged from 24 to 
> 256 mg/L, (Table 3). These MICs of metronidazole decreased under anaerobic condi-
tions. After 4 hours of anaerobic incubation, the MIC values of metronidazole dropped 
2000 bp
M 1 2 3 4 5 6 7 8
1000 bp
750 bp
500 bp
250 bp
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below the breakpoint of metronidazole (8 mg/L) for three of the eight isolates, and after 
8 hours, all MtzR isolates had become metronidazole-susceptible (Table 3). In contrast to 
metronidazole, the MICs of amoxicillin, clarithromycin and tetracycline were stable 
during anaerobic incubation (data not shown). There were no clear differences found in the 
MIC values between the E-test and agar dilution.  
 
 
Table 3. The effect of anaerobic incubation on metronidazole resistance. 
 
MIC (mg/L)a H. pylori isolates 
T0 T2 T4 T8 
Truncated rdxA gene     
   BH9711-176 24 16 12 3 
   DM9735-58 > 256 32 4 0.75 
     
Truncated frxA gene     
   BH9713-141 > 256 48 24 3 
   DM9642-108 > 256 64 24 2 
   DM9716-140 32 8 4 0.75 
     
Truncated rdxA and frxA genes     
   BH9714-19 128 48 12 4 
   DM9727-179 192 96 16 0.5 
   ATCC 43504 > 256 48 6 0.25 
a MICs shown are means of results from three independent experiments. The isolates were considered to be 
resistant when the MIC of metronidazole was ≥ 8 mg/L [11]. T0, time point zero, start point; T2, T4 and T8, after 
2, 4 and 8 hours of anaerobic incubation, respectively. 
 
 
Effect of metronidazole and anaerobic incubation and on cell viability  
To determine the effect of metronidazole and anaerobic incubation on cell viability, all 
seven MtzR H. pylori isolates and the MtzR reference strain ATCC 43504 were cultured in 
broth under microaerophilic and anaerobic conditions either in the presence or absence of 
16 mg/L metronidazole, and at different time intervals the amount of viable bacteria 
(CFU/mL) were determined. Under standard microaerophilic conditions, the amount of 
viable cells for all tested MtzR isolates varied between 106-107 CFU/mL, and there were 
no significant differences observed in CFU/mL between the cultures with and without 
metronidazole (Figure 2). Similar data were obtained for the cultures without metroni-
dazole that were incubated anaerobically (Figure 2). This suggests that neither the 
incubation with metronidazole nor anaerobic growth conditions alone affect the cell 
viability of the MtzR isolates.  
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Figure 2. The influence of metronidazole and anaerobic incubation on cell viability. H. pylori was grown 
microaerophilically in the presence (filled triangle) and absence (filled square) of 16 mg/L metronidazole, and 
anaerobically (open square). At different time point the CFU/mL was determined. Results shown are a represen-
tative example of one of the MtzR isolates, BH9714-19 and are the means (± SD) of two independent 
experiments performed in duplicate.  
 
 
However, under anaerobic conditions in the presence of metronidazole, the amount of 
viable cells dropped more then 1000-fold when the MtzR isolates were incubated for 
4 hours anaerobically. After 8 hours of anaerobic incubation in the presence of 
metronidazole there were no viable cells present anymore (Figure 3). Since there were no 
differences in cell viability or time-course observed between the MtzR isolates containing 
mutations that resulted in either a truncated RdxA protein or FrxA protein, or a truncation 
in both, this suggests that neither the rdxA gene nor the frxA gene are involved in the 
reversibility of metronidazole resistance in H. pylori. 
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Figure 3. Involvement of the rdxA and/or frxA gene in the reversibility of metronidazole resistance under 
anaerobic conditions. H. pylori was grown in microaerophilic (filled symbols) and anaerobic (open symbols) 
conditions in the presence of 16 mg/L metronidazole, and the CFU/mL were determined. Results shown are for 
representative examples of the MtzR isolates tested. Symbols: square, BH9714-19 (containing mutations 
resulting in a truncated RdxA and FrxA protein); triangle, DM9735-58 (containing mutations resulting in a 
truncated RdxA); circle, BH9713-141 (containing mutations resulting in a truncated FrxA). Results shown are 
the means (± SD) of two independent experiments performed in duplicate. 
 
 
Effect of de novo protein synthesis on reversibility of metronidazole resistance 
during anaerobic incubation. 
To determine whether H. pylori requires de novo protein synthesis for the reversibility of 
metronidazole resistance, all experiments were repeated in broth in the presence of the 
bacterial protein synthesis inhibitor chloramphenicol (10 mg/L). This concentration of 
chloramphenicol was optimized previously, and its effects on the inhibition of the protein 
synthesis and cell viability are known [20]. When the MtzR isolates were incubated 
anaerobically in the presence of metronidazole and chloramphenicol, cell viability was 
reduced (Figure 4). As there was no significant difference in cell viability between the 
cultures with and without chloramphenicol these results indicate that factors that are 
involved in the reversibility of metronidazole resistance are already present under 
microaerophilic conditions. De novo protein synthesis is not required for this 
phenomenon. 
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Figure 4. The effect of blocking de novo protein synthesis on the reversibility of metronidazole resistance. 
H. pylori was grown in broth either with or without metronidazole (16 mg/L) and/or chloramphenicol (10 mg/L) 
under microaerophilic (filled symbols) or anaerobic (open symbols) conditions. Results shown are for a 
representative example (strain BH9714-19) of the MtzR isolates tested. Symbols: square, standard; diamond, 
with metronidazole; triangle, with chloramphenicol; circle, with metronidazole and chloramphenicol. Results 
shown are the means (± SD) of two independent experiments performed in duplicate. 
 
 
Implications of experimental data 
Metronidazole, a nitroimidazole, is administrated as a prodrug that is activated by the 
reduction of the nitro group that is attached to an imidazole ring [9]. Since oxygen has a 
higher reduction potential than metronidazole, this reduction step works out most 
effectively in an environment with low oxygen tension, such as anaerobic cells and 
protozoa [15]. Surprisingly, they were also found to be active against the microaerophilic 
pathogen H. pylori [24]. In many strictly anaerobic bacteria, the activation of 
metronidazole is mediated by the pyruvate:ferredoxin oxidoreductase complex [32]. In 
H. pylori, this function might be fulfilled by the electron carriers, RdxA (HP0954), FrxA 
(HP0642), ferredoxin (FdxA, HP0277), flavodoxin (FldA, HP1161), pyruvate:ferredoxin 
oxidoreductase (PorD, HP1109) and 2-oxoglutarate ferredoxin oxidoreductase (OorD, 
HP0588). As mutations of the latter four nitroreductases were found to be lethal [18, 21], 
we only tested the involvement of the rdxA and frxA genes. In contrast with the findings 
under normal microaerophilic conditions [23, 29], we showed that neither the rdxA nor the 
frxA gene is required for the activation of metronidazole under low oxygen conditions, 
since strains with one or both genes inactivated still become susceptible to metronidazole 
under anaerobic conditions. 
As in vitro MtzR H. pylori isolates lose their resistance to metronidazole after exposure 
to short periods of anaerobiosis [4, 31], it is suggested that this reversibility is mediated by 
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compensatory metabolic pathways that are induced under anaerobic conditions [15, 30]. 
This hypothesis is not supported by our data obtained using the protein synthesis inhibitor 
chloramphenicol. The loss of metronidazole resistance is mediated by a pre-existing 
mechanism that functions under anaerobic conditions and is not dependent on de novo 
protein synthesis, when H. pylori is exposed to these conditions. Since our data excluded 
the role of the RdxA and FrxA proteins in this process, we assume that in H. pylori 
metronidazole is reduced by one of the other known nitroreductases.  
In summary, MtzR H. pylori isolates become fully metronidazole susceptible at low 
oxygen conditions, and this does not require de novo protein synthesis. This reversibility 
in metronidazole resistance also occurred in H. pylori isolates that contained mutations in 
the rdxA and/or frxA genes. Exposure of H. pylori to such low oxygen conditions in the 
gastric mucosa or gastric pit are likely to induce reduction of metronidazole, and thus 
assist in the eradication of MtzR H. pylori. 
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Helicobacter pylori infection is often diagnosed by a rapid urease test or histology of 
gastric biopsy samples; neither test allows testing for susceptibility to antibiotics. For 
amoxicillin, an antibiotic often used in these infections, this is not yet considered a 
problem because stable resistance to amoxicillin has not yet been reported, although 
several amoxicillin-tolerant strains have been isolated from gastric biopsy specimens from 
patients in Italy and the USA [1]. 
We report the isolation of an amoxicillin-resistant strain of H. pylori from an antral 
biopsy sample of a dyspeptic patient in the Netherlands. An 82-year-old man had chronic 
obstructive pulmonary disease for many years, and had received twelve courses of 
amoxicillin during the past 6 years. Biochemical testing and sequencing of 16S rDNA 
confirmed that this strain was indeed H. pylori. The minimal inhibitory concentration 
(MIC) of amoxicillin was determined by E-test, and was 8 mg/L. β-lactamase activity was 
not detected by nitrocephin or cephalosporinase assay. Resistance to amoxicillin remained 
stable after repeated cycles of storage at -80°C and culture, and after repetitive subculture 
on amoxicillin-free blood agar medium. 
Most strains of H. pylori, unlike other human pathogens, are able to take up 
chromosomal DNA from the environment by natural transformation [3]. We isolated 
chromosomal DNA from the amoxicillin-resistant H. pylori strain and introduced it into 
an amoxicillin-susceptible H. pylori strain by natural transformation [3]. In a typical 
experiment, transformation with 1 µg DNA from the resistant strain resulted in the 
occurrence of amoxicillin-resistant colonies at a frequency of one transformant per 
100000 viable bacteria; no amoxicillin-resistant colonies were observed when TE (1 mM 
Tris-HCl (pH 8.0), 0.1 mM EDTA) or DNA from an amoxicillin-susceptible strain was 
used. The MIC of the resistant mutant colonies was increased more than 100-fold 
compared with the susceptible strain, and only slightly lower than that of the resistant 
donor strain. Repetitive subculturing of the resistant mutants proved also that this acquired 
resistance was stable. 
We conclude that the amoxicillin resistance we report is a stable genetic feature, which 
can be easily transferred. Because H. pylori can exchange DNA through natural trans-
formation and also through conjugation [2, 3], spread of amoxicillin resistance among 
H. pylori is a potential threat. Our findings emphasize the importance of amoxicillin 
susceptibility testing for H. pylori in clinical practice. 
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ABSTRACT 
 
Most Helicobacter pylori strains are susceptible to amoxicillin, an important compo-
nent of combination therapies for H. pylori eradication. The isolation and initial cha-
racterization of the first reported stable amoxicillin-resistant (AmxR) H. pylori clinical 
isolate (the Hardenberg strain) have been published previously, but the underlying 
resistance mechanism was not described. Here evidence is presented that the β-lactam 
resistance of the Hardenberg strain results from a single amino acid substitution in 
HP0597, a penicillin-binding protein 1A (PBP1A) homolog of Escherichia coli. 
Replacement of the wild-type pbp1A (HP0597) gene of the amoxicillin-susceptible 
(AmxS) H. pylori strain 1061 by the Hardenberg pbp1A gene resulted in a 100-fold 
increase in the minimal inhibitory concentration (MIC) of amoxicillin. Sequence 
analysis of PBP1A of the Hardenberg strain, the AmxS H. pylori strain 1061, and four 
AmxR 1061 transformants revealed a few amino acid substitutions, of which only a 
single Ser414Arg substitution was involved in amoxicillin resistance. Although we 
cannot exclude that mutations in other genes are required for high-level amoxicillin 
resistance of the Hardenberg strain, this amino acid substitution in PBP1A resulted in 
an increased MIC of amoxicillin that was almost identical to that of the original 
Hardenberg strain. 
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INTRODUCTION 
 
Helicobacter pylori, a spiral shaped Gram-negative bacterium which colonizes the human 
stomach, is the causative agent of chronic active gastritis, peptic ulcer disease, and is 
associated with increased risk for gastric cancer and gastric lymphoma [3, 9, 21]. Anti-
H. pylori therapy often consists of the β-lactam antibiotic amoxicillin in combination with 
one or more antimicrobial drugs, a bismuth component and/or a proton pump inhibitor [9, 
12]. H. pylori is usually susceptible to amoxicillin, but occasionally strains with an 
increased MIC (minimal inhibitory concentration) have been reported. The first reported 
amoxicillin-resistant (AmxR) strains (MIC > 256 mg/L) were isolated from dyspeptic 
patients in Italy and the USA [10], but they all rapidly lost their amoxicillin resistance in 
vitro [8]. Subsequently the isolation of a stable AmxR H. pylori clinical isolate, the 
Hardenberg strain, from an 82-year-old Dutch dyspeptic patient was reported [27].  
Bacterial resistance against β-lactam antibiotics mostly results from either the produc-
tion of β-lactamase [16], structural alterations in one of the penicillin-binding proteins 
(PBPs) [24], or changes in other proteins involved in the cell wall synthesis [4, 17, 29]. 
Initial studies with H. pylori indicated the presence of three high-molecular weight PBPs, 
designated PBP1A, PBP2 and PBP3 [6]. Later a fourth, low-molecular weight PBP, 
PBP4, was identified [14], and subsequently five other potential PBPs [13] and a H. pylori 
specific β-lactamase [19] have been described. Amoxicillin resistance in H. pylori was 
found not to rely on the acquisition or expression of β-lactamase [8, 27]. The nonstable 
amoxicillin resistance of H. pylori [8] is probably due to a decreased expression of the 
penicillin-binding protein, PBP-D [7]. In the recently described in vitro-selected AmxR 
H. pylori strains amoxicillin resistance was suggested to result from alterations in PBP1A 
[5, 22].  
In this study, we describe the molecular mechanism of amoxicillin resistance of the 
Hardenberg strain. Ten genes from the published H. pylori genomes were selected as 
potential candidates based on their putative role in cell wall synthesis (Table 1). After 
genetic transformation of the amoxicillin-susceptible (AmxS) strain 1061, with PCR 
products of the selected candidate genes of the AmxR Hardenberg strain, the minimal PCR 
fragment able to transfer amoxicilline resistance was sequenced and the amino acid 
alterations responsible for amoxicillin resistance were identified. 
 
 
MATERIALS AND METHODS 
 
Bacterial strains and growth conditions 
H. pylori strains used in this study were the AmxR  Hardenberg strain [27], and the AmxS 
H. pylori strains 1061 [11], J99 [2], 26695 [25], and SS1 [15]. Bacteria were routinely 
grown on Columbia agar plates (Becton Dickonson, Cockeysville, MD, USA) supple-
mented with 7% lysed horse blood (BioTrading, Mijdrecht, the Netherlands) and H. pylori 
selective supplement (Oxoid, Basingstoke, UK) for 48 to 72 hours at 37ºC in an atmosphere 
of 5% O2, 10% CO2, 85% N2. Escherichia coli strain DH5α MCR (Life technologies BV, 
Paisley, UK) was grown on Luria-Bertani agar plates [23] for 24 hours at 37ºC in an 
aerobic environment. Selection of E. coli DH5α MCR transformed with pGEM-T Easy 
clones was performed on ampicillin-containing (100 mg/L) Luria-Bertani agar plates. 
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Determination of minimal inhibitory concentration  
The minimal inhibitory concentration (MIC) was routinely determined by E-test (AB 
Biodisk, Solna, Sweden) [10] or by agar dilution [8].  
 
DNA manipulation 
Recombinant DNA techniques were performed according to standard protocols [23]. PCR 
fragments and pGEM-T Easy clones were sequenced on an Amersham Vistra 725 DNA 
sequencer using Thermo-Sequenase pre-mixed cycle sequencing kit (Amersham, Buc-
kinghamshire, UK).  
 
Natural transformation of H. pylori 
Bacteria were transformed with approximately 1 µg total DNA, or 200 to 500 ng PCR 
product essentially as described by Wang et al. [28]. Transformants were selected on Dent 
plates containing 0.2 to 2 mg/L amoxicillin (Sigma Aldrich Chemie, Zwijndrecht, The 
Netherlands). As a control, bacteria were transformed with TE (1 mM Tris-HCl pH 8.0, 
0.1 mM EDTA) or DNA from the AmxS strain 1061.  
 
PCR 
The oligonucleotide primers (Isogen, Maarsen, The Netherlands) used in this study are in-
dicated in Table 1 and Figure 1. PCR was performed in an automated thermal cycler 
(GeneAmp PCR system 9700, Perkin-Elmer), using the PCR-core system I (Promega, 
Madison, WI, USA). 
 
 
Table 1. Transformation with PCR products of putative AmxR genes. 
 
Putitative function of selected gene 
(gene name)a 
Gene numberb Position fragmentc Transformation 
frequencyd 
Penicillin-binding protein (pbp4) HP0160 168848-169882 None 
H. pylori cysteine-rich protein A (hcpA) HP0211 218980-218291 None 
Lysis tolerance protein (lytB) HP0400 411955-411354 None 
Penicillin-binding protein (pbp1A) HP0597 632742-631000 5×10-6 
Rod-shape determining protein (rodA1) HP0743 798879-797794 None 
Rod-shape determining protein (mreC) HP1372 1436921-1436354 None 
Rod-shape determining protein (mreB) HP1373 1438015-1437011 None 
Cell division protein (ftsI) HP1556 1639818-1638044 None 
Penicillin-binding protein (pbp2) HP1565 1648924-1647271 None 
Methicillin resistance protein (llm) HP1581 1660483-1659552 None 
a Genes were selected from the published H. pylori genomes [2, 25] as potential candidates based on their 
putative role in cell wall synthesis. 
b HP gene numbers corresponding to the H. pylori 26695 genome sequence [25].  
c Position of duplicated fragment, corresponding to the H. pylori 26695 genome sequence [25]. Primers used for 
the amplification of the PCR fragments started at the outside of the fragment and had each a length of twenty 
basepairs. 
d Determined as the number of AmxR colonies per microgram of DNA per recipient CFU. Data represent the 
mean of three experiments. 
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Site-directed mutagenesis 
Four different 135 bp oligonucleotides (Isogen) were designed based on the sequence of 
the pbp1A gene of H. pylori strain 1061, except that they contained mismatches resulting 
in none, one, or two amino acid substitutions (Glu406Ala and/or Ser414Arg). For amplify-
cation, 5 pmol of the 135 bp oligonucleotides was used as template, with 25 pmol of each 
terminal primer, 5'-GCTATTCCACGACTTCTAA-3' and 5'-GCAAGGTTACAAGCCCT 
AAA-3'.  
 
Nucleotide sequence accession numbers 
The pbp1A sequences of the H. pylori Hardenberg and 1061 strains have been deposited into 
to the Genbank-database, under accession no. AF479617 and AF479618, respectively. 
 
 
RESULTS AND DISCUSSION 
 
Determination of the MIC of various antibiotics 
The MIC of the four commonly used antibiotics in the anti-H. pylori therapy, as well as 
several β-lactam antibiotics are presented in Table 2. The Hardenberg strain had an MIC 
of amoxicillin of 8 mg/L, while the MIC for strain 1061 was well below 0.016 mg/L. The 
MIC of the other β-lactam antibiotics was significantly higher for the Hardenberg strain 
than for H. pylori strain 1061. MIC values of clarithromycin and tetracycline were identi-
cal for both strains, but the Hardenberg strain was found to be susceptible to metronida-
zole, while strain 1061 is known to be resistant to that drug [11].  
As the E-test was reported to generate discrepant results when compared to the agar 
dilution method [1, 20, 26], and as the E-test does not allow determination of  amoxicillin 
MICs below 0.016 mg/L, the susceptibility to amoxicillin was also tested by agar dilution. 
The MIC of amoxicillin for the Hardenberg strain by agar dilution was slightly higher 
(10 mg/L) than by E-test. For H. pylori strain 1061, the MIC of amoxicillin was 0.01 mg/L. 
 
 
Table 2. MIC values of the Hardenberg strain, H. pylori strain 1061 and AmxR 1061 
transformants determined by E-test. 
 
MIC (mg/L)a Antibiotic 
Hardenberg 1061 Amx
R 1061 
transformantsb 
Amoxicillin 8 < 0.016  0.75 
Amoxicillin-clavulanate 2 < 0.016  0.25 
Cefotaxime  0.75    0.023  0.75 
Ceftazidime 4  0.25 3 
Penicillin 2    0.032  0.25 
Piperacilin 4 < 0.016  0.38 
Clarithromycin < 0.016 < 0.016 < 0.016 
Metronidazole    0.023 192 192 
Tetracycline < 0.016    0.023    0.032 
a Data shown are the averages of three separate experiments. 
b MIC values are the average of ten randomly selected transformants (obtained after transformation with total 
DNA of the Hardenberg strain) derived from three independent transformation experiments. 
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Transfer of amoxicillin resistance by natural transformation 
Transformation of H. pylori strain 1061 with total DNA of the Hardenberg strain resulted 
in AmxR colonies at a frequency of 1×10-5 CFU/µg DNA. The MICs of amoxicillin of ten 
at random selected transformants (obtained from three independent transformation 
experiments) as determined by E-test (Table 2) and agar dilution was 0.75 mg/L and 
1.0 mg/L, respectively. In the agar dilution method, for these transformants the MIC of 
amoxicillin was 100-fold higher than that for the 1061 acceptor strain, and it was only 
slightly lower than that of the Hardenberg donor strain. For the AmxR transformants, the 
MICs of the other β-lactam antibiotics also displayed increases (Table 2). 
 
Transformation with PCR products of cell wall synthesis-encoding genes 
Based on their putative role in cell wall synthesis, ten genes from the published H. pylori 
genome sequences of strain 26695 [25] and strain J99 [2] were selected as potential AmxR 
genes (Table 1). AmxS strain 1061 was transformed with PCR amplified products of the 
selected genes of the AmxR Hardenberg strain. Only transformation with the pbp1A gene 
resulted in AmxR colonies with a frequency of 5×10-6 CFU/µg DNA (Table 1). PCR 
products of the other putative amoxicillin resistance genes, TE, and DNA from strain 
1061 were unable to transfer amoxicillin resistance. The MIC of amoxicillin of ten at 
random selected AmxR colonies (obtained from three independent transformation 
experiments) was identical to that of strain 1061 transformed with total DNA of the 
Hardenberg strain. Repeated transformation of these transformants with either the total 
DNA or the other nine PCR products of the Hardenberg strain did not result in an increase 
of the MIC (data not shown). The MIC of these transformants could be increased to the 
same level as the Hardenberg strain only by continued exposure to amoxicillin, but this 
additional increase of the resistance was not stable. This indicated that the additional 
increase in MIC of amoxicillin for the AmxR 1061 transformants was due to a transient 
physiological change. Apparently a stable increase of amoxicillin resistance to the level of 
the Hardenberg strain requires mutations in more than one locus, and the likelihood that 
these are all transferred by transformation is relatively small. 
 
Identification of pbp1A gene mutations involved in amoxicillin resistance  
To determine the mutations of pbp1A gene responsible for amoxicillin resistance, natural 
transformation experiments were performed using small overlapping PCR fragments of 
the pbp1A gene (Figure 1). AmxR 1061 transformants (7×10-7 CFU/µg DNA) were only 
observed with the 361-bp DNA fragment that spanned nucleotides 953 to 1313 (numbering 
according to the pbp1A gene of H. pylori strain 26695). No AmxR colonies were observed 
after transformation with the seven other pbp1A PCR fragments, TE, or DNA from strain 
1061. The MIC of amoxicillin of ten randomly selected transformants (obtained from three 
independent transformation experiments) was 1.0 mg/L.  
Analysis of PBP1A sequences obtained from the Hardenberg strain, the AmxS 1061 
strain and four AmxR 1061 transformants (obtained with total DNA from the Hardenberg 
strain) showed several amino acid substitutions in the Hardenberg strain as well as in the 
transformants, that did not occur in the AmxS strain. Three transformants had incorporated 
the complete Hardenberg pbp1A gene sequence, while the fourth transformant only 
contained the second half of the gene. For this fourth transformant the DNA exchange  
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apparently occurred between nucleotide 793 and 854. This was independent proof that the 
first 792 bp of the pbp1A gene of the Hardenberg strain are not involved in amoxicillin 
resistance, as was already indicated by transformation with the pbp1A PCR fragments.  
 
 
 
Figure 1. Identification of the region of pbp1A required for amoxicillin resistance. Transformants were obtained 
by transformation of overlapping PCR fragments of the AmxR Hardenberg strain to the AmxS strain 1061. The 
transformation frequency was determined as the number of AmxR colonies per microgram of DNA. Data 
represent the mean of three experiments. Primers used for the amplification of the smaller overlapping PCR 
fragments started at the outside of the fragment and had each a length of twenty base pairs. The first and last 
fragment (hatched area’s) partially consists of the flanking genes of the pbp1A gene, namely HP0596 and 
HP0598.  
 
 
Amoxicillin resistance of pbp1A is due to the Ser414Arg substitution  
Sequence analysis of PBP1A showed two amino acid differences in the region between 
nucleotide 953 and 1313, a glutamic acid by an alanine (Glu406Ala) and a serine by an 
arginine (Ser414Arg). In order to identify which of these amino acid changes was responsible 
for the increase in amoxicillin resistance, site-directed mutagenesis was used. Strain 1061 
was transformed with four different 135 bp fragments coding for amino acids 381 to 426 
(numbering according to the pbp1A gene of H. pylori strain 26695 [25]) containing either 
no, one (Glu406Ala or Ser414Arg), or both amino acid substitutions. AmxR colonies were 
observed only after natural transformation with the two fragments that contained the 
Ser414Arg substitution with transformation frequencies of 7×10-8 and 4×10-8 CFU/µg DNA, 
respectively. Sequence analysis of PBP1A of four randomly selected transformants, 
obtained from two independent transformation experiments with the 135 bp Ser414Arg 
fragment, confirmed that only this substitution was present in these AmxR transformants. 
The MIC of amoxicillin for these transformants was 1.0 mg/L. Beside MIC values of 
amoxicillin, the growth rates (optical density at 600 nm measured at regular intervals 
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during a time period of 48 hours), sizes, and shapes of the bacteria were determined. In 
the absence of amoxicillin no differences between the Hardenberg strain, the four AmxR 
transformants, and strain 1061 were found in growth rates, sizes, or shapes of the bacteria. 
Under amoxicillin pressure (1 mg/L), the bacteria became a little bit shorter and thicker, but 
in spite of this morphological change there was no significant change in growth rates (data 
not shown). 
Site-directed mutagenesis, indicated that the Ser414Arg substitution in PBP1A repre-
sents the main factor in amoxicillin resistance of the Hardenberg strain. Recently, other 
investigators [22] reported that amino acid substitutions, Tyr484Cys, Thr541Ile and Pro600Thr 
in PBP1A are responsible for amoxicillin resistance of an in vitro-selected AmxR H. pylori 
strain. None of these amino acid substitutions play a role in amoxicillin resistance of the 
Hardenberg strain, since these substitutions were not present in the AmxR Hardenberg 
strain. Further, the Ser414Arg substitution in PBP1A in the Hardenberg strain and AmxR 
1061 transformants had no influence on the expressed amount of PBP1A molecules com-
pared to the wild-type PBP1A of H. pylori strain 1061 (data not shown). Probably the 
amino acid substitutions in PBP1A of the Hardenberg strain and the in vitro-selected 
AmxR strain [22] affect the binding affinity of PBP1A for penicillins, but this was not tested.  
 
Role of the pbp1A gene in amoxicillin resistance of other H. pylori strains  
To test the generality of our findings we also transformed the H. pylori strains J99, 26695 
and SS1 (MICs of amoxicillin of 0.01 mg/L, 0.01 mg/L, and 0.2 mg/L, respectively) either 
with PCR product of the pbp1A gene or with total DNA from the Hardenberg strain. With 
all strains, AmxR transformants were isolated at high frequency. Ten AmxR transformants 
of each strain (obtained from two independent transformation experiments) were selected 
at random, and the MIC of amoxicillin was determined. All transformants had a MIC of 
1.0 mg/L, which was identical to the MIC of the AmxR H. pylori 1061 transformants, but 
lower than the MIC of the AmxR Hardenberg strain. These results indicated that also in 
other strains than 1061, the introduction of the pbp1A gene from the Hardenberg increased 
their MIC of amoxicillin.  
The results of our study showed that a single serine to arginine substitution in PBP1A 
induces high-level amoxicillin resistance in H. pylori. Since the existence of H. pylori 
strains with a moderate resistance level against amoxicillin already has been reported [18, 
30], and apparently a single mutation is sufficient to increase the MIC of amoxicillin, an 
increase of naturally occurring high-level AmxR H. pylori strains can be expected in the 
near future. 
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ABSTRACT 
 
Amoxicillin-based therapies are still highly effective in the treatment of Helicobacter 
pylori infections. However, the incidence of amoxicillin resistance in H. pylori is 
increasing, resulting in reduced therapy efficacies. In the present study, the molecular 
mechanism underlying amoxicillin resistance of seven naturally occurring amoxicillin-
resistant (AmxR) H. pylori isolates was investigated. All seven H. pylori isolates were 
negative for β-lactamase activity. Gene transfer experiments indicate that in these 
AmxR H. pylori isolates, resistance is mediated via mutations in the gene encoding the 
penicillin-binding protein 1A (PBP1A). Replacement of the wild-type pbp1A gene of 
the amoxicillin-susceptible (AmxS) H. pylori reference strain 26695 by the pbp1A gene 
of the AmxR H. pylori isolates resulted in an increased MIC of amoxicillin (MIC 0.5-
1.0 mg/L). Analysis of the proteins encoded by the pbp1A genes of the AmxS H. pylori 
strain 26695, the seven AmxR isolates, and their AmxR 26695 transformants revealed 
that three of the AmxR H. pylori isolates contained the previously reported serine to 
arginine substitution at amino acid position 414, whereas the four other isolates 
contained amino acid differences within or adjacent to one of the conserved penicillin-
binding motifs. These differences may affect the structural conformation and stability 
of the PBP1A protein, and thereby cause amoxicillin resistance in H. pylori. Although 
we cannot exclude the role of other genes in amoxicillin resistance of H. pylori, our 
results indicate that mutational changes in the pbp1A gene are the major cause of 
amoxicillin resistance in H. pylori.  
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INTRODUCTION 
 
Helicobacter pylori is a common human pathogen that is strongly associated with the 
development of active gastritis, peptic ulcer diseases and gastric cancer [29]. Successful 
treatment of H. pylori infections not only leads to eradication of the bacterium, but also to 
regression of the associated diseases [14, 30]. In the United States and Europe most anti-
H. pylori therapies consist of two antibiotics in combination with a proton pump inhibitor 
and/or bismuth component [19]. The antibiotic amoxicillin is one of the key components 
of such H. pylori eradication therapies [13]. 
Until the end of the 20th century it was generally accepted that amoxicillin resistance 
in H. pylori was very rare [20], but this is no longer the case. At first, amoxicillin-resistant 
(AmxR) H. pylori isolates were obtained from dyspeptic patients in Italy and the United 
States [6]. As these isolates lost their amoxicillin resistance phenotype upon freezing at 
-80°C, they are often referred to as amoxicillin-tolerant [6]. Later, stable AmxR H. pylori 
isolates were obtained from dyspeptic patients living in different geographic regions [21, 
33, 34]. Currently available amoxicillin resistance rates vary between 0.8% to 1.4% [11, 
22]. If amoxicillin resistance in H. pylori spreads further, serious problems would arise, 
resul-ting in reduced efficacy of amoxicillin-containing regimens [7]. 
In Gram-negative bacteria, resistance to β-lactam antibiotics like amoxicillin is often 
due to the enzymatic degradation of the antibiotic by β-lactamase [18]. Other mechanisms 
such as structural alterations in penicillin-binding proteins (PBPs), decreased membrane 
permeability of antibiotics into the bacterial cell and/or active efflux of the antimicrobial 
drug out of the bacterial cell have also been reported [3, 8, 24]. Although the H. pylori 
genome contains β-lactamase-like genes [23], no significant ß-lactamase activity has been 
detected and thus it seems that amoxicillin resistance in H. pylori does not rely on the 
acquisition or expression of a β-lactamase [5, 33].  
To our knowledge the molecular mechanism underlying amoxicillin resistance has 
thus far only been described for five amoxicillin-tolerant H. pylori isolates [5], three natu-
rally occurring amoxicillin-resistant (AmxR) H. pylori isolates [9, 17, 26], and two in 
vitro-selected AmxR mutants [4, 27]. In the amoxicillin-tolerant H. pylori isolates the 
resistance depends on a lack of the low-molecular-weight penicillin-binding protein 
PBP-D (also called PBP 4, HP0160) [5], whereas in the AmxR H. pylori isolates and in 
vitro-selected mutants the resistance is mediated by mutational changes in the gene 
encoding the penicillin-binding protein 1A (pbp1A; HP0597) [4, 9, 17, 26, 27]. 
In this study we describe the molecular mechanism of amoxicillin resistance in seven 
naturally occurring AmxR H. pylori isolates that were obtained between 1999 and 2003 
from dyspeptic patients from Brazil (n=4) and the Netherlands (n=3). 
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MATERIAL AND METHODS 
 
Bacterial strains and growth conditions 
H. pylori isolates used in this study are listed in Table 1. The H. pylori isolates were 
routinely cultured on Columbia agar plates (Becton Dickonson and Company, Cockeys-
ville, MD, USA) supplemented with 7% lysed horse blood (BioTrading, Mijdrecht, the 
Netherlands) and H. pylori selective supplement (Oxoid, Basingstoke, UK). H. pylori was 
grown for 48 to 72 hours at 37ºC in an atmosphere of 5% O2, 10% CO2, and 85% N2.  
 
Determination of minimal inhibitory concentration  
The minimal inhibitory concentration (MIC) of amoxicillin was routinely determined by 
agar dilution using Mueller-Hinton (Difco, Sparks, MD, USA) plates supplemented with 
5% sheep blood (BioTrading), according to the protocols of the National Committee for 
Clinical Laboratory Standard (NCCLS) [25]. Two µL of 2.0 MacFarland bacterial 
suspensions were inoculated on plates containing a 2-fold serial dilution of amoxicillin 
(Sigma Aldrich Chemie, Zwijndrecht, The Netherlands). As controls, the amoxicillin-
susceptible (AmxS) strain 26695 and AmxR Hardenberg strain were always included, and 
MIC determination was only accepted if the MIC of amoxicillin for these two strains were 
< 0.125 mg/L and > 4 mg/L, respectively. Isolates were considered to be resistant when 
the MIC of amoxicillin exceeded 0.25 mg/L [11]. All MICs of amoxicillin were 
determined in three independent experiments.  
 
Detection of β-lactamase activity 
Production of β-lactamase by H. pylori was tested using the Nitrocefin BBLTM DrySlideTM 
(Becton Dickinson and Company, sparks, MD, USA) according to the manufacturer's 
instructions.  
 
Natural transformation of H. pylori 
The AmxS H. pylori reference strain 26695 was transformed with ~1 µg of genomic DNA 
from an AmxR strain (Table 1), or ~250 ng of pbp1A gene products amplified from 
genomic DNA dissolved in TE (1 mM Tris-HCl (pH 8.0), 0.1 mM EDTA). AmxR trans-
formants were selected on Columbia agar-plates supplemented with 7% lysed horse blood 
and 0.25 mg/L amoxicillin. As controls, bacteria were transformed with either DNA from 
the original Hardenberg strain (AmxR), DNA from strain 26695 (TetS), or TE without 
DNA. 
 
General DNA techniques 
Oligonucleotide primers (Isogen, Maarsen, the Netherlands) used in this study are listed in 
Table 2. PCR was performed in an automated thermal cycler (I-cycler, Biorad Labora-
tories BV, Veenendaal, The Netherlands) using the PCR-core system I (Promega, 
Madison, WI, USA). Direct sequencing of the obtained PCR products was performed by 
Baseclear Inc. (Leiden, The Netherlands).  
 
Nucleotide sequence accession numbers 
The pbp1A gene sequences of the seven AmxR H. pylori isolates have been deposited into 
the GenBank database (Table 1). 
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Table 2. Oligonucleotides used in this study.  
 
Primer name Primer sequence (5'-3')a Position pbp1A geneb 
Hp0597-F1 AGTTTGGGTAACTACGGATA 78 to 97, forward 
Hp0597-F2 TTTGGGCATGGGTATTATGG 505 to 524, forward 
Hp0597-F3 CTAACGCGTCTAATGAAGAT 953 to 972, forward 
Hp0597-F4 TAACCCTTTCAGYGCTGATG 1583 to 1602, forward 
Hp0597-R1 CGCATGAAATACGAATACAC  1820 to 1801, reverse 
Hp0597-R2 AATCTTACCGGTGCTCGTGT 1026 to 1007, reverse 
Hp0597-R3 CTCGTGTGAGCACCATGTTT 400 to 381, reverse 
a Oligonucleotides used for amplification of the pbp1A gene were based on the published genome sequence of 
H. pylori strain 26695 [31]. 
b Position of oligonucleotides are given to the relative start point of the pbp1A gene of H. pylori strain 26695 [31]. 
 
 
RESULTS 
 
MICs of amoxicillin and determination of β-lactamase activity 
The MICs of amoxicillin for four Brazilian and three Dutch AmxR H. pylori isolates were 
determined by agar dilution, and compared with previously described AmxR H. pylori 
strain Hardenberg (MIC 8 mg/L) and the AmxS H. pylori reference strain 26695 (MIC 
< 0.125 mg/L) (Table 1). The MICs of amoxicillin for the four Brazilian AmxR H. pylori 
isolates ranged from 2 to 8 mg/L (susceptibility breakpoint > 0.25 mg/L), whereas the 
MICs of amoxicillin for the three Dutch AmxR H. pylori isolates (SZ79 and the two 
follow-up isolates of the Harderberg strain, H-I and H-II) ranged from 4 to 16 mg/L. All 
MICs remained stable after storage -80°C and repetitive subculturing on amoxicillin-free 
agar plates, indicating that amoxicillin resistance in these seven novel AmxR H. pylori 
isolates is stable. 
There was no β-lactamase activity detectable in any of the isolates when tested by 
using the chromogenic cephalosporin method, excluding a role for β-lactamase in 
amoxicillin resistance in these AmxR isolates. 
 
Transfer of amoxicillin resistance by natural transformation  
To examine whether the resistance to amoxicillin of the seven AmxR strains was 
transferable to AmxS H. pylori, natural transformation was performed using genomic 
DNA isolated from the AmxR strains, with the AmxS H. pylori reference strain 26695 as a 
recipient. AmxR colonies were consistently obtained after transformation with genomic 
DNA isolated from AmxR H. pylori strains, but not when DNA from the AmxS 26695 
strain or TE without DNA was used. The transformation frequencies with DNA from the 
AmxR isolates were identical to that of the Hardenberg positive control and ranged from 
10-4 to 10-7 CFU/µg DNA. MICs of amoxicillin for the AmxR 26695 transformants (two 
transformants from two independent transformation experiments for each isolate tested) 
were determined by agar dilution, and ranged from 0.5 to 1.0 mg/L.  
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The pbp1A gene is involved in amoxicillin resistance 
As stable amoxicillin resistance in all AmxR H. pylori isolates studied thus far is mediated 
by mutations in the pbp1A gene, H. pylori reference strain 26695 (AmxS) was transformed 
with pbp1A PCR fragments amplified from the genomic DNA of the seven AmxR isolates. 
AmxR colonies were obtained for all seven isolates with a transformation frequency of 10-4 
to 10-7 CFU/µg DNA. No AmxR transformants were observed after transformation with 
total DNA or PCR-amplified pbp1A of the AmxS H. pylori reference strain 26695 or TE 
without DNA.  
The MICs of amoxicillin for the obtained transformants ranged between 0.5 and 
1.0 mg/L. Repeated transformation of these transformants with total DNA of their AmxR 
donor strain did not result in an increase of the MIC of amoxicillin. Consistent with pre-
vious observations [9, 26, 27], the MICs of amoxicillin for the AmxR transformants were 
still five to ten-fold lower than the MICs of the original strains. All AmxR transformants 
were then transformed with either total DNA from the Hardenberg strain or total DNA 
from one of the other six AmxR isolates, and plating out on agar plates containing 1-2 mg/L 
amoxicillin to assess an increase in resistance. No AmxR colonies were obtained after 
transformation on agar plates containing 1-2 mg/L amoxicillin.  
 
Identification of PBP1A mutations by sequence analysis 
Sequence analysis of the pbp1A gene PCR fragments obtained from the AmxS H. pylori 
reference strain 26695, the seven AmxR clinical isolates, and their AmxR 26695 
transformants (obtained with chromosomal DNA) revealed multiple amino acid 
differences (Table 3). Most of them were located in the C-terminal part (encoded by 
nucleotide 960 to 1980 [12]) of the PBP1A protein (Table 3). Of the in total 52 amino acid 
differences, the involvement of 24 amino acid differences in amoxicillin resistance can be 
excluded, since 19 of them were present both in AmxS and AmxR H. pylori isolates 
(Figure 1), and the five others were not exchanged by natural transformation (Table 3). Of 
all amino acid differences, there are two amino acid substitutions that stand out, (i) a 
serine to a glycine substitution observed within the PBP1A motif SKN402-404 of two 
Brazilian AmxR isolates (BH13, and 13) and (ii) the previous described [9] serine to 
arginine substitution at position 414 found in the three Dutch AmxR isolates. 
 
 
DISCUSSION 
 
Most H. pylori isolates are still susceptible to amoxicillin, an antibiotic commonly used in 
eradication therapy of H. pylori. Nevertheless, amoxicillin resistance is emerging in 
clinical isolates, especially in countries where this antibiotic can be obtained without 
prescription. Thus far, the molecular mechanism underlying amoxicillin resistance has 
only been identified for a few AmxR and amoxicillin-tolerant H. pylori isolates [4, 5, 9, 
17, 26]. In the AmxR H. pylori isolates the resistance was mediated by differences in the 
gene encoding the PBP1A [9, 17, 26], whereas in the two amoxicillin-tolerant H. pylori 
isolates the resistance was mediated by a lack in PBP-D [5]. In this study, the mechanism 
of amoxicillin resistance was established for seven additional naturally occurring AmxR 
H. pylori isolates.  
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In Gram-negative bacteria, resistance to β-lactams is mostly due to the production 
of β-lactamase, either chromosomally encoded, or plasmid-borne [2]. In contrast, 
alterations in PBPs, have mainly been described in β-lactam-resistant Gram-positive 
bacteria, but they have also been reported in some Gram-negative bacterial species [10, 
28]. Consistent with earlier findings in H. pylori [5, 17, 26, 33], amoxicillin resistance in 
all seven AmxR H. pylori isolates did not rely on an increased β-lactamase activity. In this 
study, we have demonstrated that amoxicillin resistance in these seven AmxR H. pylori 
isolates is stable and mediated by various mutational changes in the gene encoding the 
PBP1A protein.  
Sequence analysis of the PBP1A from the obtained AmxR 26695 transformants 
showed that the majority of the amino acid differences are located in the C-terminal part 
of this protein (Table 3). This region, also called transpeptidase domain of the PBP1A 
[12], contains three conserved PBP motifs: SXXK, SXN and KTG [15]. In H. pylori it is 
thought that the PBP motifs SXN402-404 and KTG555-557 are involved in the formation and 
stabilization of an active cleft [15]. Since in several other bacterial species β-lactam 
resistance is caused by mutations in or adjacent to one of the two motifs [1, 16, 32], it is 
likely that the amino acid changed Ser402Gly, Ser414Arg, Asn562Tyr, or Ile563Val (marked 
in Figure 1) are involved in amoxicillin resistance of H. pylori, but this remains to be 
confirmed by targeted mutational studies.  
In summary, in naturally occurring AmxR H. pylori isolates, amoxicillin resistance is 
mediated by various mutational changes in the pbp1A gene. Although we cannot exclude 
the role of other genes in amoxicillin resistance, our results indicate that mutational 
changes in the pbp1A gene are the major contributing factor to this resistance.  
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An estimated 4 to 5 million individuals in the Netherlands are actively infected with 
Helicobacter pylori. Eradication of this bacterium becomes more difficult as the prevalence 
of antibiotic resistance is increasing worldwide. Most H. pylori infections are now 
diagnosed by non-invasive testing (i.e. urea breath test, serology, stool test), and thus data 
on antibiotic susceptibility are lacking. Furthermore, once the antibiotic susceptibility is 
assessed using conventional culture-based methods by means of an E-test, agar dilution or 
disc-diffusion, then data are difficult to compare between different centers due to lack of 
standardization. Molecular-based methods are reproducible and easily standardized, and 
thus they can offer an attractive alternative. To develop molecular-based methods know-
ledge of molecular mechanisms underlying antibiotic resistance is mandatory. The re-
search presented in this thesis aims to obtain information on molecular mechanisms of 
antibiotic resistance in H. pylori. The clinical implications, the molecular mechanisms of 
antibiotic resistance in H. pylori and molecular detection methods developed thus far are 
presented in Chapter 2. 
 
 
Molecular mechanism of tetracycline resistance in H. pylori  
 
Most H. pylori strains are susceptible to tetracycline, but currently the incidence of 
tetracycline resistance in H. pylori seems to increase. In Chapter 3 the isolation and 
characterization of the first Dutch tetracycline-resistant H. pylori isolate (strain 181) is 
described. In this study, twelve genes were selected from the published H. pylori genome 
sequences as potential candidates (i.e. seven efflux genes, three ribosomal protection 
genes and two 16S rRNA genes), and tested for the ability to transfer tetracycline 
resistance to tetracycline-susceptible H. pylori strains. Only the two 16S rRNA genes 
(rrnA and rrnB) were able to transfer the resistance. Subsequently it was shown that a 
single triple-base-pair substitution AGA926-928TTC (numbering according to 16S rrnA of 
H. pylori strain 26695), present within both copies of the 16S rRNA genes mediates 
tetracycline resistance in H. pylori strain 181. As the minimal inhibitory concentration 
(MIC) of tetracycline for the tetracycline-resistant H. pylori strain 181 and the obtained 
tetracycline-resistant transformants containing the AGA926-928TTC substitution were 
similar, we believe that this substitution is fully responsible for tetracycline resistance in 
H. pylori strain 181. 
In Chapter 4, site-directed mutants containing single-, double- or triple-base-pair 
substitutions at position 926 to 928 of the 16S rRNA genes were constructed in the 
tetracycline-susceptible H. pylori reference strain 26695. In a similar isogenic back-
ground, the effect of the different 16S rRNA mutations on the growth rate, stability and 
the level of tetracycline resistance (MIC) were studied. Replacement of one or two base 
pairs in the 16S rRNA region 926 to 928 of the tetracycline-susceptible H. pylori strain 
reduced growth rates without inducing tetracycline resistance. Mutants that contained the 
naturally occurring TTC substitution had the highest growth rates and highest MIC values 
(MIC of tetracycline 8 mg/L). Apart from the TGA and AGC mutations, all other 
16S rRNA mutations were stable upon repeated subculturing both in the presence and in 
the absence of tetracycline. The preference in H. pylori for the AGA926-928TTC triple-base- 
pair substitution as main mechanism for tetracycline resistance in H. pylori most likely 
results from differences in growth rates, levels of resistance, and the stability of the 
mutations. 
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The study presented in Chapter 5 confirms and extends the conclusions of Chapter 3. 
In five unrelated tetracycline-resistant H. pylori clinical isolates obtained from dyspeptic 
patients from Brazil, tetracycline resistance was mediated by the exact same triple-base-
pair substitution as was present in the Dutch isolate, H. pylori strain 181. Both studies 
imply that, to confer tetracycline resistance, H. pylori requires the triple-base-pair 
AGA926-928TTC substitution within both copies 16S rRNA genes.  
Tetracycline resistance in H. pylori probably emerges by a stepwise process that is 
driven by selection depending on the duration and the dose of tetracycline in treatment. 
Therefore, it was not a surprise that low-level tetracycline-resistant H. pylori strains 
(MICs below the tetracycline susceptibility breakpoint of 4 mg/L) were isolated that 
contain single- or double-base-pair substitutions at position 926 to 928, i.e. A926G, A928C 
AG926-927GT, and A926G/A928C (Chapter 6 and [5]).  
The finding that H. pylori requires for tetracycline resistance a triple-base-pair substi-
tution within both copies of the 16S rRNA genes, may explain the low prevalence of this 
resistance. However, we expect a higher incidence of low-level tetracycline-resistant H. pylori 
isolates with single- and double-base-pair substitutions as a result of insufficient antibiotic 
therapy. In order to evaluate the prevalence of single-, double-, and triple-base-pair substi-
tutions in this region, we need to develop quick molecular screening techniques.  
 
 
Molecular detection methods for tetracycline resistance in H. pylori  
 
Conventional methods to assess levels of tetracycline resistance of H. pylori are culture- 
based. These methods are slow (data are usually obtained only after 6 to 10 days), 
cumbersome, and fail in approximately 10% of the cases due to contamination of the 
biopsy samples or growth failure. Since tetracycline resistance seems to be restricted to 
the occurrence of specific 16S rRNA mutations, molecular methods offer an attractive 
alternative. In Chapter 5 a PCR-based restriction fragment length polymorphism (RFLP) 
was used to detect the triple-base-pair substitution AGA926-928TTC. This simple assay 
distinguishes tetracycline-resistant H. pylori isolates from the low-level tetracycline-
resistant and tetracycline-susceptible H. pylori isolates, and thus allows rapid detection of 
tetracycline resistance in H. pylori. 
In Chapter 6, a real-time PCR followed by melting curve analysis using LightCycler 
technology was developed. In contrast to the PCR-RFLP develop in Chapter 5, this assay 
was able to detect all previous reported mutations. The wild-type AGA sequence showed 
the highest melting temperature (57.4°C), whereas the single- (49.6-53.8°C), double- 
(46.3-49.1°C) and triple-base-pair (46.0°C) substitution displayed lower melting points. 
This method was originally developed on DNA extracts from cultured H. pylori isolates, 
and is now optimized for direct detection of H. pylori tetracycline resistance in gastric 
biopsy samples. 
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Oxygen-dependent metronidazole resistance in H. pylori 
 
Metronidazole resistance in H. pylori reduces the efficacy of metronidazole-containing 
regimens. Nevertheless, it does not make them completely ineffective as therapeutically 
agent. The discrepancy observed between in vitro metronidazole resistance and treatment 
outcome may partially be explained by the antimicrobial activity of other components in 
the regimens and/or duration and doses of the therapy. Apart from these factors, it is 
thought that a low oxygen tension in the gastric environment also participates in this 
process, as in vitro metronidazole-resistant H. pylori strains become metronidazole-
susceptible after short periods of anaerobiosis [4].  
Metronidazole is administrated as a prodrug that needs to be activated by a reduction 
reaction. In H. pylori the rdxA and frxA genes encode reductases have been associated 
with the activation of metronidazole. Inactivation of these genes potentially results in 
metronidazole resistance. In Chapter 7 the role of inactivating mutations in these genes 
on oxygen-dependent metronidazole resistance was investigated. Clinical isolates of 
H. pylori containing null mutations in the rdxA and frxA gene were incubated under 
anaerobic conditions either in the presence or absence of metronidazole, and the effect on 
reversibility of metronidazole resistance was determined. All metronidazole-resistant iso-
lates became susceptible under anaerobic conditions, which suggests that metronidazole 
susceptibility may be restored at low oxygen conditions through the activation of potential 
anaerobic reduction pathways. However the loss of metronidazole resistance also occurred 
in the presence of the protein synthesis inhibitor chloramphenicol. This indicates that 
metronidazole is reduced by a pre-existing mechanism that functions under anaerobic con-
ditions, and does not require de novo protein synthesis. Moreover, the results suggest that 
the RdxA and the FrxA proteins do not participate in oxygen-dependent metronidazole 
resistance, since metronidazole-resistant H. pylori containing inactivated rdxA and/or frxA 
genes become metronidazole-susceptible under anaerobic conditions. It is likely that 
metronidazole is activated by one of the other known nitroreductases such as ferredoxin 
(FdxA, HP0277), ferredoxin-like protein (FdxB, HP1508), flavodoxin (FldA, HP1161), 
pyruvate:ferredoxin oxidoreductase (PorD, HP1109) and/or 2-oxoglutarate ferredoxin 
oxidoreductase (OorD, HP0588). 
 
 
Molecular mechanism of amoxicillin resistance in H. pylori 
 
Amoxicillin-based therapies are still highly effective for the treatment of H. pylori 
infections, but the incidence of amoxicillin resistance is increasing, resulting in reduced 
therapy efficacies. Chapter 8 describes the isolation of the first reported stable 
amoxicillin-resistant H. pylori clinical isolate (the Hardenberg strain). This strain was 
isolated from an 82-year-old Dutch dyspeptic patient who had received twelve courses of 
amoxicillin over the past 6 years for the treatment of chronic obstructive pulmonary 
disease. The Hardenberg strain was negative for β-lactamase activity. In a transformation 
experiment, it was shown that the resistance in the Hardenberg strain could be transferred 
to an amoxicillin-susceptible H. pylori strain, indicating that a genetic feature achieves the 
resistance. Chapter 9 describes the characterization of the molecular mechanism 
underlying amoxicillin resistance in the Hardenberg strain. Based on their putative role in 
cell wall synthesis, ten genes were selected from the published H. pylori genome  
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sequences as potential candidates in amoxicillin resistance. These genes were amplified 
from genomic DNA of the Hardenberg strain and tested for their ability to transfer 
amoxicillin resistance to amoxicillin-susceptible H. pylori strains. Only the replacement of 
the wild-type pbp1A gene (encoding the penicillin-binding protein 1A, HP0597) by the 
pbp1A gene of the Hardenberg resulted in an increased MIC of amoxicillin. Sequence 
analysis of the minimal fragment able to transfer amoxicillin resistance revealed two 
amino acid substitutions (Glu406Ala and Ser414Arg) that either participates alone or 
together in amoxicillin resistance of the Hardenberg strain. Using site-directed 
mutagenesis we showed that amoxicillin resistance of the Hardenberg strain was mediated 
by the Ser414Arg substitution in PBP1A.  
Chapter 10 describes the molecular mechanism underlying amoxicillin resistance of 
seven additional amoxicillin-resistant H. pylori clinical isolates, obtained between 1999 
and 2003 from dyspeptic patients from Brazil and the Netherlands. Consistent with the 
findings of Chapter 9, amoxicillin resistance in these seven amoxicillin-resistant 
H. pylori isolates was mediated by mutational changes in the gene encoding the PBP1A 
protein. Three of the amoxicillin-resistant H. pylori isolates contained the previously men-
tioned Ser414Arg substitution, whereas the four other isolates contained mutations within 
or adjacent to one of the conserved penicillin-binding motifs. These mutations may affect 
the structural conformation of the PBP1A protein and consequently reduce the affinity of 
the PBP1A protein for amoxicillin, thereby causing amoxicillin resistance in H. pylori. 
However, this hypothesis remains to be investigated by targeted mutational studies and/or 
affinity binding studies with amoxicillin and PBP1A. 
As the MICs of amoxicillin for the obtained amoxicillin-resistant transformants were 
slightly lower than that of the original amoxicillin-resistant H. pylori strains (Chapter 8, 9 
and 10), we cannot exclude the role of additional genes in H. pylori amoxicillin resis-
tance. In this context, it has been demonstrated that decreased membrane permeability 
enhances amoxicillin resistance in H. pylori [6, 14]. Changes in lipopolysaccharides, 
phospholipid bilayers and outer membrane proteins, like porins HopA to HopE, may all 
affect the permeability of the membrane and thereby mediate the decreased uptake of 
amoxicillin in H. pylori. However, this issue remains to be investigated. 
 
 
Concluding remarks  
 
H. pylori infections is now generally accepted as an important cause of chronic active 
gastritis, peptic ulcer disease and gastric cancer. Infection with H. pylori is a worldwide 
problem, and currently, the only feasible cure for H. pylori is antibiotics treatment. The 
extensive use and limited choice of antibiotics for this therapy contributes to the develop-
ment of antibiotic resistance, and may threaten the treatment of H. pylori-related disorders. 
To gain a better understanding of the effect of resistance on therapy outcome and to guide 
anti-H. pylori therapy, antibiotic resistance in H. pylori should be monitored. Data obtained 
by national and international surveillance programs can be used to improve therapy 
strategies, and slow down the development of antibiotic resistance in H. pylori. As in most 
countries, including the Netherlands, H. pylori infections are diagnosed by non-invasive 
testing (no data available on antibiotic susceptibility), and surveillance programs to 
monitor antibiotic resistance in H. pylori are lacking, most therapies are prescribed on 
insufficient data.  
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The research described in this thesis has primarily been focused on the elucidation of 
the molecular mechanisms underlying tetracycline, metronidazole and amoxicillin 
resistance in H. pylori. In summary, tetracycline resistance in H. pylori is mediated by the 
triple-base-pair substitution AGA926-928TTC in both 16S rRNA genes (Chapter 3, 4 
and 5), whereas metronidazole resistance in H. pylori is caused on mutational changes in 
the rdxA and frxA genes (Chapter 7), and amoxicillin resistance in H. pylori seems to be 
based by various mutations in the pbp1A gene (Chapter 9 and 10). These findings are 
consistent with previous reported antibiotic resistance mechanisms of H. pylori; they all 
rely on point mutations of genes located in the chromosome [8, 11, 16, 20]. Although in 
H. pylori horizontal gene transfer among susceptible and resistant strains has been 
described [18], it appears that most mutations conferring antibiotic resistance arise de 
novo [21]. Therefore, mono- and dual-therapies based on one antibiotic should be avoided, 
as it will promote the induction and spread of antibiotic resistance in H. pylori.  
Conventional culture-based susceptibility testing of H. pylori is not only time-
consuming, but also standardization of the tests is lacking. As the majority of antibiotic 
resistance mechanisms in H. pylori are restricted to specific point mutations, molecular-
based methods offer an attractive alternative. In contrast to culture-based susceptibility 
assays, these methods are reproducible and easily standardized, as they are independent of 
cell viability and growth rate of the bacteria. Moreover, they are faster than the conven-
tional culture-based assays. When directly applied on gastric biopsy samples (transport 
time excluded), data can be obtained at the day of endoscopy. Using the knowledge on 
molecular mechanisms of antibiotic resistance in H. pylori, several molecular-based 
methods are now for hand to assess clarithromycin, tetracycline, and ciprofloxacin 
resistance in H. pylori. For metronidazole and amoxicillin resistance such methods are 
lacking, and do not seem to be forthcoming.  
As nowadays most H. pylori infections are diagnosed by non-invasive testing, time 
and effort should be invested in the development of simple non-invasive molecular-based 
techniques that are able to detect antibiotic resistance of H. pylori in alternative clinical 
samples such as feces.  
 
 
Future perspectives  
 
In H. pylori, several virulence factors, such as urease, the vacuolating toxin A (VacA), the 
cytotoxin-associated antigen (CagA), and the blood-group-antigen binding adhesin 
(BabA) have all been used for the development of vaccines. Although phase I and II 
clinical trials are performed in humans [2, 7, 15], a commercial vaccine is still not 
available. Other potential developments in H. pylori treatment are: (i) antimicrobial 
peptides such as magainins, LL-37/hCAP18, and defensins [1, 10, 12]. They participate in 
the innate and adaptive immunity of nearly all living creatures [13]; (ii) porphyrins, they 
are a class of naturally occurring compounds that exhibit antimicrobial activity through 
catalyzing peroxidase and oxidase reactions [19]; and (iii) new diets, based on essential 
oils [3, 17] or probiotics [9]. These agents may be used as monotherapy, or synergistically 
to enhance the efficacy of existing anti-H. pylori therapy. Initial studies using these 
components are promising, and open a new field of research to improve the treatment of 
H. pylori infections. 
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SAMENVATTING EN CONCLUSIES 
 
Ruim 4 miljoen Nederlanders zijn besmet met Helicobacter pylori. Door de wereldwijde 
toename van antibioticum resistentie wordt de behandeling van een maaginfectie met deze 
bacterie steeds gecompliceerder. Daar op dit moment de meeste H. pylori infecties 
gediagnostiseerd worden met behulp van niet-invasieve testen (b.v. ureum ademtest, sero-
logie, stool antigen test), is informatie over antibioticum gevoeligheid van deze bacterie 
vaak niet voor handen. Echter, indien de gevoeligheid wordt bepaald met op kweek 
gebaseerde technieken (E-test, agar dilutie en disk diffusie), kunnen de verkregen waarden 
moeilijk met elkaar worden vergeleken door het ontbreken van standaardisatie. Mole-
culaire testen daarentegen zijn reproduceerbaar en gemakkelijk te standaardiseren; zij 
bieden dus een aantrekkelijk alternatief. De ontwikkeling van deze technieken vereist 
echter inzicht in moleculaire mechanismen van antibioticum resistentie. Het onderzoek 
gepresenteerd in dit proefschrift was voornamelijk gericht op het ontrafelen van mole-
culaire mechanismen van antibioticum resistentie in H. pylori. De klinische implicaties, de 
moleculaire mechanismen van antibioticum resistentie in H. pylori en de tot op heden 
ontwikkelde moleculaire detectie technieken zijn beschreven in hoofdstuk 2. 
 
 
Moleculair mechanisme van tetracycline resistentie in H. pylori  
 
De meeste H. pylori stammen zijn gevoelig voor het antibioticum tetracycline, maar in de 
laatste paar jaar neemt de incidentie van tetracycline resistentie in H. pylori gestaag toe. 
Hoofdstuk 3 rapporteert de isolatie en karakterisatie van de eerste Nederlandse tetracycline-
resistente H. pylori stam (181). Voor dit onderzoek werd uit de gepubliceerde H. pylori 
genoom sequentie twaalf genen geselecteerd als potentiële kandidaten voor tetracycline 
resistentie. Dit betrof zeven efflux genen, drie ribosomale protectie genen en twee 
16S rRNA genen. Alle twaalf genen werden in een transformatie experiment getest op hun 
vermogen om tetracycline resistentie over te dragen naar een tetracycline-gevoelige 
H. pylori stam. Slechts twee genen, de 16S rrnA and rrnB genen waren hiertoe in staat. 
Vervolgens werd in deze genen aangetoond dat één enkele drievoudige basenpaar 
verandering AGA926-928TTC verantwoordelijk is voor de resistentie. Aangezien de 
resistentie waarden (ook wel MIC genoemd) van de tetracycline-resistente H. pylori stam 
181 en de verkregen tetracycline-resistente AGA926-928TTC transformanten gelijk waren, 
is het aannemelijk dat de AGA926-928TTC verandering volledig verantwoordelijk is voor de 
resistentie in stam 181. 
In hoofdstuk 4 werden zeven gerichte mutanten gecreëerd in de tetracycline-gevoelige 
H. pylori referentie stam 26695. Deze mutanten bevatten één, twee of drie basenpaar 
veranderingen op de 16S rRNA posities 926 tot 928. In een gelijkwaardige, isogene 
achtergrond werd het effect van het verschillende 16S rRNA mutaties op de groeisnelheid, 
stabiliteit en het resistentie niveau gemeten. Vervanging van één of twee basenparen in de 
16S rRNA regio 926 tot 928 van de tetracycline-gevoelige H. pylori stam leidde tot een 
verlaging van de groeisnelheid, echter zonder inductie van tetracycline resistentie. De 
mutanten die de natuurlijk voorkomende TTC mutatie bevatten, hadden de hoogste groei-
snelheden en de hoogste MIC waarden (MIC van 8 mg/L). Met uitzondering van de TGA 
en AGC mutaties, waren alle 16S rRNA mutaties stabiel tijdens herhaalde 
kweekexperimenten in de aan- en afwezigheid van tetracycline. De voorkeur van H. pylori 
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voor de drievoudige AGA926-928TTC mutatie als voornaamste mechanisme van tetracycline 
resistentie in H. pylori wordt kennelijk veroorzaakt door verschillen in groeisnelheid, 
niveau van resistentie en stabiliteit van de mutatie. 
De studie gepresenteerd in hoofdstuk 5 ondersteunt de conclusies van hoofdstuk 3. In 
vijf niet-verwante klinische tetracycline-resistente H. pylori isolaten, verkregen van 
Braziliaanse dyspeptische patiënten, werd tetracycline resistentie veroorzaakt door dezelf-
de drievoudige basenpaar verandering als gevonden in stam 181. Beide studies impliceren 
dat H. pylori de drievoudige AGA926-928TTC mutatie in beide 16S rRNA genen vereist 
voor tetracycline resistentie.  
In H. pylori ontstaat tetracycline resistentie waarschijnlijk door een stapsgewijs 
proces, dat berust op selectie afhankelijk van de duur en de dosis van tetracycline in de 
therapie. Om deze reden was het ook geen verrassing dat laag-resistente H. pylori 
stammen (MIC waarden beneden het tetracycline gevoeligheidsbreekpunt van 4 mg/L) 
werden geïsoleerd met één of twee basenpaar veranderingen op positie 926 tot 928 
namelijk A926G, A928C, AG926-927GT en A926G/A928C (hoofdstuk 6 en [5]). 
Het gegeven dat in H. pylori voor tetracycline resistentie meerdere mutaties in twee 
genen vereist zijn, verklaart mogelijk de lage prevalentie van deze resistentie. Tevens is 
het aannemelijk dat het aantal H. pylori isolaten met één en twee basenpaar veranderingen 
hoger is dan de tot nu toe gerapporteerde aantal, als gevolg van falende antibioticum 
therapieën. Voor de evaluatie van de prevalentie van één, twee en drievoudige basenpaar 
veranderingen in deze regio, dienen snelle moleculaire detectie technieken te worden 
ontwikkeld.  
 
 
Moleculaire detectie technieken voor tetracycline resistentie in H. pylori 
 
De traditionele technieken voor de bepaling van tetracycline resistentie in H. pylori zijn 
op kweek gebaseerd. Deze technieken zijn langzaam (resultaten worden meestal pas 
verkregen na 6 tot 10 dagen) en falen in ongeveer 10% van de gevallen door contaminatie 
van het biopt of door groeiproblemen. Aangezien tetracycline resistentie waarschijnlijk 
beperkt is tot het voorkomen van specifieke 16S rRNA veranderingen, bieden moleculaire 
technieken een aantrekkelijk alternatief. In hoofdstuk 5 werd een PCR gebaseerde 
restrictie fragment lengte polymorfisme (RFLP) gebruikt voor de detectie van de drie-
voudige basenpaar verandering AGA926-928TTC. Deze eenvoudige methode onderscheidt 
tetracycline-resistente H. pylori isolaten met de AGA926-928TTC mutatie van laag-resistente 
en gevoelige H. pylori isolaten.  
In hoofdstuk 6 werd een real-time PCR gevolgd door een smeltpunt analyse 
beschreven op basis van LightCyler technologie. In tegenstelling tot de PCR-RFLP 
beschreven in hoofdstuk 5 is deze methode in staat om alle tot nu toe gerapporteerde 
veranderingen te detecteren. De wild-type AGA sequentie vertoonde de hoogste 
smelttemperatuur (57,4ºC), terwijl de smelttemperaturen van de enkele (49,6-53,8ºC), 
dubbele (46,3-49,1ºC) en drievoudige (46,0ºC) basenpaar veranderingen lager waren. 
Deze techniek was oorspronkelijk ontwikkeld op geëxtraheerd DNA van gekweekte 
H. pylori isolaten, maar wordt momenteel geoptimaliseerd voor de directe detectie van 
tetracycline resistentie in H. pylori positieve maagbiopten. 
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Zuurstof-afhankelijke metronidazol resistentie in H. pylori   
 
Metronidazol resistentie in H. pylori reduceert de effectiviteit van een metronidazol 
gebaseerde anti-H. pylori therapie. Het maakt echter deze therapie niet volledig ongeschikt. 
De waargenomen discrepantie tussen de metronidazol resistentie waarden en het slagings-
percentages van de therapieën kan gedeeltelijk verklaard worden door de antimicrobiële 
activiteit van de andere componenten, de duur en/of de dosis van de therapie. Aangezien 
in vitro metronidazol-resistente H. pylori stammen metronidazol gevoelig worden na een 
korte periode van anaerobiosis, denkt men dat een lagere zuurstofspanning in de maag 
tevens een bijdrage levert in dit proces [4]. 
Het antibioticum metronidazol is een prodrug die geactiveerd dient te worden. In 
H. pylori zijn de rdxA en frxA gen coderende reductases hiervoor verantwoordelijk. 
Inactivatie van deze genen leidt dan ook meestal tot metronidazol resistentie. In hoofdstuk 7 
werd de rol van inactiverende rdxA en frxA genmutaties op zuurstof-afhankelijke metro-
nidazol resistentie bestudeerd. Zeven klinische H. pylori isolaten met een nul mutatie 
(geïnactiveerd gen) in het rdxA en/of frxA gen werden gekweekt onder anaërobe condities, 
in aan- en afwezigheid van metronidazol. Vervolgens werd het effect van deze condities 
op de omkeerbaarheid van metronidazol resistentie onderzocht. Alle metronidazol-
resistente isolaten werden metronidazol gevoelig onder anaërobe condities. Dit suggereert 
dat metronidazol gevoeligheid hersteld kan worden onder lage zuurstof condities, 
mogelijk door de activatie van één of meerdere anaërobe reductie routes. Het verlies van 
metronidazol resistentie trad echter ook op in aanwezigheid van de eiwitsyntheseremmer 
chlooramfenicol. Dit impliceert dat metronidazol wordt gereduceerd door een reeds 
bestaand mechanisme dat functioneert onder anaërobe condities en geen de novo eiwit-
synthese vereist. Verder suggereren de resultaten dat de RdxA en FrxA eiwitten geen rol 
spelen in zuurstof-afhankelijke metronidazol resistentie, aangezien metronidazol-resistente 
H. pylori stammen met een geïnactiveerd rdxA en/of frxA gen metronidazol gevoelig 
worden onder anaërobe condities. Mogelijk wordt metronidazol onder deze condities 
geactiveerd door een reeds bekend nitroreductase, bijvoorbeeld ferredoxine (FdxA, 
HP0277), ferredoxine-achtig eiwit (FdxB, HP1508) flavodoxine (FldA, HP1161), 
pyruvaat:ferredoxine oxidoreductase (PorD, HP1109) en/of 2-oxoglutarate ferredoxine 
oxidoreductase (OorD, HP0588).  
 
 
Moleculaire mechanisme van amoxicilline resistentie in H. pylori  
 
Tot voor kort waren de meeste anti-H. pylori therapieën gebaseerd op amoxicilline zeer 
effectief. Echter door de stijgende incidentie van amoxicilline resistentie neemt de 
effectiviteit van deze therapieën gestaag af. Hoofdstuk 8 beschrijft de isolatie van het 
eerste gerapporteerde stabiele amoxicilline-resistente H. pylori isolaat, ook wel de 
Hardenberg stam genoemd. Deze stam werd geïsoleerd bij een 82-jarige Nederlandse 
dyspeptische patiënt die in de afgelopen 6 jaar twaalf maal een amoxicilline kuur had 
ontvangen voor de behandeling van een chronische obstructieve longziekte. De Hardenberg 
stam vertoonde geen β-lactamase activiteit. Tijdens een transformatie experiment werd 
aangetoond dat de resistentie in de Hardenberg stam overgedragen kon worden naar een 
amoxicilline-gevoelige H. pylori stam. Dit wijst erop dat de resistentie waarschijnlijk 
berust op een genetische verandering.  
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Hoofdstuk 9 beschrijft de karakterisatie van het moleculaire mechanisme van amoxi-
cilline resistentie in de Hardenberg stam. Op basis van hun vermeende rol in de celwand 
synthese werden tien genen als potentiële kandidaten geselecteerd uit de gepubliceerde 
H. pylori genoom sequentie. Deze genen werden geamplificeerd van genomisch DNA van 
de Hardenberg stam en getest op hun vermogen om amoxicilline resistentie over te dragen 
op een amoxicilline-gevoelige H. pylori stam. Alleen vervanging van het wild-type pbp1A 
gen (codeert voor het penicilline bindende eiwit 1A, HP0597) door het pbp1A gen van de 
Hardenberg stam resulteerde in een verhoging van de MIC. Sequentie analyse van het 
kleinst mogelijke fragment dat in staat was de resistentie over te dragen, liet twee 
aminozuur veranderingen zien, een Glu406Ala en Ser414Arg. Vervolgens werd, door 
gebruik te maken van gerichte mutanten, aangetoond dat amoxicilline resistentie in de 
Hardenberg stam wordt veroorzaakt door de Ser414Arg verandering in het PBP1A eiwit. 
Hoofdstuk 10 beschrijft het moleculaire resistentie mechanisme van zeven additionele 
klinische amoxicilline-resistente H. pylori isolaten. Deze isolaten werden tussen 1999 en 
2003 geïsoleerd uit Braziliaanse en Nederlandse patiënten met dyspeptische klachten. 
Overeenkomstig met de bevindingen van hoofdstuk 9, werd de resistentie in deze zeven 
amoxicilline-resistente H. pylori isolaten veroorzaakt door mutaties in het pbp1A gen. 
Drie van de isolaten bevatten de hierboven genoemde Ser414Arg verandering, terwijl de 
vier andere isolaten mutaties bevatten die gelegen zijn in of aangrenzend aan één van de 
geconserveerde penicilline bindingsmotieven. Deze veranderingen kunnen een effect 
hebben op structurele samenstelling van het PBP1A eiwit, met als gevolg een reductie van 
de affiniteit van het PBP1A eiwit voor amoxicilline, wat op hun beurt kan leiden tot 
amoxicilline resistentie. Echter dient deze hypothese nog onderzocht te worden met 
gerichte mutant studies en/of affiniteit bindingsstudies met amoxicilline en het PBP1A 
eiwit. 
Aangezien de resistentie waarden van de amoxicilline-resistente H. pylori trans-
formanten iets lager waren dan de resistentie waarden van de originele amoxicilline-
resistente stammen, kan de rol van additionele genen in amoxicilline resistentie bij 
H. pylori niet worden uitgesloten. In lijn met deze veronderstelling is recent gebleken dat 
amoxicilline resistentie in H. pylori toeneemt door een verlaagde membraanpermeabiliteit 
[6, 14]. Veranderingen in lipopolysacchariden, fosfolipiden en buitenmembraaneiwitten, 
zoals de porines HopA tot HopE, kunnen allen effect hebben op de membraanpermea-
biliteit en dus een rol spelen in de verlaagde opname van amoxicilline door H. pylori. Dit 
laatste vraagstuk is echter nog niet opgehelderd.  
 
 
Conclusies 
 
Het is nu algemeen geaccepteerd dat H. pylori infecties een belangrijke rol spelen in de 
ontwikkeling van chronische actieve gastritis, peptische zweren en maagkanker. Infectie 
met H. pylori komt wereldwijd voor. Momenteel berust de enige geschikte behandeling 
van H. pylori op antibiotica. Het intensieve gebruik en de beperkte keuze van antibiotica 
voor de behandeling van H. pylori hebben bijgedragen aan de ontwikkeling van antibio-
ticum resistentie, en dit kan een bedreiging vormen voor de behandeling van H. pylori 
gerelateerde afwijkingen. Om een beter inzicht te krijgen in het effect van resistentie op 
het slagen van de therapie, dient antibioticum resistentie in H. pylori gecontroleerd te 
worden. De gegevens die verkregen worden via nationale en internationale surveillance  
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programma’s kunnen gebruikt worden ter verbetering van de huidige behandelings-
strategieën. Aangezien in de meeste landen (waaronder Nederland) infecties met H. pylori 
worden vastgesteld met niet-invasieve testen en landelijke surveillance programma’s voor 
de detectie van antibioticum resistentie in H. pylori vaak ontbreken, worden de meeste 
anti-H. pylori therapieën voorgeschreven op basis van onvolledige data.  
Het onderzoek beschreven in dit proefschrift was voornamelijk gericht op de ophel-
dering van de moleculaire resistentie mechanismen van tetracycline, metronidazole en 
amoxicilline resistentie in H. pylori. In samenvatting, tetracycline resistentie in H. pylori 
wordt veroorzaakt door een drievoudige basenpaar verandering AGA926-928TTC in beide 
16S rRNA genen (hoofdstuk 3, 4 en 5), terwijl metronidazol resistentie in H. pylori wordt 
veroorzaakt door veranderingen in het rdxA en frxA gen (hoofdstuk 7). Amoxicilline 
resistentie in H. pylori daarentegen lijkt te berusten op verschillende mutaties in het 
pbp1A gen (hoofdstuk 9 en 10). Deze data zijn in overeenstemming met de reeds eerder 
beschreven antibioticum resistentie mechanismen in H. pylori, die allen berusten op 
puntmutaties in genen die gelokaliseerd zijn op het chromosoom [8, 11, 16, 20]. Alhoewel 
in H. pylori horizontale genoverdracht tussen gevoelige en resistente stammen incidenteel 
is beschreven [18], lijkt het erop dat antibioticum resistentie in deze bacterie ontstaat door 
spontane mutaties [21]. Om deze reden dient het gebruik van mono- of duo-therapieën 
gebaseerd op één antibioticum vermeden te worden, aangezien zij het ontstaan en de 
verspreiding van antibioticum resistentie in H. pylori bevorderen. 
Antibioticum gevoeligheidsbepalingen gebaseerd op kweek zijn niet alleen tijdrovend, 
maar moeilijk te interpreteren door het ontbreken van standaardisatie. Aangezien de 
meeste van de resistentie mechanismen in H. pylori veroorzaakt worden de specifieke 
puntmutaties, bieden moleculair gebaseerde detectie technieken een aantrekkelijk alternatief. 
In tegenstelling tot op kweek gebaseerde technieken, zijn deze methoden reproduceerbaar 
en gemakkelijk te standaardiseren, aangezien zij onafhankelijk zijn van de levensvat-
baarheid en groeisnelheid van de bacterie. Daarnaast zijn deze technieken sneller dan de 
op kweek gebaseerde technieken. Indien de detectie direct plaatsvindt op maagbiopten kan 
de uitslag nog op de dag van endoscopie worden verkregen. Door gebruik te maken van 
de moleculaire kennis op het gebied van antibioticum resistentie zijn reeds enkele testen 
voor de detectie van clarithromycine, tetracycline en ciprofloxacine resistentie in H. pylori 
ontwikkeld. Voor metronidazole en amoxicilline resistentie ontbreken deze testen echter, 
en het lijkt erop dat zij ook niet op korte termijn ontwikkeld gaan worden. Aangezien de 
meeste H. pylori infecties momenteel gediagnostiseerd worden met niet-invasieve testen, 
dient meer tijd en inspanning geïnvesteerd te worden in de ontwikkeling van simpele niet-
invasieve moleculaire technieken die in staat zijn om antibioticum resistentie van 
H. pylori aan te tonen in alternatieve klinische monsters, bijvoorbeeld in faeces. 
 
 
Toekomstperspectieven 
 
In H. pylori zijn verscheidene virulentie factoren, zoals urease, het vacuolating cytotoxine 
A (VacA), het cytotoxine geassocieerde antigeen (CagA) en het bloedgroep antigeen 
bindende adhesine (BabA) gebruikt voor de ontwikkeling van vaccins. Hoewel fase I en II 
klinische trials op mensen zijn uitgevoerd [2, 7, 15], is een commercieel vaccin nog steeds 
niet beschikbaar. Andere potentiële ontwikkelingen ter verbetering van de huidige 
H. pylori therapieën berusten op (i) antimicrobiële peptiden zoals magainines, LL-37/hCAP18 
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en defensines [1, 10, 12]. Deze peptiden participeren in de aangeboren en verkregen 
afweer van bijna alle levende individuen [13]; (ii) porfyrines, zij behoren tot een klasse 
van natuurlijk voorkomende componenten die antimicrobiële activiteit vertonen doordat 
zij peroxidase en oxidase reacties versnellen [19]; en (iii) nieuwe diëten, gebaseerd op 
essentiële oliën [3, 17] of probiotica [9]. Deze componenten kunnen gebruikt worden in 
de vorm van monotherapieën of in combinatie met de huidige anti-H. pylori therapieën. 
Aangezien de eerste studieresultaten met deze componenten hoopgevend lijken, openen 
zij nieuwe perspectieven voor de behandeling van H. pylori. 
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